BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Baumgart DC, Sandborn WJ. Crohn's disease. The Lancet 2012;380:1590-605. [DOI: 10.1016/s0140-6736(12)60026-9] [Cited by in Crossref: 1283] [Cited by in F6Publishing: 1376] [Article Influence: 116.6] [Reference Citation Analysis]
Number Citing Articles
1 Ouyang Y, Zhao J, Wang S. Multifunctional hydrogels based on chitosan, hyaluronic acid and other biological macromolecules for the treatment of inflammatory bowel disease: A review. Int J Biol Macromol 2023;227:505-23. [PMID: 36495992 DOI: 10.1016/j.ijbiomac.2022.12.032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Börekci H, Baş H. New Diagnostic Marker for Crohn’s Disease — Ileocecal Lipomatosis. Indian J Surg 2023. [DOI: 10.1007/s12262-023-03693-4] [Reference Citation Analysis]
3 Pan J, Fei CJ, Hu Y, Wu XY, Nie L, Chen J. Current understanding of the cGAS-STING signaling pathway: Structure, regulatory mechanisms, and related diseases. Zool Res 2023;44:183-218. [PMID: 36579404 DOI: 10.24272/j.issn.2095-8137.2022.464] [Reference Citation Analysis]
4 Geng Z, Li J, Huang J, Zhao T, Wang X, Bao Y, Ding Y, Deng M, Wang Y, Song X, Zhang X, Wang L, Zuo L, Hu J. Nodakenin ameliorated TNBS-induced experimental colitis in mice by inhibiting intestinal epithelial cell pyroptosis.. [DOI: 10.21203/rs.3.rs-2482997/v1] [Reference Citation Analysis]
5 Włodarczyk J, Burzyński J, Czerwiński B, Prusisz M, Socała K, Poleszak E, Fichna J, Maryńczak K, Włodarczyk M, Dziki Ł. Management of Pelvic Pain in Patients with Crohn's Disease-Current Overview. J Clin Med 2023;12. [PMID: 36675454 DOI: 10.3390/jcm12020526] [Reference Citation Analysis]
6 Arulprakasam KR, Dharumadurai D. Biosynthetic gene clusters of symbiotic gut microbiome in succession of human health. Microbial Symbionts 2023. [DOI: 10.1016/b978-0-323-99334-0.00007-4] [Reference Citation Analysis]
7 Forss A, Clements M, Myrelid P, Strid H, Söderman C, Wagner A, Andersson D, Hjelm F, Olén O, Halfvarson J, Ludvigsson JF; PROSE SWIBREG study group. Ustekinumab Is Associated with Real-World Long-Term Effectiveness and Improved Health-Related Quality of Life in Crohn's Disease. Dig Dis Sci 2023;68:65-76. [PMID: 35459973 DOI: 10.1007/s10620-022-07501-z] [Reference Citation Analysis]
8 Fletcher J, Brown M, Hewison M, Swift A, Cooper SC. Prevalence of vitamin D deficiency and modifiable risk factors in patients with Crohn's disease: A prospective observational study. J Adv Nurs 2022. [PMID: 36281072 DOI: 10.1111/jan.15476] [Reference Citation Analysis]
9 Kiernan MG, Dunne SS, Mcdermott K, Jakeman P, Gilmore B, Thompson TP, Kelly S, Coffey JC, Dunne CP. Mesenteric Microbiology and Inflammatory Bowel Disease: Improved Understanding Due to Accelerating Innovation and Sophistication of Molecular Technology. The Mesentery and Inflammation 2023. [DOI: 10.1007/978-3-031-17774-3_7] [Reference Citation Analysis]
10 Brand S. Phänotypen und extraintestinale Manifestationen. Pflege bei chronisch-entzündlichen Darmerkrankungen 2023. [DOI: 10.1007/978-3-662-64938-1_5] [Reference Citation Analysis]
11 Gurram B. Diarrhea. Nelson Pediatric Symptom-Based Diagnosis: Common Diseases and their Mimics 2023. [DOI: 10.1016/b978-0-323-76174-1.00014-6] [Reference Citation Analysis]
12 Mao Q, Pan H, Zhang Y, Zhang Y, Zhu Q, Hong Y, Huang Z, Li Y, Feng X, Fang Y, Chen W, Chen P, Shen B, Ouyang H, Liang Y. GelNB molecular coating as a biophysical barrier to isolate intestinal irritating metabolites and regulate intestinal microbial homeostasis in the treatment of inflammatory bowel disease. Bioactive Materials 2023;19:251-67. [DOI: 10.1016/j.bioactmat.2022.04.001] [Reference Citation Analysis]
13 Cirillo G, Negrete-Diaz F, Yucuma D, Virtuoso A, Korai SA, De Luca C, Kaniusas E, Papa M, Panetsos F. Vagus Nerve Stimulation: A Personalized Therapeutic Approach for Crohn's and Other Inflammatory Bowel Diseases. Cells 2022;11. [PMID: 36552867 DOI: 10.3390/cells11244103] [Reference Citation Analysis]
14 Bai Z, Wang J, Li J, Yuan H, Wang P, Zhang M, Feng Y, Cao X, Cao X, Kang G, de Marco A, Huang H. Design of nanobody-based bispecific constructs by in silico affinity maturation and umbrella sampling simulations. Comput Struct Biotechnol J 2023;21:601-13. [PMID: 36659922 DOI: 10.1016/j.csbj.2022.12.021] [Reference Citation Analysis]
15 Ai LS, Yu YB. Role of Paneth cells-associated Crohn's disease susceptibility genes in development of Crohn's disease. Shijie Huaren Xiaohua Zazhi 2022; 30(23): 1009-1015 [DOI: 10.11569/wcjd.v30.i23.1009] [Reference Citation Analysis]
16 Lee KE, Lim F, Faye AS, Shen B, Hur C. Endoscopic Balloon Dilation Is Cost-Effective for Crohn's Disease Strictures. Dig Dis Sci 2022;67:5462-71. [PMID: 35290570 DOI: 10.1007/s10620-022-07420-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Chen Y, Wang P, Zhang Y, Du XY, Zhang YJ. Comparison of effects of aminosalicylic acid, glucocorticoids and immunosuppressive agents on the expression of multidrug-resistant genes in ulcerative colitis. Sci Rep 2022;12:20656. [PMID: 36450761 DOI: 10.1038/s41598-022-19612-8] [Reference Citation Analysis]
18 Robinson P, Magness E, Montoya K, Engineer N, Eckols TK, Rodriguez E, Tweardy DJ. Genetic and Small-Molecule Modulation of Stat3 in a Mouse Model of Crohn's Disease. J Clin Med 2022;11. [PMID: 36498596 DOI: 10.3390/jcm11237020] [Reference Citation Analysis]
19 Schweda A, Becker E, Wiendl M, Atreya R, Atreya I, Müller TM, Neurath MF, Zundler S. Etrolizumab-s Does Not Induce Residual Trafficking of Regulatory T Cells. Inflamm Bowel Dis 2022;28:1746-55. [PMID: 35815779 DOI: 10.1093/ibd/izac137] [Reference Citation Analysis]
20 Chaparro M, Baston-Rey I, Fernández-Salgado E, González García J, Ramos L, Diz-Lois Palomares MT, Argüelles-Arias F, Iglesias Flores E, Cabello M, Rubio Iturria S, Núñez Ortiz A, Charro M, Ginard D, Dueñas Sadornil C, Merino Ochoa O, Busquets D, Iyo E, Gutiérrez Casbas A, Ramírez de la Piscina P, Boscá-Watts MM, Arroyo M, García MJ, Hinojosa E, Gordillo J, Martínez Montiel P, Velayos Jiménez B, Quílez Ivorra C, Vázquez Morón JM, María Huguet J, González-Lama Y, Muñagorri Santos AI, Amo VM, Martín-Arranz MD, Bermejo F, Martínez Cadilla J, Rubín de Célix C, Fradejas Salazar P, San Román AL, Jiménez N, García López S, Figuerola A, Jiménez I, Martínez Cerezo FJ, Taxonera C, Varela P, de Francisco R, Monfort D, Molina Arriero G, Hernández Camba A, García-Alonso FJ, Van Domselaar M, Pajares Villarroya R, Núñez A, Rodríguez Moranta F, Marín-Jiménez I, Robles Alonso V, Martín Rodríguez MDM, Camo-Monterde P, García Tercero I, Navarro Llavat M, Arias García L, Hervías Cruz D, Sulleiro S, Novella C, Vispo E, Barreiro-de Acosta M, Gisbert JP. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study. Inflamm Bowel Dis 2022;28:1725-36. [PMID: 35166347 DOI: 10.1093/ibd/izab357] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
21 Bisgaard TH, Allin KH, Keefer L, Ananthakrishnan AN, Jess T. Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment. Nat Rev Gastroenterol Hepatol 2022;19:717-26. [PMID: 35732730 DOI: 10.1038/s41575-022-00634-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
22 Xu R, Weber MC, Hu X, Neumann PA, Kamaly N. Annexin A1 based inflammation resolving mediators and nanomedicines for inflammatory bowel disease therapy. Semin Immunol 2022;61-64:101664. [PMID: 36306664 DOI: 10.1016/j.smim.2022.101664] [Reference Citation Analysis]
23 Zhang W, Lyu M, Bessman NJ, Xie Z, Arifuzzaman M, Yano H, Parkhurst CN, Chu C, Zhou L, Putzel GG, Li TT, Jin WB, Zhou J, Hu H, Tsou AM, Guo CJ, Artis D; JRI Live Cell Bank. Gut-innervating nociceptors regulate the intestinal microbiota to promote tissue protection. Cell 2022;185:4170-4189.e20. [PMID: 36240781 DOI: 10.1016/j.cell.2022.09.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
24 Shimoda F, Naito T, Kakuta Y, Kawai Y, Shimoyama Y, Moroi R, Shiga H, Nagasaki M, Kinouchi Y, Masamune A. Clinical and genetic factors associated with clinical relapse during anti-tumor necrosis factor therapy in Japanese patients with Crohn’s disease.. [DOI: 10.21203/rs.3.rs-2180536/v1] [Reference Citation Analysis]
25 Di Hu, Tianliang Huang, Mika Shigeta, Yuta Ochi, Shigeru Kabayama, Yasuyoshi Watanabe, Yilong Cui. Electrolyzed Hydrogen Water Alleviates Abdominal Pain through Suppression of Colonic Tissue Inflammation in a Rat Model of Inflammatory Bowel Disease. Nutrients 2022;14:4451. [PMID: 36364715 DOI: 10.3390/nu14214451] [Reference Citation Analysis]
26 Wang S, Miao S, Qiu X, Wu J, Wang Y. Fecal calprotectin in predicting small bowel capsule endoscopy findings in pediatric patients with known Crohn's disease. Medicine (Baltimore) 2022;101:e31163. [PMID: 36281159 DOI: 10.1097/MD.0000000000031163] [Reference Citation Analysis]
27 Fiaidhi J, Mohammed S, Zezos P. An Investigation into Crohn’s Disease Lesions Variability Sensing Using Video Colonoscopy and Machine Learning Techniques. 2022 IEEE International Conference on E-health Networking, Application & Services (HealthCom) 2022. [DOI: 10.1109/healthcom54947.2022.9982753] [Reference Citation Analysis]
28 Fujimura H, Hashimoto S, Shimizu K, Onoda H, Tanabe M, Higashi M, Ogawa R, Goto A, Hamabe K, Nishikawa J, Ito K, Takami T. The Evaluation of Transmural Healing by Low-dose Computed Tomography Enterography in Patients with Crohn's Disease. Intern Med 2022;61:2999-3007. [DOI: 10.2169/internalmedicine.9066-21] [Reference Citation Analysis]
29 Kridin K, Goral D, Shihade W, Tzur-Bitan D, Onn E, Zoller L, Cohen AD. Vitiligo and Crohn's disease form an autoimmune cluster: insights from a population-based study. Scand J Gastroenterol 2022;:1-6. [PMID: 36222357 DOI: 10.1080/00365521.2022.2131332] [Reference Citation Analysis]
30 Narula N, Wong ECL, Aruljothy A, Dulai PS, Colombel JF, Marshall JK, Ferrante M, Reinisch W. Baseline Patient-reported Symptoms Less Predictive Than MM-SES-CD for Endoscopic Remission in Crohn's Disease. J Clin Gastroenterol 2022. [PMID: 36227009 DOI: 10.1097/MCG.0000000000001774] [Reference Citation Analysis]
31 Gomez-Nguyen A, Gupta N, Sanaka H, Gruszka D, Pizarro A, DiMartino L, Basson A, Menghini P, Osme A, DeSalvo C, Pizarro T, Cominelli F. Chronic stress induces colonic tertiary lymphoid organ formation and protection against secondary injury through IL-23/IL-22 signaling. Proc Natl Acad Sci U S A 2022;119:e2208160119. [PMID: 36161939 DOI: 10.1073/pnas.2208160119] [Reference Citation Analysis]
32 Castro PCSD, Magro DO, Nones RB, Furlan TK, Miranda EF, Kotze PG. USTEKINUMAB IN CROHN’S DISEASE MANAGEMENT: A BRAZILIAN OBSERVATIONAL STUDY. Arq Gastroenterol 2022;59:501-507. [DOI: 10.1590/s0004-2803.202204000-89] [Reference Citation Analysis]
33 Pray C, Wong ECL, Aruljothy A, Dulai PS, Marshall JK, Reinisch W, Narula N. Ulcer Size After Induction Therapy Performs Better Than Symptom Assessment for Prediction of One Year Endoscopic Remission in Crohn's Disease: A Post Hoc Analysis. Inflamm Bowel Dis 2022:izac210. [PMID: 36179118 DOI: 10.1093/ibd/izac210] [Reference Citation Analysis]
34 Yin J, Li Y, Chen Y, Wang C, Song X. Adalimumab for induction of remission in patients with Crohn's disease: a systematic review and meta-analysis. Eur J Med Res 2022;27:190. [PMID: 36175983 DOI: 10.1186/s40001-022-00817-6] [Reference Citation Analysis]
35 Koyuncu AG, Akyüz EY. Dietary polyphenols in the treatment of inflammatory bowel diseases. J Surg Med 2022;6:829-832. [DOI: 10.28982/josam.1060925] [Reference Citation Analysis]
36 Fan Y, Wu D, Zhang X, Jiang W, Nie M, Liu X, Xiang T, Liu M, Chen Y, Feng D, Huang J, Gao C, Jiang R. The inflammatory cellular feature in the peripheral blood of chronic subdural hematoma patients. Clinical Laboratory Analysis. [DOI: 10.1002/jcla.24706] [Reference Citation Analysis]
37 Sivaraman K, Shanthi C. Purified fish skin collagen hydrolysate attenuates TNF-α induced barrier dysfunction in-vitro and DSS induced colitis in-vivo model. Int J Biol Macromol 2022;222:448-61. [PMID: 36116587 DOI: 10.1016/j.ijbiomac.2022.09.122] [Reference Citation Analysis]
38 Gadjalova I, Heinze JM, Goess MC, Hofmann J, Albers JJ, Spallek R, Blissenbach B, Buck A, Weber M, Scherer E, Kampick M, Öllinger R, Krut O, Rad R, Steiger K, Winter C, Janssen K, Neumann P, Geha RS, Ruland J, Keppler SJ. B/T cell crosstalk and aberrant inflammatory IgG exacerbate autoimmune intestinal inflammation.. [DOI: 10.1101/2022.09.12.507066] [Reference Citation Analysis]
39 Liu D, Chen Y, Li Q, Xu M, Liao J, Wang B. Integrative bioinformatics analysis to identify the effects of circadian rhythm on Crohn’s disease. Front Mol Biosci 2022;9:961481. [DOI: 10.3389/fmolb.2022.961481] [Reference Citation Analysis]
40 Gorenjak M, Jezernik G, Krušič M, Skok P, Potočnik U. Identification of Novel Loci Involved in Adalimumab Response in Crohn’s Disease Patients Using Integration of Genome Profiling and Isoform-Level Immune-Cell Deconvoluted Transcriptome Profiling of Colon Tissue. Pharmaceutics 2022;14:1893. [DOI: 10.3390/pharmaceutics14091893] [Reference Citation Analysis]
41 Alrubia S, Mao J, Chen Y, Barber J, Rostami-Hodjegan A. Altered Bioavailability and Pharmacokinetics in Crohn's Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs. Clin Pharmacokinet 2022. [PMID: 36056298 DOI: 10.1007/s40262-022-01169-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Lv Y, Lou Y, Yang G, Luo Y, Lou J, Cheng Q, Yu J, Fang Y, Zhao H, Peng K, Chen J, M'koma A. Outcomes of Pediatric Patients with Crohn’s Disease Received Infliximab or Exclusive Enteral Nutrition during Induction Remission. Gastroenterology Research and Practice 2022;2022:1-9. [DOI: 10.1155/2022/3813915] [Reference Citation Analysis]
43 Yuan G, He Y, Cao QH, Tang MM, Xie ZL, Qiu Y, Zeng ZR, Peng S, Chen MH. Visceral adipose volume is correlated with surgical tissue fibrosis in Crohn's disease of the small bowel. Gastroenterol Rep (Oxf) 2022;10:goac044. [PMID: 36042948 DOI: 10.1093/gastro/goac044] [Reference Citation Analysis]
44 Abdulla M, Mohammed N. A Review on Inflammatory Bowel Diseases: Recent Molecular Pathophysiology Advances. BTT 2022;Volume 16:129-140. [DOI: 10.2147/btt.s380027] [Reference Citation Analysis]
45 Cavalu S, Sharaf H, Saber S, Youssef ME, Abdelhamid AM, Mourad AAE, Ibrahim S, Allam S, Elgharabawy RM, El-Ahwany E, Amin NA, Shata A, Eldegla M, Atef M, Aboraya M, Mohamed M, Anz N, Elmotelb DA, Gabr F, Elzablawy D, Hamada M, Yehia A, Osama D, Mohammed OA. Ambroxol, a mucolytic agent, boosts HO-1, suppresses NF-κB, and decreases the susceptibility of the inflamed rat colon to apoptosis: A new treatment option for treating ulcerative colitis. FASEB J 2022;36:e22496. [PMID: 35947115 DOI: 10.1096/fj.202200749R] [Reference Citation Analysis]
46 Lan N, Shen B. Endoscopic Therapy for Fistulas and Abscesses in Crohn Disease. Gastrointestinal Endoscopy Clinics of North America 2022. [DOI: 10.1016/j.giec.2022.05.006] [Reference Citation Analysis]
47 Lee J, Kim KS, Koh H, Lee D, Kang NJ. Diet-Induced Host–Microbe Interactions: Personalized Diet Strategies for Improving Inflammatory Bowel Disease. Current Developments in Nutrition 2022;6. [DOI: 10.1093/cdn/nzac110] [Reference Citation Analysis]
48 Demiryas S, Orhan A. Advancements in Gastrointestinal System Biomarkers. Biomarkers in Medicine 2022. [DOI: 10.2174/9789815040463122010016] [Reference Citation Analysis]
49 Becker HE, Kameli N, Rustichelli A, Heijnens BA, Stassen F, Penders J, Jonkers DM. Higher in vitro mucin degradation, but no increased paracellular permeability by faecal water from Crohn’s disease patients.. [DOI: 10.1101/2022.08.26.505386] [Reference Citation Analysis]
50 Fu L, Liu H, Chen W, Hooft JM, Øverland M, Cai W, Han D, Zhu X, Yang Y, Jin J, Xie S. Enhancement of liver mitochondrial complex I and energy metabolism induced by enteritis: The key role of gut microbiota derived endotoxins. Front Immunol 2022;13:981917. [DOI: 10.3389/fimmu.2022.981917] [Reference Citation Analysis]
51 Nonnecke EB, Castillo PA, Akahoshi DT, Goley SM, Bevins CL, Lönnerdal B. Characterization of an intelectin-1 (Itln1) knockout mouse model. Front Immunol 2022;13:894649. [PMID: 36072603 DOI: 10.3389/fimmu.2022.894649] [Reference Citation Analysis]
52 Tornero-Aguilera JF, Sánchez-Molina J, Parraca JA, Morais A, Clemente-Suárez VJ. Are Crohn's Disease Patients Limited in Sport Practise? An UltraEndurance Case-Control Study Response. Int J Environ Res Public Health 2022;19:10007. [PMID: 36011641 DOI: 10.3390/ijerph191610007] [Reference Citation Analysis]
53 Haque R, Das II, Sawant PB, Chadha NK, Sahoo L, Kumar R, Sundaray JK. Tenets in Microbial Endocrinology: A New Vista in Teleost Reproduction. Front Physiol 2022;13:871045. [DOI: 10.3389/fphys.2022.871045] [Reference Citation Analysis]
54 Ding S, Liu C, Zhang Y, Sun L, Xiang L, Liu H, Fang Y, Ren W, Zhao H, Sun X, Zhang K, Zhang C, Xu X, Xu H. Contrast-enhanced ultrasound in the assessment of Crohn’s disease activity: comparison with computed tomography enterography. Radiol med 2022;127:1068-1078. [DOI: 10.1007/s11547-022-01535-z] [Reference Citation Analysis]
55 Bouhnik Y, Atreya R, Casey D, Górecki M, Baik D, Yoon SW, Kwon TS, Jang M. Cost-effectiveness Analysis of Subcutaneous Infliximab for Inflammatory Bowel Diseases in Sequential Biologic Treatment. Inflamm Bowel Dis 2022:izac160. [PMID: 35942647 DOI: 10.1093/ibd/izac160] [Reference Citation Analysis]
56 Ferretti F, Monico MC, Cannatelli R, Carmagnola S, Lenti MV, Di Sabatino A, Conforti F, Pastorelli L, Caprioli F, Bezzio C, Saibeni S, Mazza S, Vecchi M, Maconi G, Ardizzone S. The impact of biologic therapies on extra-intestinal manifestations in inflammatory bowel disease: A multicenter study. Front Med 2022;9. [DOI: 10.3389/fmed.2022.933357] [Reference Citation Analysis]
57 Li L, Sohn J, Genco RJ, Wactawski-wende J, Goodison S, Diaz PI, Sun Y. Computational approach to modeling microbiome landscapes associated with chronic human disease progression. PLoS Comput Biol 2022;18:e1010373. [DOI: 10.1371/journal.pcbi.1010373] [Reference Citation Analysis]
58 Mattila K, Rankala R, Voutilainen M, Mustonen A. Inflammatory bowel disease: perceived impact on leisure-time activities. Scand J Gastroenterol 2022;57:930-5. [PMID: 35196200 DOI: 10.1080/00365521.2022.2042593] [Reference Citation Analysis]
59 Said Ameen Z, Umar Ibrahim A, Saleh Mubarak A, Al-turjman F, Muhammad Ghali U. Deep Learning Methods For Prediction of HLA-Peptide Interactions in IDB. 2022 International Conference on Artificial Intelligence in Everything (AIE) 2022. [DOI: 10.1109/aie57029.2022.00021] [Reference Citation Analysis]
60 Kusan S, Surat G, Kelm M, Anger F, Kim M, Germer CT, Schlegel N, Flemming S. Microbial Spectrum and Antibiotic Resistance in Patients Suffering from Penetrating Crohn's Disease. J Clin Med 2022;11:4343. [PMID: 35893433 DOI: 10.3390/jcm11154343] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Bharti S, Bharti M. The Business of T Cell Subsets and Cytokines in the Immunopathogenesis of Inflammatory Bowel Disease. Cureus 2022. [DOI: 10.7759/cureus.27290] [Reference Citation Analysis]
62 Fan Y, Zhang L, Omidakhsh N, Bohn RL, Thompson JS, Brodovicz KG, Deepak P. Patients With Stricturing or Penetrating Crohn's Disease Phenotypes Report High Disease Burden and Treatment Needs. Inflamm Bowel Dis 2022:izac162. [PMID: 35880838 DOI: 10.1093/ibd/izac162] [Reference Citation Analysis]
63 Kwon OC, Han K, Chun J, Kim R, Hong SW, Kim JH, Youn YH, Park H, Park MC; Gastroenterology, Neurology and Rheumatology National Data Science Research (GUARANTEE) Group. Effects of immune-mediated inflammatory diseases on cardiovascular diseases in patients with type 2 diabetes: a nationwide population-based study. Sci Rep 2022;12:11548. [PMID: 35798796 DOI: 10.1038/s41598-022-15436-8] [Reference Citation Analysis]
64 Xiong S, Whitehurst CE, Li L, Heo GS, Lai CW, Jain U, Muegge BD, Espenschied ST, Musich RJ, Chen M, Liu Y, Liu TC, Stappenbeck TS. Reverse translation approach generates a signature of penetrating fibrosis in Crohn's disease that is associated with anti-TNF response. Gut 2022;71:1289-301. [PMID: 34261752 DOI: 10.1136/gutjnl-2020-323405] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
65 Abraham BP, Ott E, Busse C, Murphy C, Miller L, Baumgart DC, Scherl E, Gasink C. Ustekinumab Exposure in Pregnant Women From Inflammatory Bowel Disease Clinical Trials: Pregnancy Outcomes Through Up To 5 Years in Crohn’s Disease and 2 Years in Ulcerative Colitis. Crohn's & Colitis 360 2022;4. [DOI: 10.1093/crocol/otac025] [Reference Citation Analysis]
66 Nakashima T, Fujii K, Seki T, Aoyama M, Azuma A, Kawasome H. Novel Gut Microbiota Modulator, Which Markedly Increases Akkermansia muciniphila Occupancy, Ameliorates Experimental Colitis in Rats. Dig Dis Sci 2022;67:2899-911. [PMID: 34259969 DOI: 10.1007/s10620-021-07131-x] [Reference Citation Analysis]
67 Nakashima T, Fujii K, Seki T, Aoyama M, Azuma A, Kawasome H. Novel Gut Microbiota Modulator, Which Markedly Increases Akkermansia muciniphila Occupancy, Ameliorates Experimental Colitis in Rats. Dig Dis Sci 2022;67:2899-911. [PMID: 34259969 DOI: 10.1007/s10620-021-07131-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
68 Alghoul Z, Yang C, Merlin D. The Current Status of Molecular Biomarkers for Inflammatory Bowel Disease. Biomedicines 2022;10:1492. [PMID: 35884797 DOI: 10.3390/biomedicines10071492] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Lin Y, Liu H, Bu L, Chen C, Ye X. Review of the Effects and Mechanism of Curcumin in the Treatment of Inflammatory Bowel Disease. Front Pharmacol 2022;13:908077. [DOI: 10.3389/fphar.2022.908077] [Reference Citation Analysis]
70 Zhang S, Liang Y, Yao J, Li DF, Wang LS. Role of Pyroptosis in Inflammatory Bowel Disease (IBD): From Gasdermins to DAMPs. Front Pharmacol 2022;13:833588. [PMID: 35677444 DOI: 10.3389/fphar.2022.833588] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
71 Peyrin-Biroulet L, Arkkila P, Armuzzi A, Danese S, Guardiola J, Jahnsen J, Lees C, Louis E, Lukáš M, Reinisch W, Roblin X, Jang M, Byun HG, Kim DH, Lee SJ, Atreya R. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis. BMC Gastroenterol 2022;22:291. [PMID: 35676620 DOI: 10.1186/s12876-022-02347-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Yarani R, Shojaeian A, Palasca O, Doncheva NT, Jensen LJ, Gorodkin J, Pociot F. Differentially Expressed miRNAs in Ulcerative Colitis and Crohn’s Disease. Front Immunol 2022;13:865777. [DOI: 10.3389/fimmu.2022.865777] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Wu X, Zhang Y, Zhang W, Liu G, Huang H, Jiang H, Zhang X. The Prevalence and Associated Risk Factors of Erectile Dysfunction in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. The Journal of Sexual Medicine 2022;19:950-960. [DOI: 10.1016/j.jsxm.2022.03.615] [Reference Citation Analysis]
74 Garza-hernandez D, Estrada K, Trevino V. Multivariate genome-wide association study models to improve prediction of Crohn’s disease risk and identification of potential novel variants. Computers in Biology and Medicine 2022;145:105398. [DOI: 10.1016/j.compbiomed.2022.105398] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Omer OS, Hertweck A, Roberts LB, Lo JW, Clough JN, Jackson I, Pantazi ED, Irving PM, MacDonald TT, Pavlidis P, Jenner RG, Lord GM. Cyclin-dependent Kinase 9 as a Potential Target for Anti-TNF-resistant Inflammatory Bowel Disease. Cell Mol Gastroenterol Hepatol 2022;14:625-41. [PMID: 35660024 DOI: 10.1016/j.jcmgh.2022.05.011] [Reference Citation Analysis]
76 Lo CH, Khandpur N, Rossato SL, Lochhead P, Lopes EW, Burke KE, Richter JM, Song M, Ardisson Korat AV, Sun Q, Fung TT, Khalili H, Chan AT, Ananthakrishnan AN. Ultra-processed Foods and Risk of Crohn's Disease and Ulcerative Colitis: A Prospective Cohort Study. Clin Gastroenterol Hepatol 2022;20:e1323-37. [PMID: 34461300 DOI: 10.1016/j.cgh.2021.08.031] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 22.0] [Reference Citation Analysis]
77 Sands BE, Irving PM, Hoops T, Izanec JL, Gao L, Gasink C, Greenspan A, Allez M, Danese S, Hanauer SB, Jairath V, Kuehbacher T, Lewis JD, Loftus EV, Mihaly E, Panaccione R, Scherl E, Shchukina OB, Sandborn WJ, Afzali A, Aitova L, Aldeguer i Mante X, Allez M, Altorjay I, Argüelles Arias F, Armuzzi A, Augustyn M, Bafutto M, Barrio J, Begun J, Behrend C, Bezemer G, Bonnaud G, Brankovic M, Byung IJ, Calvet Calvo X, Chachu K, Chebli JMF, Cheon JH, Cichoz-lach H, Clark L, Cummings F, Dalal K, Danese S, De Boer N, De Lourdes Ferrari M, Désilets E, Dugalic P, Duvall G, Fedorishina O, Filip R, Flores C, Fogel R, Fon J, Frankel M, Friedenberg K, Fries W, Galina V, Gietka P, Goel R, Hasselblatt P, Herfarth H, Herszényi L, Hindryckx P, Hoentjen F, Horjus Talabur Horje C, Iduru S, Irving P, Isfort R, Jairath V, Jones M, Kalimullina D, Katz J, Kaur M, Khurana SK, Kim JS, Kim Y, Kleczkowski D, Knezevic S, Knoll A, Korman LY, Kotzev I, Kulyapin A, Lee KM, Leemreis D, Leszczyszyn J, Limdi J, Lissauer J, Loftus E, Malecka-panas E, Marshall J, Mihály E, Milan L, Monteleone G, Nagorni A, Owczarek D, Palekar N, Panaccione R, Park YS, Park SH, Parra R, Patai Á, Patel K, Patel B, Pershko A, Petrova E, Pineton de Chambrun G, Randall C, Riestra Menendez S, Ritter T, Rivero M, Roblin X, Rocca R, Romatowski J, Rydzewska G, Saibeni S, Salzberg B, Sarles H, Saunders J, Savarino EV, Serclova Z, Shchukina O, Siegel J, Soofi N, Sparrow M, Stokesberry D, Suiter D, Svorcan P, Tkachev A, Tsonev N, Tünde K, Ulbrych J, Vanasek T, Varga M, Vermeire S, Vicente Lidon R, Weiss ML, Wesley E, Winstead N, Wojcik K, Wypych J, Zaltman C, Zdena Z. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. The Lancet 2022;399:2200-11. [DOI: 10.1016/s0140-6736(22)00688-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
78 Watanabe Y, Mizushima T, Okumura R, Fujino S, Ogino T, Miyoshi N, Takahashi H, Uemura M, Matsuda C, Yamamoto H, Takeda K, Doki Y, Eguchi H. Fecal Stream Diversion Changes Intestinal Environment, Modulates Mucosal Barrier, and Attenuates Inflammatory Cells in Crohn's Disease. Dig Dis Sci 2022;67:2143-57. [PMID: 34041649 DOI: 10.1007/s10620-021-07060-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
79 Peng Z, Xu D, Li Y, Peng Y, Liu X. Phase Angle as a Comprehensive Tool for Nutritional Monitoring and Management in Patients with Crohn’s Disease. Nutrients 2022;14:2260. [DOI: 10.3390/nu14112260] [Reference Citation Analysis]
80 Hellstrom WJG, Dolhain RJEM, Ritter TE, Watkins TR, Arterburn SJ, Dekkers G, Gillen A, Tonussi C, Gilles L, Oortwijn A, Van Beneden K, de Vries DE, Sikka SC, Vanderschueren D, Reinisch W. MANTA and MANTA-RAy: Rationale and Design of Trials Evaluating Effects of Filgotinib on Semen Parameters in Patients with Inflammatory Diseases. Adv Ther 2022. [PMID: 35614292 DOI: 10.1007/s12325-022-02168-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
81 Otake-kasamoto Y, Kayama H, Kishikawa T, Shinzaki S, Tashiro T, Amano T, Tani M, Yoshihara T, Li B, Tani H, Liu L, Hayashi A, Okuzaki D, Motooka D, Nakamura S, Okada Y, Iijima H, Takeda K, Takehara T. Lysophosphatidylserines derived from microbiota in Crohn’s disease elicit pathological Th1 response. Journal of Experimental Medicine 2022;219:e20211291. [DOI: 10.1084/jem.20211291] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Liu D, Saikam V, Skrada KA, Merlin D, Iyer SS. Inflammatory bowel disease biomarkers. Medicinal Research Reviews. [DOI: 10.1002/med.21893] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Nardone OM, Calabrese G, Testa A, Caiazzo A, Fierro G, Rispo A, Castiglione F. The Impact of Intestinal Ultrasound on the Management of Inflammatory Bowel Disease: From Established Facts Toward New Horizons. Front Med 2022;9:898092. [DOI: 10.3389/fmed.2022.898092] [Reference Citation Analysis]
84 Vadapalli S, Abdelhalim H, Zeeshan S, Ahmed Z. Artificial intelligence and machine learning approaches using gene expression and variant data for personalized medicine. Brief Bioinform 2022:bbac191. [PMID: 35595537 DOI: 10.1093/bib/bbac191] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
85 Pokryszka J, Wagner A, Wiedermann U, Tobudic S, Herkner H, Winkler S, Brehovsky S, Reinisch W, Novacek G. Course of Fecal Calprotectin after mRNA SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Diseases. Vaccines 2022;10:759. [DOI: 10.3390/vaccines10050759] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 Aximujiang K, Kaheman K, Wushouer X, Wu G, Ahemaiti A, Yunusi K. Lactobacillus acidophilus and HKL Suspension Alleviates Ulcerative Colitis in Rats by Regulating Gut Microbiota, Suppressing TLR9, and Promoting Metabolism. Front Pharmacol 2022;13:859628. [DOI: 10.3389/fphar.2022.859628] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
87 Hu S, Mok J, Gowans M, Ong DEH, Hartono JL, Lee JWJ. Oral Microbiome of Crohn's Disease Patients With and Without Oral Manifestations. J Crohns Colitis 2022;16:1628-36. [PMID: 35511486 DOI: 10.1093/ecco-jcc/jjac063] [Reference Citation Analysis]
88 Garcia-Olmo D, Gilaberte I, Binek M, D Hoore AJL, Lindner D, Selvaggi F, Spinelli A, Panés J. Follow-up Study to Evaluate the Long-term Safety and Efficacy of Darvadstrocel (Mesenchymal Stem Cell Treatment) in Patients With Perianal Fistulizing Crohn's Disease: ADMIRE-CD Phase 3 Randomized Controlled Trial. Dis Colon Rectum 2022;65:713-20. [PMID: 34890373 DOI: 10.1097/DCR.0000000000002325] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
89 Wong ECL, Dulai PS, Marshall JK, Jairath V, Reinisch W, Narula N. Resolution of dominant patient-reported outcome at end of induction predicts clinical and endoscopic remission in Crohn's disease. Aliment Pharmacol Ther 2022;55:1151-9. [PMID: 35166396 DOI: 10.1111/apt.16805] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
90 Sharma AH, Lawlor BW, Wang JY, Sharma Y, Sengupta S, Fernandes P, Zulqarnain F, May E, Syed S, Brown DE. Deep Learning for Predicting Pediatric Crohn's Disease Using Histopathological Imaging. 2022 Systems and Information Engineering Design Symposium (SIEDS) 2022. [DOI: 10.1109/sieds55548.2022.9799299] [Reference Citation Analysis]
91 Hirayama H, Morita Y, Imai T, Takahashi K, Yoshida A, Bamba S, Inatomi O, Andoh A. Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn's disease. BMC Gastroenterol 2022;22:195. [PMID: 35448957 DOI: 10.1186/s12876-022-02271-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
92 Landini L, Souza Monteiro de Araujo D, Titiz M, Geppetti P, Nassini R, De Logu F. TRPA1 Role in Inflammatory Disorders: What Is Known So Far? Int J Mol Sci 2022;23:4529. [PMID: 35562920 DOI: 10.3390/ijms23094529] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
93 Chandrasinghe P. Surgical Management of Small Bowel Crohn's Disease. Front Surg 2022;9:759668. [DOI: 10.3389/fsurg.2022.759668] [Reference Citation Analysis]
94 Turri G, Carvello M, Ben David N, Spinelli A. Intriguing Role of the Mesentery in Ileocolic Crohn's Disease. Clin Colon Rectal Surg. [DOI: 10.1055/s-0042-1743590] [Reference Citation Analysis]
95 Garza-Hernandez D, Sepulveda-Villegas M, Garcia-Pelaez J, Aguirre-Gamboa R, Lakatos PL, Estrada K, Martinez-Vazquez M, Trevino V. A systematic review and functional bioinformatics analysis of genes associated with Crohn's disease identify more than 120 related genes. BMC Genomics 2022;23:302. [PMID: 35418025 DOI: 10.1186/s12864-022-08491-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Kawahira H, Fujii K, Ohi H, Kanekura T. Invasive squamous cell carcinoma arising from long‐lasting enterocutaneous fistula due to Crohn's disease. J Cutaneous Imm & Allergy. [DOI: 10.1002/cia2.12237] [Reference Citation Analysis]
97 Bao S, Tang Y, Lee HH, Gao R, Yang Q, Yu X, Chiron S, Coburn LA, Wilson KT, Roland JT, Landman BA, Huo Y. Inpainting missing tissue in multiplexed immunofluorescence imaging. Medical Imaging 2022: Digital and Computational Pathology 2022. [DOI: 10.1117/12.2611827] [Reference Citation Analysis]
98 Loras C, Mañosa M, Andújar X, Sánchiz V, Martí-gallostra M, Zabana Y, Gutiérrez A, Barreiro-de Acosta M. Position Statement. Recommendations of the Spanish Group on Crohn’s Disease and Ulcerative Colitis (GETECCU) on the treatment of strictures in Crohn’s disease. Gastroenterología y Hepatología (English Edition) 2022;45:315-334. [DOI: 10.1016/j.gastre.2022.04.002] [Reference Citation Analysis]
99 Cortés Correa C, Peñaranda Contreras E, Camacho Pérez L, Chaparro-reyes D. Diagnóstico diferencial de las lesiones supurativas en los pliegues, no todo es hidradenitis supurativa. Piel 2022;37:231-237. [DOI: 10.1016/j.piel.2020.11.001] [Reference Citation Analysis]
100 Oh K, Kwon EJ, Kim JH, Kim K, Lee JY, Hong HS, Hong SW, Park JH, Hwang SW, Yang D, Ye BD, Byeon J, Myung S, Yang S, Park JY, Park SH. Medication Adherence in Korean Patients with Inflammatory Bowel Disease and Its Associated Factors. Ewha Med J 2022;45:35-45. [DOI: 10.12771/emj.2022.45.2.35] [Reference Citation Analysis]
101 Khanna R, Ma C, Jairath V, Vande Casteele N, Zou G, Feagan BG. Endoscopic Assessment of Inflammatory Bowel Disease Activity in Clinical Trials. Clin Gastroenterol Hepatol 2022;20:727-736.e2. [PMID: 33338657 DOI: 10.1016/j.cgh.2020.12.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
102 Gomollón F, Gisbert JP, Guerra I, Plaza R, Pajares Villarroya R, Moreno Almazán L, López Martín MC, Domínguez Antonaya M, Vera Mendoza MI, Aparicio J, Martínez V, Tagarro I, Fernández-Nistal A, Lumbreras S, Maté C, Montoto C; Premonition-CD Study Group. Clinical characteristics and prognostic factors for Crohn's disease relapses using natural language processing and machine learning: a pilot study. Eur J Gastroenterol Hepatol 2022;34:389-97. [PMID: 34882644 DOI: 10.1097/MEG.0000000000002317] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
103 Saccon TD, Dhahbi JM, Schneider A, Nunez Lopez YO, Qasem A, Cavalcante MB, Sing LK, Naser SA, Masternak MM. Plasma miRNA Profile of Crohn’s Disease and Rheumatoid Arthritis Patients. Biology 2022;11:508. [DOI: 10.3390/biology11040508] [Reference Citation Analysis]
104 Ambrose PA, Goodman WA. Impact of COVID-19 on Patients with Inflammatory Bowel Disease. J Explor Res Pharmacol 2022;7:37-44. [DOI: 10.14218/jerp.2021.00014] [Reference Citation Analysis]
105 Forss A, Clements M, Bergman D, Roelstraete B, Kaplan GG, Myrelid P, Halfvarson J, Olén O, Ludvigsson JF. A nationwide cohort study of the incidence of inflammatory bowel disease in Sweden from 1990 to 2014. Aliment Pharmacol Ther 2022;55:691-9. [PMID: 34907544 DOI: 10.1111/apt.16735] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
106 Battat R, Qatomah A, Kopylov U, Wyse J, Cohen A, Afif W, Lakatos PL, Seidman E, Bitton A, Bessissow T. Fucosyltransferase 2 Mutations Are Associated With a Favorable Clinical Course in Crohn's Disease. J Clin Gastroenterol 2022;56:e166-70. [PMID: 34739405 DOI: 10.1097/MCG.0000000000001626] [Reference Citation Analysis]
107 Sun M, Ban W, Ling H, Yu X, He Z, Jiang Q, Sun J. Emerging nanomedicine and prodrug delivery strategies for the treatment of inflammatory bowel disease. Chinese Chemical Letters 2022. [DOI: 10.1016/j.cclet.2022.03.061] [Reference Citation Analysis]
108 Lyall K, Beswick L, Evans S, Cummins RA, Mikocka-walus A. Mindfulness Practice Is Associated With Subjective Wellbeing Homeostasis Resilience in People With Crohn's Disease but Not Ulcerative Colitis. Front Psychiatry 2022;13:797701. [DOI: 10.3389/fpsyt.2022.797701] [Reference Citation Analysis]
109 Lechner K, Zeeshana M, Noack M, Ali H, Neurath M, Weigmanna B. Small but powerful: Will nanoparticles be the future state‐of‐the‐art therapy for IBD? Expert Opinion on Drug Delivery. [DOI: 10.1080/17425247.2022.2043847] [Reference Citation Analysis]
110 Sutton RT, Zai Ane OR, Goebel R, Baumgart DC. Artificial intelligence enabled automated diagnosis and grading of ulcerative colitis endoscopy images. Sci Rep 2022;12:2748. [PMID: 35177717 DOI: 10.1038/s41598-022-06726-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
111 Ogundepo S, Chiamaka AM, Olatinwo M, Adepoju D, Aladesanmi MT, Celestine UO, Ali KC, Umezinwa OJ, Olasore J, Alausa A. The role of diosgenin in crohn’s disease. Clin Phytosci 2022;8. [DOI: 10.1186/s40816-022-00338-z] [Reference Citation Analysis]
112 Babiker AM, Alkharraz AHA, Yusef Alsaeed HA, Aldubaiyan AAR. Mild Abdominal Trauma Complicated With Bowel Perforation in Patient With Crohn’s Disease: Clinical and Intraoperative Findings. Cureus. [DOI: 10.7759/cureus.21977] [Reference Citation Analysis]
113 Debourdeau E, Charmard C, Carriere I, Plat J, Villain M, Boivineau L, Altwegg R, Daien V. Retinal Microcirculation Changes in Crohn’s Disease Patients under Biologics, a Potential Biomarker of Severity: A Pilot Study. JPM 2022;12:230. [DOI: 10.3390/jpm12020230] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
114 Wang CJ, Byun MJ, Kim S, Park W, Park HH, Kim T, Lee JS, Park CG. Biomaterials as therapeutic drug carriers for inflammatory bowel disease treatment. Journal of Controlled Release 2022. [DOI: 10.1016/j.jconrel.2022.02.028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
115 Rocha HC, Vilela EG. Clinical aspects and prognosis of patients with inflammatory bowel disease associated with autoimmune liver diseases. Gastroenterología y Hepatología (English Edition) 2022;45:83-90. [DOI: 10.1016/j.gastre.2021.03.011] [Reference Citation Analysis]
116 Aghdaei HA, Ghavami SB, Farmani M, Sherkat G, Shahrokh S, Zali MR. Overexpression of toll-like receptors and co-stimulatory molecules on immature dendritic cells of Crohn's disease. Gene Reports 2022. [DOI: 10.1016/j.genrep.2022.101579] [Reference Citation Analysis]
117 Sands BE, Peyrin-Biroulet L, Kierkus J, Higgins PDR, Fischer M, Jairath V, Hirai F, D'Haens G, Belin RM, Miller D, Gomez-Valderas E, Naegeli AN, Tuttle JL, Pollack PF, Sandborn WJ. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease. Gastroenterology 2022;162:495-508. [PMID: 34748774 DOI: 10.1053/j.gastro.2021.10.050] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 14.0] [Reference Citation Analysis]
118 Ueno A, Jijon HB, Peng R, Sparksman S, Mainoli B, Filyk A, Li Y, Wilson S, Novak K, Panaccione R, Hirota S, Dufour A, Lu C, Beck PL. Association of Circulating Fibrocytes With Fibrostenotic Small Bowel Crohn's Disease. Inflamm Bowel Dis 2022;28:246-58. [PMID: 34428284 DOI: 10.1093/ibd/izab157] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
119 Panés J, Bouma G, Ferrante M, Kucharzik T, Nachury M, de la Portilla de Juan F, Reinisch W, Selvaggi F, Tschmelitsch J, Brett NR, Ladouceur M, Binek M, Hantsbarger G, Campbell-Hill S, Karki C, Buskens C. INSPECT: A Retrospective Study to Evaluate Long-term Effectiveness and Safety of Darvadstrocel in Patients With Perianal Fistulizing Crohn's Disease Treated in the ADMIRE-CD Trial. Inflamm Bowel Dis 2022;28:1737-45. [PMID: 35099555 DOI: 10.1093/ibd/izab361] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
120 Madla CM, Gavins FKH, Trenfield SJ, Basit AW. Special Populations. Biopharmaceutics 2022. [DOI: 10.1002/9781119678366.ch13] [Reference Citation Analysis]
121 Santacroce G, Lenti MV, Di Sabatino A. Therapeutic Targeting of Intestinal Fibrosis in Crohn's Disease. Cells 2022;11:429. [PMID: 35159238 DOI: 10.3390/cells11030429] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
122 Sorboni SG, Moghaddam HS, Jafarzadeh-Esfehani R, Soleimanpour S. A Comprehensive Review on the Role of the Gut Microbiome in Human Neurological Disorders. Clin Microbiol Rev 2022;35:e0033820. [PMID: 34985325 DOI: 10.1128/CMR.00338-20] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 29.0] [Reference Citation Analysis]
123 Elfert P, Berndt J, Dierkes L, Eichelberg M, Rösch N, Hein A, Diekmann R. A Novel Digital Nutrition Diary for Geriatric Patients at High Risk of Frailty Syndrome. Nutrients 2022;14:400. [DOI: 10.3390/nu14030400] [Reference Citation Analysis]
124 Andersen IM, Jørgensen SF. Gut inflammation in CVID: causes and consequences. Expert Rev Clin Immunol 2022;:1-15. [PMID: 34978241 DOI: 10.1080/1744666X.2021.2008241] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
125 Chatterjee S, Mavani A, Bhatttacharyya J. Chemistry and mechanism of the diseases caused by digestive disorders. Nutrition and Functional Foods in Boosting Digestion, Metabolism and Immune Health 2022. [DOI: 10.1016/b978-0-12-821232-5.00025-2] [Reference Citation Analysis]
126 Pranay K, Jha DK, Bhaskar R, Gupta MK. Hematopoietic stem cell transplantation: Sources of cells, cryopreservation, and applications. Cardiovascular toxicity and therapeutic modalities targeting cardio-oncology 2022. [DOI: 10.1016/b978-0-323-90461-2.00007-9] [Reference Citation Analysis]
127 Shi H, Sun S, Zhou X, He Y, Peng Q. GBP4 is an immune-related biomarker for patients with ileocolonic Crohn’s disease by comprehensive analysis. Eur J Inflamm 2022;20:1721727X2211167. [DOI: 10.1177/1721727x221116743] [Reference Citation Analysis]
128 References. Eosinophil Ultrastructure 2022. [DOI: 10.1016/b978-0-12-813755-0.09990-1] [Reference Citation Analysis]
129 Venkatapurapu SP, Iwakiri R, Udagawa E, Patidar N, Qi Z, Takayama R, Kumar K, Sato Y, Behar M, Offner P, Dwivedi G, Miyasaka H, Suzuki RK, Hamada AL, D'Alessandro PM, Fernandez J. A Computational Platform Integrating a Mechanistic Model of Crohn's Disease for Predicting Temporal Progression of Mucosal Damage and Healing. Adv Ther 2022;39:3225-47. [PMID: 35581423 DOI: 10.1007/s12325-022-02144-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
130 Bisseling T, van der Marel S, Boleij A, Bruggeling C, van Meeteren MW. Maag-, darm- en leverziekten. Handboek leefstijlgeneeskunde 2022. [DOI: 10.1007/978-90-368-2761-4_7] [Reference Citation Analysis]
131 Lacerda DC, Trindade da Costa PC, Paulino do Nascimento LC, de Brito Alves JL. Probiotics for gastrointestinal health and disease treatment. Probiotics for Human Nutrition in Health and Disease 2022. [DOI: 10.1016/b978-0-323-89908-6.00022-4] [Reference Citation Analysis]
132 Ali SI, Rather MA, Sheikh WM, Nabi SU, Ganai A, Altaf M, Nath S, Ahmad SB, Wani IA, Bashir SM. Immunopharmaco-genomics: future of clinical medicine. A Molecular Approach to Immunogenetics 2022. [DOI: 10.1016/b978-0-323-90053-9.00007-5] [Reference Citation Analysis]
133 Bashir H, Bhat MH, Ali S, Pir NA, Nazki FIA, Majid S. Therapeutic approaches of immunogenetic molecules in inflammatory bowel disease management. Clinical Applications of Immunogenetics 2022. [DOI: 10.1016/b978-0-323-90250-2.00016-9] [Reference Citation Analysis]
134 Melo RC, Dvorak AM, Weller PF. Eosinophil-associated diseases (EADs). Eosinophil Ultrastructure 2022. [DOI: 10.1016/b978-0-12-813755-0.00008-3] [Reference Citation Analysis]
135 Li M, Weigmann B. A Novel Pathway of Flavonoids Protecting against Inflammatory Bowel Disease: Modulating Enteroendocrine System. Metabolites 2022;12:31. [PMID: 35050153 DOI: 10.3390/metabo12010031] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
136 Bao S, Li J, Cui C, Tang Y, Deng R, Remedios LW, Lee HH, Chiron S, Patterson NH, Lau KS, Coburn LA, Wilson KT, Roland JT, Landman BA, Liu Q, Huo Y. MxIF Q-score: Biology-Informed Quality Assurance for Multiplexed Immunofluorescence Imaging. Lecture Notes in Computer Science 2022. [DOI: 10.1007/978-3-031-16961-8_5] [Reference Citation Analysis]
137 Smith RK, Holubar SD. Medical Therapy for Crohn’s Disease. The ASCRS Textbook of Colon and Rectal Surgery 2022. [DOI: 10.1007/978-3-030-66049-9_46] [Reference Citation Analysis]
138 Catalán-serra I, Ricanek P, Grimstad T. "Out of the box� new therapeutic strategies for Crohn�s disease: moving beyond biologics. Rev Esp Enferm Dig 2022. [DOI: 10.17235/reed.2022.9010/2022] [Reference Citation Analysis]
139 Qi Y, Wu HM, Yang Z, Zhou YF, Jin L, Yang MF, Wang FY. New Insights into the Role of Oral Microbiota Dysbiosis in the Pathogenesis of Inflammatory Bowel Disease. Dig Dis Sci 2022;67:42-55. [PMID: 33527328 DOI: 10.1007/s10620-021-06837-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
140 Zou M, Zeng QS, Nie J, Yang JH, Luo ZY, Gan HT. The Role of E3 Ubiquitin Ligases and Deubiquitinases in Inflammatory Bowel Disease: Friend or Foe? Front Immunol 2021;12:769167. [PMID: 34956195 DOI: 10.3389/fimmu.2021.769167] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
141 Antoniussen CS, Rasmussen HH, Holst M, Lauridsen C. Reducing Disease Activity of Inflammatory Bowel Disease by Consumption of Plant-Based Foods and Nutrients. Front Nutr 2021;8:733433. [PMID: 34957174 DOI: 10.3389/fnut.2021.733433] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
142 Kumric M, Zivkovic PM, Ticinovic Kurir T, Vrdoljak J, Vilovic M, Martinovic D, Bratanic A, Lizatovic IK, Bozic J. Role of B-Cell Activating Factor (BAFF) in Inflammatory Bowel Disease. Diagnostics 2022;12:45. [DOI: 10.3390/diagnostics12010045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
143 Al-Zahrani MS, Alhassani AA, Zawawi KH. Clinical manifestations of gastrointestinal diseases in the oral cavity. Saudi Dent J 2021;33:835-41. [PMID: 34938023 DOI: 10.1016/j.sdentj.2021.09.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
144 Baban YN, Edicheria CM, Joseph J, Kaur P, Mostafa JA. Osteoporosis Complications in Crohn's Disease Patients: Factors, Pathogenesis, and Treatment Outlines. Cureus 2021. [DOI: 10.7759/cureus.20564] [Reference Citation Analysis]
145 Willis D, Cameron D, Kasmai B, Vassiliou VS, Malcolm PN, Baio G. A novel method for measuring bowel motility and velocity with dynamic magnetic resonance imaging in two and three dimensions. NMR Biomed 2021;:e4663. [PMID: 34913200 DOI: 10.1002/nbm.4663] [Reference Citation Analysis]
146 Golusda L, Kühl AA, Siegmund B, Paclik D. Reducing Pain in Experimental Models of Intestinal Inflammation Affects the Immune Response. Inflamm Bowel Dis 2022;28:801-7. [PMID: 34871378 DOI: 10.1093/ibd/izab290] [Reference Citation Analysis]
147 Xia B, Yang M, Nguyen LH, He Q, Zhen J, Yu Y, Di M, Qin X, Lu K, Kuo ZC, He Y, Zhang C, Meng W, Yuan J. Regular Use of Proton Pump Inhibitor and the Risk of Inflammatory Bowel Disease: Pooled Analysis of 3 Prospective Cohorts. Gastroenterology 2021;161:1842-1852.e10. [PMID: 34389338 DOI: 10.1053/j.gastro.2021.08.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
148 Snyder EF, Davis S, Aldrich K, Veerabagu M, Larussa T, Abenavoli L, Boccuto L. Crohn disease: Identification, diagnosis, and clinical management. Nurse Pract 2021;46:22-30. [PMID: 34808643 DOI: 10.1097/01.NPR.0000798212.61425.4f] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
149 Han H, Kim S, Shin J, Lee H, Chung K, Rhee YK, Cho C, Hong H, Lee K. Polysaccharide fraction isolated from the leaves of Hordeum vulgare L. protects against colonic inflammation of systemic immune responses. Journal of Functional Foods 2021;87:104765. [DOI: 10.1016/j.jff.2021.104765] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
150 Kim MS, Kim YD, Kang S, Kwon O, Shin J, Kim JY. Cinnamon(Cinnamomum japonicum) subcritical water extract suppresses gut damage induced by dextran sodium sulfate in mouse colitis model. Journal of Functional Foods 2021;87:104775. [DOI: 10.1016/j.jff.2021.104775] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
151 Stiegeler S, Mercurio K, Iancu MA, Corr SC. The Impact of MicroRNAs during Inflammatory Bowel Disease: Effects on the Mucus Layer and Intercellular Junctions for Gut Permeability. Cells 2021;10:3358. [PMID: 34943865 DOI: 10.3390/cells10123358] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
152 Kurnik-Łucka M, Pasieka P, Łączak P, Wojnarski M, Jurczyk M, Gil K. Gastrointestinal Dopamine in Inflammatory Bowel Diseases: A Systematic Review. Int J Mol Sci 2021;22:12932. [PMID: 34884737 DOI: 10.3390/ijms222312932] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
153 Rubbino F, Greco L, di Cristofaro A, Gaiani F, Vetrano S, Laghi L, Bonovas S, Piovani D. Journey through Crohn's Disease Complication: From Fistula Formation to Future Therapies. J Clin Med 2021;10:5548. [PMID: 34884247 DOI: 10.3390/jcm10235548] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
154 Damasceno ROS, Soares PMG, Barbosa ALR, Nicolau LAD, Medeiros JR, Souza MHLP. MODULATORY ROLE OF CARBON MONOXIDE ON THE INFLAMMATORY RESPONSE AND OXIDATIVE STRESS LINKED TO GASTROINTESTINAL DISORDERS. Antioxid Redox Signal 2021. [PMID: 34806398 DOI: 10.1089/ars.2020.8223] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
155 Shaler CR, Parco AA, Elhenawy W, Dourka J, Jury J, Verdu EF, Coombes BK. Psychological stress impairs IL22-driven protective gut mucosal immunity against colonising pathobionts. Nat Commun 2021;12:6664. [PMID: 34795263 DOI: 10.1038/s41467-021-26992-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
156 Li L, Cheng L, Li Z, Li C, Hong Y, Gu Z. Butyrylated starch protects mice from DSS-induced colitis: combined effects of butyrate release and prebiotic supply. Food Funct 2021;12:11290-302. [PMID: 34635904 DOI: 10.1039/d1fo01913a] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
157 Nayar S, Cho JH. From single-target to cellular niche targeting in Crohn's disease: intercepting bad communications. EBioMedicine 2021;74:103690. [PMID: 34773892 DOI: 10.1016/j.ebiom.2021.103690] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
158 Zhang CB, Tang J, Wang XD, Lyu KS, Huang M, Gao X. Multi-alleles predict primary non-response to infliximab therapy in Crohn's disease. Gastroenterol Rep (Oxf) 2021;9:427-34. [PMID: 34733528 DOI: 10.1093/gastro/goaa070] [Reference Citation Analysis]
159 Mansour HH, Alajerami YS, Najim AA, Abushab KM. Computed Tomography Enterography Demonstrates Association to Histopathological Grading of Small Bowel Crohn’s Activity. ELECTRON J GEN MED 2021;18:em330. [DOI: 10.29333/ejgm/11317] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
160 Gaowa A, Park EJ, Kawamoto E, Qin Y, Shimaoka M. Recombinant soluble thrombomodulin accelerates epithelial stem cell proliferation in mouse intestinal organoids and promotes the mucosal healing in colitis. J Gastroenterol Hepatol 2021;36:3149-57. [PMID: 34370890 DOI: 10.1111/jgh.15656] [Reference Citation Analysis]
161 Lee SH, Turpin W, Espin-Garcia O, Raygoza Garay JA, Smith MI, Leibovitzh H, Goethel A, Turner D, Mack D, Deslandres C, Cino M, Aumais G, Panaccione R, Jacobson K, Bitton A, Steinhart AH, Huynh HQ, Princen F, Moayyedi P, Griffiths AM, Silverberg MS, Paterson AD, Xu W, Croitoru K; Crohn’s and Colitis Canada Genetics Environment Microbial Project Research Consortium. Anti-Microbial Antibody Response is Associated With Future Onset of Crohn's Disease Independent of Biomarkers of Altered Gut Barrier Function, Subclinical Inflammation, and Genetic Risk. Gastroenterology 2021;161:1540-51. [PMID: 34293299 DOI: 10.1053/j.gastro.2021.07.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
162 Hyun HK, Yu J, Kang EA, Park J, Park SJ, Park JJ, Kim TI, Kim WH, Cheon JH. Radiology plus ileocolonoscopy versus radiology alone in Crohn's disease: prognosis prediction and mutual agreement. Korean J Intern Med 2021. [PMID: 34695881 DOI: 10.3904/kjim.2021.233] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
163 Włodarczyk M, Czerwińska K, Włodarczyk J, Fichna J, Dziki A, Dziki Ł. Current Overview on the Use of Mesenchymal Stem Cells for Perianal Fistula Treatment in Patients with Crohn's Disease. Life (Basel) 2021;11:1133. [PMID: 34833009 DOI: 10.3390/life11111133] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
164 Kargarpour Z, Nasirzade J, Panahipour L, Miron RJ, Gruber R. Platelet-Rich Fibrin Decreases the Inflammatory Response of Mesenchymal Cells. Int J Mol Sci 2021;22:11333. [PMID: 34768764 DOI: 10.3390/ijms222111333] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
165 Bali A, Rani M. Recent Advances in Diagnosis and Management of Crohn’s Disease. Crohn’s Disease Recent Advances 2021. [DOI: 10.5772/intechopen.97693] [Reference Citation Analysis]
166 Kameli N, Becker HEF, Welbers T, Jonkers DMAE, Penders J, Savelkoul P, Stassen FR. Metagenomic Profiling of Fecal-Derived Bacterial Membrane Vesicles in Crohn's Disease Patients. Cells 2021;10:2795. [PMID: 34685776 DOI: 10.3390/cells10102795] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
167 Crain MA, Kupec JT. Superimposed Infectious Colitis in Crohn's Disease. Case Rep Gastroenterol 2021;15:475-7. [PMID: 34616242 DOI: 10.1159/000513976] [Reference Citation Analysis]
168 Balart MT, Russell L, Narula N, Bajaj G, Chauhan U, Khan KJ, Marwaha AN, Ching E, Biro J, Halder S, Tse F, Marshall JK, Collins SM, Moayyedi P, Bercik P, Verdu EF, Leontiadis GI, Armstrong D, Pinto-Sanchez MI. Declining Use of Corticosteroids for Crohn's Disease Has Implications for Study Recruitment: Results of a Pilot Randomized Controlled Trial. J Can Assoc Gastroenterol 2021;4:214-21. [PMID: 34617003 DOI: 10.1093/jcag/gwaa037] [Reference Citation Analysis]
169 Verdalle-Cazes M, Charpentier C, Benard C, Joly LM, Dacher JN, Savoye G, Savoye-Collet C. Abdominopelvic CT-scan in emergency departments for patients with suspected complications of Crohn's disease: a single tertiary center experience. BMC Emerg Med 2021;21:113. [PMID: 34620106 DOI: 10.1186/s12873-021-00512-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
170 Narula N, Wong ECL, Dulai PS, Marshall JK, Colombel JF, Reinisch W. Outcomes of Passable and Non-passable Strictures in Clinical Trials of Crohn's Disease: A Post-hoc Analysis. J Crohns Colitis 2021;15:1649-57. [PMID: 33693522 DOI: 10.1093/ecco-jcc/jjab045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
171 Zhang C, Yu D, Hong L, Zhang T, Liu H, Fan R, Wang L, Zhong J, Wang Z. Prevalence of Sarcopenia and Its Effect on Postoperative Complications in Patients with Crohn's Disease. Gastroenterol Res Pract 2021;2021:3267201. [PMID: 34608386 DOI: 10.1155/2021/3267201] [Reference Citation Analysis]
172 Takenaka K, Kawamoto A, Hibiya S, Suzuki K, Fujii T, Motobayashi M, Shimizu H, Nagahori M, Saito E, Okamoto R, Watanabe M, Ohtsuka K. Higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease. Aliment Pharmacol Ther 2021;54:1052-60. [PMID: 34323301 DOI: 10.1111/apt.16551] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
173 Teeple A, Sah J, Mallampati R, Adams C, Waters D, Muser E. Persistence, Dosing, and Other Treatment Patterns Among Crohn’s Disease Patients Initiating Biologics in United States. Crohn's & Colitis 360 2021;3. [DOI: 10.1093/crocol/otab076] [Reference Citation Analysis]
174 Oyama T, Ishida S, Maeyama K, Miyagawa T, Imai Y. Liquid transport produced by a cluster of peristaltic contractions in a circular channel. Phys Rev Fluids 2021;6:093102. [DOI: 10.1103/physrevfluids.6.093102] [Reference Citation Analysis]
175 Kishimoto K, Nozaki Y, Sakurai T, Kinoshita K, Funauchi M, Matsumura I. Takayasu's Arteritis Diagnosed in an Adolescent Patient with Crohn's Disease: Management of Biologicals. Life (Basel) 2021;11:1019. [PMID: 34685390 DOI: 10.3390/life11101019] [Reference Citation Analysis]
176 Lin SN, Mao R, Qian C, Bettenworth D, Wang J, Li J, Bruining D, Jairath V, Feagan B, Chen M, Rieder F; Stenosis Therapy and Antifibrotic Research (STAR) Consortium. Development of Anti-fibrotic Therapy in Stricturing Crohn's Disease: Lessons from Randomized Trials in Other Fibrotic Diseases. Physiol Rev 2021. [PMID: 34569264 DOI: 10.1152/physrev.00005.2021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
177 Kelm M, Germer CT, Schlegel N, Flemming S. The Revival of Surgery in Crohn's Disease-Early Intestinal Resection as a Reasonable Alternative in Localized Ileitis. Biomedicines 2021;9:1317. [PMID: 34680434 DOI: 10.3390/biomedicines9101317] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
178 Pagnini C, Cominelli F. Tumor Necrosis Factor's Pathway in Crohn's Disease: Potential for Intervention. Int J Mol Sci 2021;22:10273. [PMID: 34638616 DOI: 10.3390/ijms221910273] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
179 Zheng HB, Doran BA, Kimler K, Yu A, Tkachev V, Niederlova V, Cribbin K, Fleming R, Bratrude B, Betz K, Cagnin L, Mcguckin C, Keskula P, Albanese A, Sacta M, de Sousa Casal J, Taliaferro F, Ford M, Ambartsumyan L, Suskind DL, Lee D, Deutsch G, Deng X, Collen LV, Mitsialis V, Snapper SB, Wahbeh G, Shalek AK, Ordovas-montanes J, Kean LS. A Treatment-Naïve Cellular Atlas of Pediatric Crohn’s Disease Predicts Disease Severity and Therapeutic Response.. [DOI: 10.1101/2021.09.17.21263540] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
180 Bao S, Chiron S, Tang Y, Heiser CN, Southard-Smith AN, Lee HH, Ramirez MA, Huo Y, Washington MK, Scoville EA, Roland JT, Liu Q, Lau KS, Wilson KT, Coburn LA, Landman BA. A cross-platform informatics system for the Gut Cell Atlas: integrating clinical, anatomical and histological data. Proc SPIE Int Soc Opt Eng 2021;11601:1160106. [PMID: 34539029 DOI: 10.1117/12.2581074] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
181 Kamel S, Sakr M, Hamed W, Eltabbakh M, Sherief A, Rashad H, Elghamrini Y, Elbaz A. Characterization of Crohn's disease patients in Egypt: Risk factors for postoperative recurrence (A cohort study). Ann Med Surg (Lond) 2021;69:102781. [PMID: 34527234 DOI: 10.1016/j.amsu.2021.102781] [Reference Citation Analysis]
182 Kim ES, Kim MJ. Upper gastrointestinal tract involvement of Crohn disease: clinical implications in children and adolescents. Clin Exp Pediatr 2022;65:21-8. [PMID: 34530520 DOI: 10.3345/cep.2021.00661] [Reference Citation Analysis]
183 Chen G, Pedarla V, Null KD, Cazzetta SE, Khan QR, Schwartz DA. Health Care Costs and Resource Utilization Among Patients With Crohn's Disease With and Without Perianal Fistula. Inflamm Bowel Dis 2022;28:870-7. [PMID: 34525184 DOI: 10.1093/ibd/izab198] [Reference Citation Analysis]
184 Linssen MD, Hooghiemstra WTR, Jorritsma-Smit A, Allersma DP, Dijkstra G, Nagengast WB. Development and Characterisation of Antibody-Based Optical Imaging Probes for Inflammatory Bowel Disease. Pharmaceuticals (Basel) 2021;14:922. [PMID: 34577622 DOI: 10.3390/ph14090922] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
185 Truyens M, De Ruyck E, Gonzales GB, Bos S, Laukens D, De Vos M. Prevalence of Fatigue and Unrecognized Depression in Patients with Inflammatory Bowel Disease in Remission under Immunosuppressants and Biologicals. J Clin Med 2021;10:4107. [PMID: 34575218 DOI: 10.3390/jcm10184107] [Reference Citation Analysis]
186 Kong Z, He M, Luo Q, Huang X, Wei P, Cheng Y, Chen L, Liang Y, Lu Y, Li X, Chen J. Multi-Task Classification and Segmentation for Explicable Capsule Endoscopy Diagnostics. Front Mol Biosci 2021;8:614277. [PMID: 34490342 DOI: 10.3389/fmolb.2021.614277] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
187 Garg R, Mohan BP, Ponnada S, Regueiro M, Lightner AL, Click B. Postoperative outcomes after preoperative ustekinumab exposure in patients with Crohn's disease: a systematic review and meta-analysis. Ann Gastroenterol 2021;34:691-8. [PMID: 34475740 DOI: 10.20524/aog.2021.0634] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
188 Sun L, Kong R, Li H, Wang D. The Role of T Follicular Helper Cells and Interleukin-21 in the Pathogenesis of Inflammatory Bowel Disease. Gastroenterol Res Pract 2021;2021:9621738. [PMID: 34471409 DOI: 10.1155/2021/9621738] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
189 Grażyńska A, Kufel J, Dudek A, Cebula M. Shear Wave and Strain Elastography in Crohn's Disease-A Systematic Review. Diagnostics (Basel) 2021;11:1609. [PMID: 34573952 DOI: 10.3390/diagnostics11091609] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
190 D'Haens GR, Reinisch W, Lee SD, Tarabar D, Louis E, Kłopocka M, Klaus J, Schreiber S, Il Park D, Hébuterne X, Nagy P, Cataldi F, Martin SW, Nayak S, Banerjee A, Gorelick KJ, Sandborn WJ. Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II Study. Inflamm Bowel Dis 2022;28:1034-44. [PMID: 34427633 DOI: 10.1093/ibd/izab215] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
191 Keshavarz Shahbaz S, Koushki K, Ayati SH, Bland AR, Bezsonov EE, Sahebkar A. Inflammasomes and Colorectal Cancer. Cells 2021;10:2172. [PMID: 34571825 DOI: 10.3390/cells10092172] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
192 Xiang XW, Wang R, Yao LW, Zhou YF, Sun PL, Zheng B, Chen YF. Anti-Inflammatory Effects of Mytilus coruscus Polysaccharide on RAW264.7 Cells and DSS-Induced Colitis in Mice. Mar Drugs 2021;19:468. [PMID: 34436307 DOI: 10.3390/md19080468] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
193 Wang R, Yao Q, Chen W, Gao F, Li P, Wu J, Yu J, Cao H. Stem cell therapy for Crohn's disease: systematic review and meta-analysis of preclinical and clinical studies. Stem Cell Res Ther 2021;12:463. [PMID: 34407875 DOI: 10.1186/s13287-021-02533-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
194 Vermeire S, D'Haens G, Baert F, Danese S, Kobayashi T, Loftus EV, Bhatia S, Agboton C, Rosario M, Chen C, Zhang W, Kisfalvi K, Sandborn WJ. Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial. J Crohns Colitis 2022;16:27-38. [PMID: 34402887 DOI: 10.1093/ecco-jcc/jjab133] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 8.5] [Reference Citation Analysis]
195 Gibiino G, Sartini A, Gitto S, Binda C, Sbrancia M, Coluccio C, Sambri V, Fabbri C. The Other Side of Malnutrition in Inflammatory Bowel Disease (IBD): Non-Alcoholic Fatty Liver Disease. Nutrients 2021;13:2772. [PMID: 34444932 DOI: 10.3390/nu13082772] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
196 Chewchuk S, Jahan S, Lohnes D. Cdx2 regulates immune cell infiltration in the intestine. Sci Rep 2021;11:15841. [PMID: 34349205 DOI: 10.1038/s41598-021-95412-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
197 Zhao J, Liao D, Wilkens R, Krogh K, Glerup H, Gregersen H. Bowel stiffness associated with histopathologic scoring of stenosis in patients with Crohn's disease. Acta Biomater 2021;130:332-42. [PMID: 34119715 DOI: 10.1016/j.actbio.2021.06.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
198 Gareb B, Beugeling M, Posthumus S, Otten AT, Dijkstra G, Kosterink JG, Frijlink HW. Infliximab formulation strategy for a stable ileo-colonic targeted oral dosage form intended for the topical treatment of inflammatory bowel disease. Journal of Drug Delivery Science and Technology 2021;64:102552. [DOI: 10.1016/j.jddst.2021.102552] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
199 Hartwig O, Shetab Boushehri MA, Shalaby KS, Loretz B, Lamprecht A, Lehr CM. Drug delivery to the inflamed intestinal mucosa - targeting technologies and human cell culture models for better therapies of IBD. Adv Drug Deliv Rev 2021;175:113828. [PMID: 34157320 DOI: 10.1016/j.addr.2021.113828] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
200 Miyazu T, Ishida N, Takano R, Tamura S, Yamade M, Hamaya Y, Tani S, Iwaizumi M, Osawa S, Furuta T, Sugimoto K. Usefulness of the capsule endoscopy Crohn's disease activity index in assessing the necessity of early additional treatment in patients with Crohn's disease in clinical remission. Medicine (Baltimore) 2021;100:e26550. [PMID: 34398010 DOI: 10.1097/MD.0000000000026550] [Reference Citation Analysis]
201 Mizushima T, Ota M, Fujitani Y, Kanauchi Y, Iwakiri R. Diagnostic Features of Perianal Fistula in Patients With Crohn’s Disease: Analysis of a Japanese Claims Database. Crohn's & Colitis 360 2021;3. [DOI: 10.1093/crocol/otab055] [Reference Citation Analysis]
202 Anyane-Yeboa A, Li B, Traboulsi C, Erondu AI, Sossenheimer P, Rai V, Rubin DT. Black Race and Public Insurance Are Predictive of Inappropriate Evaluation of Iron Deficiency Anemia and Diarrhea. Dig Dis Sci 2021;66:2200-6. [PMID: 32638203 DOI: 10.1007/s10620-020-06434-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
203 Teich N, Schulze H, Knop J, Obermeier M, Stallmach A. Novel Approaches Identifying Relevant Patient-Reported Outcomes in Patients With Inflammatory Bowel Diseases—LISTEN 1. Crohn's & Colitis 360 2021;3. [DOI: 10.1093/crocol/otab050] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
204 Haring E, Zeiser R, Apostolova P. Interfering With Inflammation: Heterogeneous Effects of Interferons in Graft-Versus-Host Disease of the Gastrointestinal Tract and Inflammatory Bowel Disease. Front Immunol 2021;12:705342. [PMID: 34249014 DOI: 10.3389/fimmu.2021.705342] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
205 Villumsen M, Schelde AB, Jimenez-Solem E, Jess T, Allin KH. GLP-1 based therapies and disease course of inflammatory bowel disease. EClinicalMedicine 2021;37:100979. [PMID: 34386751 DOI: 10.1016/j.eclinm.2021.100979] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
206 Nonnecke EB, Castillo PA, Dugan AE, Almalki F, Underwood MA, De La Motte CA, Yuan W, Lu W, Shen B, Johansson MEV, Kiessling LL, Hollox EJ, Lönnerdal B, Bevins CL. Human intelectin-1 (ITLN1) genetic variation and intestinal expression. Sci Rep 2021;11:12889. [PMID: 34145348 DOI: 10.1038/s41598-021-92198-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
207 Kurowski JA, Milinovich A, Ji X, Bauman J, Sugano D, Kattan MW, Achkar JP. Differences in Biologic Utilization and Surgery Rates in Pediatric and Adult Crohn's Disease: Results From a Large Electronic Medical Record-derived Cohort. Inflamm Bowel Dis 2021;27:1035-44. [PMID: 32914165 DOI: 10.1093/ibd/izaa239] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
208 Boucher G, Paradis A, Chabot-Roy G, Coderre L, Hillhouse EE, Bitton A, Des Rosiers C, Levings MK, Schumm LP, Lazarev M, Brant SR, Duerr R, McGovern D, Silverberg MS, Cho J, Lesage S, Rioux JD; iGenoMed Consortium, NIDDK IBD Genetics Consortium. Serum Analyte Profiles Associated With Crohn's Disease and Disease Location. Inflamm Bowel Dis 2022;28:9-20. [PMID: 34106269 DOI: 10.1093/ibd/izab123] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
209 Fokam Tagne MA, Tchoffo A, Noubissi PA, Mazo AG, Kom B, Ngakou Mukam J, Sokeng Dongmo S, Kamgang R. Effects of hydro-ethanolic extract of leaves of Maesa lanceolata (Mursinaceae) on acetic acid-induced ulcerative colitis in rats. Inflammopharmacology 2021;29:1211-23. [PMID: 34101116 DOI: 10.1007/s10787-021-00825-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
210 Becker HEF, Jamin C, Bervoets L, Boleij A, Xu P, Pierik MJ, Stassen FRM, Savelkoul PHM, Penders J, Jonkers DMAE. Higher Prevalence of Bacteroides fragilis in Crohn's Disease Exacerbations and Strain-Dependent Increase of Epithelial Resistance. Front Microbiol 2021;12:598232. [PMID: 34168621 DOI: 10.3389/fmicb.2021.598232] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
211 Qian K, Yuan L, Wang S, Kuang Y, Jin Q, Long D, Jiang Y, Zhao H, Liu K, Yao H. Inhibitor of apoptosis-stimulating p53 protein protects against inflammatory bowel disease in mice models by inhibiting the nuclear factor kappa B signaling. Clin Exp Immunol 2021;205:246-56. [PMID: 33942299 DOI: 10.1111/cei.13613] [Reference Citation Analysis]
212 Liebert A, Wileńska A, Czuber-Dochan W, Kłopocka M. Translation and validation of the inflammatory bowel disease fatigue (IBD-F) patient self-assessment questionnaire. Prz Gastroenterol 2021;6:136-43. [PMID: 34276841 DOI: 10.5114/pg.2021.106665] [Reference Citation Analysis]
213 Gencer S, Can M, Yüksel İ. Reelin levels in inflammatory bowel disease: A case-control study. Journal of Surgery and Medicine 2021;5:633-637. [DOI: 10.28982/josam.855197] [Reference Citation Analysis]
214 Forss A, Clements M, Myrelid P, Strid H, Söderman C, Wagner A, Andersson D, Hjelm F, Olén O, Ludvigsson JF, Halfvarson J; PROSE SWIBREG study group. Prospective observational study on Stelara (ustekinumab) assessing effectiveness in Crohn's disease (PROSE): a 16-week follow-up. Scand J Gastroenterol 2021;56:680-6. [PMID: 33794731 DOI: 10.1080/00365521.2021.1906946] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
215 Zhang J, Wang XJ, Wu LJ, Yang L, Yang YT, Zhang D, Hong J, Li XY, Dong XQ, Guo XC, Han R, Ma X. Herb-partitioned moxibustion alleviates colonic inflammation in Crohn's disease rats by inhibiting hyperactivation of the NLRP3 inflammasome via regulation of the P2X7R-Pannexin-1 signaling pathway. PLoS One 2021;16:e0252334. [PMID: 34043726 DOI: 10.1371/journal.pone.0252334] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
216 Louis E, Ramos-Goñi JM, Cuervo J, Kopylov U, Barreiro-de Acosta M, McCartney S, Rosenfeld G, Bettenworth D, Hart A, Novak K, Donnet X, Easton D, Saldaña R, Protze K, Tzur E, Alperovich G, Casellas F. A Qualitative Research for Defining Meaningful Attributes for the Treatment of Inflammatory Bowel Disease from the Patient Perspective. Patient 2020;13:317-25. [PMID: 31997116 DOI: 10.1007/s40271-019-00407-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
217 Yadav V, Mai Y, McCoubrey LE, Wada Y, Tomioka M, Kawata S, Charde S, Basit AW. 5-Aminolevulinic Acid as a Novel Therapeutic for Inflammatory Bowel Disease. Biomedicines 2021;9:578. [PMID: 34065300 DOI: 10.3390/biomedicines9050578] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
218 Chen G, Yang Z, Wen D, Guo J, Xiong Q, Li P, Zhao L, Wang J, Wu C, Dong L. Polydatin has anti-inflammatory and antioxidant effects in LPS-induced macrophages and improves DSS-induced mice colitis. Immun Inflamm Dis 2021;9:959-70. [PMID: 34010516 DOI: 10.1002/iid3.455] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
219 Wong ECL, Marshall JK, Reinisch W, Narula N. Body Mass Index Does Not Impact Clinical Efficacy of Ustekinumab in Crohn's Disease: A Post Hoc Analysis of the IM-UNITI Trial. Inflamm Bowel Dis 2021;27:848-54. [PMID: 32812022 DOI: 10.1093/ibd/izaa214] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
220 Nashiry MA, Sumi SS, Sharif Shohan MU, Alyami SA, Azad AKM, Moni MA. Bioinformatics and system biology approaches to identify the diseasome and comorbidities complexities of SARS-CoV-2 infection with the digestive tract disorders. Brief Bioinform 2021:bbab126. [PMID: 33993223 DOI: 10.1093/bib/bbab126] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
221 Rezazadeh Ardabili A, Goudkade D, Wintjens D, Romberg-Camps M, Winkens B, Pierik M, Grabsch HI, Jonkers D. Histopathological Features in Colonic Biopsies at Diagnosis Predict Long-term Disease Course in Patients with Crohn's Disease. J Crohns Colitis 2021;15:1885-97. [PMID: 33987670 DOI: 10.1093/ecco-jcc/jjab087] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
222 Belvedere A, Scoglio R, Viola A, Costantino G, Sitibondo A, Muscianisi M, Inferrera S, Alibrandi A, Fries W. A real world investigation on prevalence, clinical features, and therapy of inflammatory bowel disease in the city of Messina, Italy. Acta Biomed 2021;92:e2021161. [PMID: 33988169 DOI: 10.23750/abm.v92i2.9593] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
223 Cai C, Zhu S, Tong J, Wang T, Feng Q, Qiao Y, Shen J. Relating the transcriptome and microbiome by paired terminal ileal Crohn disease. iScience 2021;24:102516. [PMID: 34113837 DOI: 10.1016/j.isci.2021.102516] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
224 Kvivik I, Grimstad T, Jonsson G, Kvaløy JT, Omdal R. Anti-HMGB1 auto-Abs influence fatigue in patients with Crohn's disease. Innate Immun 2021;27:286-93. [PMID: 33940970 DOI: 10.1177/17534259211014252] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
225 Abdulla M, Chew TS. Molecular targets and the use of biologics in the management of small bowel fibrosis in inflammatory bowel disease. Curr Opin Gastroenterol 2021;37:275-83. [PMID: 33769380 DOI: 10.1097/MOG.0000000000000729] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
226 Fotis L, Kourti A, Prountzos S, Alexopoulou E, Papaevangelou V, Fessatou S. Takayasu arteritis in an adolescent with Crohn's disease. Rheumatol Int 2021. [PMID: 33907878 DOI: 10.1007/s00296-021-04869-5] [Reference Citation Analysis]
227 O’grady J, Shanahan F, Bronte F. Changing phenotype of inflammatory bowel disease and neglected metabolic health. Cogent Medicine 2021;8:1918318. [DOI: 10.1080/2331205x.2021.1918318] [Reference Citation Analysis]
228 Chi H, Wang D, Chen M, Lin J, Zhang S, Yu F, Zhou J, Zheng X, Zou Y. Shaoyao Decoction Inhibits Inflammation and Improves Intestinal Barrier Function in Mice With Dextran Sulfate Sodium-Induced Colitis. Front Pharmacol 2021;12:524287. [PMID: 33959000 DOI: 10.3389/fphar.2021.524287] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
229 Marafini I, Stolfi C, Troncone E, Lolli E, Onali S, Paoluzi OA, Fantini MC, Biancone L, Calabrese E, Di Grazia A, Monteleone I, Lenti MV, Di Sabatino A, Monteleone G. A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn's Disease: A Phase II, Open-Label Study. BioDrugs 2021;35:325-36. [PMID: 33871807 DOI: 10.1007/s40259-021-00482-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
230 Mikkelsen G, Lillebo B, Faxvaag A. Disease-associated reference intervals for twenty laboratory tests in patients with rheumatoid arthritis, Crohn's disease or ulcerative colitis. Pract Lab Med 2021;25:e00225. [PMID: 34095413 DOI: 10.1016/j.plabm.2021.e00225] [Reference Citation Analysis]
231 Honjo H, Watanabe T, Kamata K, Minaga K, Kudo M. RIPK2 as a New Therapeutic Target in Inflammatory Bowel Diseases. Front Pharmacol 2021;12:650403. [PMID: 33935757 DOI: 10.3389/fphar.2021.650403] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
232 Hanson ED, Bates LC, Bartlett DB, Campbell JP. Does exercise attenuate age- and disease-associated dysfunction in unconventional T cells? Shining a light on overlooked cells in exercise immunology. Eur J Appl Physiol 2021;121:1815-34. [PMID: 33822261 DOI: 10.1007/s00421-021-04679-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
233 Ratajczak AE, Szymczak-Tomczak A, Rychter AM, Zawada A, Dobrowolska A, Krela-Kaźmierczak I. Impact of Cigarette Smoking on the Risk of Osteoporosis in Inflammatory Bowel Diseases. J Clin Med 2021;10:1515. [PMID: 33916465 DOI: 10.3390/jcm10071515] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
234 Qiu XM, Jiang L. [New diagnostic classification of cheilitis and its clinical diagnostic pathway]. Hua Xi Kou Qiang Yi Xue Za Zhi 2021;39:238-44. [PMID: 33834683 DOI: 10.7518/hxkq.2021.02.019] [Reference Citation Analysis]
235 Bendix M, Dige A, Jørgensen SP, Dahlerup JF, Bibby BM, Deleuran B, Agnholt J. Seven Weeks of High-Dose Vitamin D Treatment Reduces the Need for Infliximab Dose-Escalation and Decreases Inflammatory Markers in Crohn's Disease during One-Year Follow-Up. Nutrients 2021;13:1083. [PMID: 33810258 DOI: 10.3390/nu13041083] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
236 Sheng X, Liu D, Gamage SK, Luo Y, Viennois E, Merlin D, Iyer SS. Point-of-Care Monitoring of Colitis Using Intestinal Alkaline Phosphatase in Inflammatory Bowel Disease. ACS Sens 2021;6:698-702. [PMID: 33635063 DOI: 10.1021/acssensors.0c02177] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
237 Lee SM, Lee KH, Park SY, Kim DH, Chung JO, Ju JK, Lee JH, Kim HS. Expression of Cyr61 is associated with clinical course in patients with Crohn's disease. BMC Gastroenterol 2021;21:129. [PMID: 33743589 DOI: 10.1186/s12876-021-01713-9] [Reference Citation Analysis]
238 Poyato-Borrego M, Segura-Egea JJ, Martín-González J, Jiménez-Sánchez MC, Cabanillas-Balsera D, Areal-Quecuty V, Segura-Sampedro JJ. Prevalence of endodontic infection in patients with Crohn´s disease and ulcerative colitis. Med Oral Patol Oral Cir Bucal 2021;26:e208-15. [PMID: 32851982 DOI: 10.4317/medoral.24135] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
239 Lo CH, Khalili H, Lochhead P, Song M, Lopes EW, Burke KE, Richter JM, Chan AT, Ananthakrishnan AN. Immune-mediated diseases and risk of Crohn's disease or ulcerative colitis: a prospective cohort study. Aliment Pharmacol Ther 2021;53:598-607. [PMID: 33280139 DOI: 10.1111/apt.16210] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
240 Manandhar I, Alimadadi A, Aryal S, Munroe PB, Joe B, Cheng X. Gut microbiome-based supervised machine learning for clinical diagnosis of inflammatory bowel diseases. Am J Physiol Gastrointest Liver Physiol 2021;320:G328-37. [PMID: 33439104 DOI: 10.1152/ajpgi.00360.2020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
241 Hu S, Png E, Gowans M, Ong DEH, de Sessions PF, Song J, Nagarajan N. Ectopic gut colonization: a metagenomic study of the oral and gut microbiome in Crohn's disease. Gut Pathog 2021;13:13. [PMID: 33632307 DOI: 10.1186/s13099-021-00409-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
242 Chen H, Yang H, Deng J, Fan D. Ginsenoside Rk3 Ameliorates Obesity-Induced Colitis by Regulating of Intestinal Flora and the TLR4/NF-κB Signaling Pathway in C57BL/6 Mice. J Agric Food Chem 2021;69:3082-93. [PMID: 33621094 DOI: 10.1021/acs.jafc.0c07805] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
243 Lee HS, Jeong GS. 6,7,4'-Trihydroxyflavanone Protects against Dextran Sulfate Sodium-Induced Colitis by Regulating the Activity of T Cells and Colon Cells In Vivo. Int J Mol Sci 2021;22:2083. [PMID: 33669855 DOI: 10.3390/ijms22042083] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
244 O'Connell L, Winter DC, Aherne CM. The Role of Organoids as a Novel Platform for Modeling of Inflammatory Bowel Disease. Front Pediatr 2021;9:624045. [PMID: 33681101 DOI: 10.3389/fped.2021.624045] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
245 Esse S, Mason KJ, Green AC, Warren RB. Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases: A Systematic Review and Meta-analysis. JAMA Dermatol 2020;156:787-94. [PMID: 32432649 DOI: 10.1001/jamadermatol.2020.1300] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
246 Bouland GA, Beulens JWJ, Nap J, van der Slik AR, Zaldumbide A, 't Hart LM, Slieker RC. CONQUER: an interactive toolbox to understand functional consequences of GWAS hits. NAR Genom Bioinform 2020;2:lqaa085. [PMID: 33575630 DOI: 10.1093/nargab/lqaa085] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
247 Xu P, Elizalde M, Masclee A, Pierik M, Jonkers D. Corticosteroid enhances epithelial barrier function in intestinal organoids derived from patients with Crohn's disease. J Mol Med (Berl) 2021;99:805-15. [PMID: 33575854 DOI: 10.1007/s00109-021-02045-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
248 Lee HS, Lobbestael E, Vermeire S, Sabino J, Cleynen I. Inflammatory bowel disease and Parkinson's disease: common pathophysiological links. Gut 2021;70:408-17. [PMID: 33067333 DOI: 10.1136/gutjnl-2020-322429] [Cited by in Crossref: 30] [Cited by in F6Publishing: 40] [Article Influence: 15.0] [Reference Citation Analysis]
249 Penna FGC, Rosa RM, Pereira FH, Cunha PFS, Sousa SCS, Ferrari TCA, Cara C, Ferrari MDLA. Combined evaluation of fecal calprotectin and C-reactive protein as a therapeutic target in the management of patients with Crohn's disease. Gastroenterología y Hepatología (English Edition) 2021;44:87-95. [DOI: 10.1016/j.gastre.2020.04.010] [Reference Citation Analysis]
250 Yang Y, Lv X, Zhan L, Chen L, Jin H, Tang X, Shi Q, Zou Q, Xiang J, Zhang W, Zeng Z, Jiang H, Lv X. Case Report: IL-21 and Bcl-6 Regulate the Proliferation and Secretion of Tfh and Tfr Cells in the Intestinal Germinal Center of Patients With Inflammatory Bowel Disease. Front Pharmacol 2020;11:587445. [PMID: 33584264 DOI: 10.3389/fphar.2020.587445] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
251 Yoo SW, Oh G, Ahn JC, Chung E. Non-Oncologic Applications of Nanomedicine-Based Phototherapy. Biomedicines 2021;9:113. [PMID: 33504015 DOI: 10.3390/biomedicines9020113] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
252 Valvano M, Magistroni M, Mancusi A, D'Ascenzo D, Longo S, Stefanelli G, Vernia F, Viscido A, Necozione S, Latella G. The Usefulness of Serum Vitamin D Levels in the Assessment of IBD Activity and Response to Biologics. Nutrients 2021;13:323. [PMID: 33499406 DOI: 10.3390/nu13020323] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
253 Bianco C, Coluccio E, Prati D, Valenti L. Diagnosis and Management of Autoimmune Hemolytic Anemia in Patients with Liver and Bowel Disorders. J Clin Med 2021;10:423. [PMID: 33499290 DOI: 10.3390/jcm10030423] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
254 de Carvalho LGF, Lima WG, Coelho LGV, Cardoso VN, Fernandes SOA. Circulating Leptin Levels as a Potential Biomarker in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Inflamm Bowel Dis 2021;27:169-81. [PMID: 32095814 DOI: 10.1093/ibd/izaa037] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
255 Effenberger M, Reider S, Waschina S, Bronowski C, Enrich B, Adolph TE, Koch R, Moschen AR, Rosenstiel P, Aden K, Tilg H. Microbial Butyrate Synthesis Indicates Therapeutic Efficacy of Azathioprine in IBD Patients. J Crohns Colitis 2021;15:88-98. [PMID: 32687146 DOI: 10.1093/ecco-jcc/jjaa152] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 11.0] [Reference Citation Analysis]
256 Xue G, Hua L, Zhou N, Li J. Characteristics of immune cell infiltration and associated diagnostic biomarkers in ulcerative colitis: results from bioinformatics analysis. Bioengineered 2021;12:252-65. [PMID: 33323040 DOI: 10.1080/21655979.2020.1863016] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
257 Andersen V, Pedersen AK, Möller S, Green A. Chronic Inflammatory Diseases - Diabetes Mellitus, Rheumatoid Arthritis, Coeliac Disease, Crohn's Disease, and Ulcerative Colitis Among the Offspring of Affected Parents: A Danish Population-Based Registry Study. Clin Epidemiol 2021;13:13-20. [PMID: 33442298 DOI: 10.2147/CLEP.S286623] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
258 Wittmann Dayagi T, Werner L, Pinsker M, Salamon N, Barschak I, Weiss B, Shouval DS. Mucosal IL-10 and IL-10 receptor expression patterns in paediatric patients with ulcerative colitis. Int J Exp Pathol 2021;102:4-10. [PMID: 33405352 DOI: 10.1111/iep.12382] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
259 Wartak A, Garber JG, Yuan Q, Shreffler WG, Hesterberg PE, Katz AJ, Osman H, Leung HM, Gao A, Otuya DO, Grant C, Gardecki JA, Nishioka N, Tearney GJ, Apiou-sbirlea G. In vivo optical endomicroscopy: two decades of translational research towards next generation diagnosis of eosinophilic esophagitis. transl med commun 2021;6. [DOI: 10.1186/s41231-020-00080-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
260 Słowińska-Solnica K, Pawlica-Gosiewska D, Gawlik K, Owczarek D, Cibor D, Pocztar H, Mach T, Solnica B. Serum inflammatory markers in the diagnosis and assessment of Crohn's disease activity. Arch Med Sci 2021;17:252-7. [PMID: 33488879 DOI: 10.5114/aoms/130842] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
261 Nemade SV, Shinde KJ. Crohn’s Disease. Granulomatous diseases in Otorhinolaryngology, Head and Neck 2021. [DOI: 10.1007/978-981-16-4047-6_23] [Reference Citation Analysis]
262 Iqbal P, Khaliq R, Sheergojri AR. Mathematical Approach in Colitis-Related Colon Cancer Genomics. Diagnostic and Treatment Methods for Ulcerative Colitis and Colitis-Associated Cancer 2021. [DOI: 10.4018/978-1-7998-3580-6.ch008] [Reference Citation Analysis]
263 Amirzade-iranaq MH, Boojar FMA. Systemic Diseases with Oral Manifestations. Innovative Perspectives in Oral and Maxillofacial Surgery 2021. [DOI: 10.1007/978-3-030-75750-2_42] [Reference Citation Analysis]
264 Lo CH, Khalili H, Song M, Lochhead P, Burke KE, Richter JM, Giovannucci EL, Chan AT, Ananthakrishnan AN. Healthy Lifestyle Is Associated With Reduced Mortality in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2021;19:87-95.e4. [PMID: 32142939 DOI: 10.1016/j.cgh.2020.02.047] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 15.5] [Reference Citation Analysis]
265 Collyer R, Clancy A, Agrawal G, Borody TJ. Crohn’s strictures open with anti-mycobacterial antibiotic therapy: A retrospective review. World J Gastrointest Endosc 2020; 12(12): 542-554 [PMID: 33362907 DOI: 10.4253/wjge.v12.i12.542] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
266 Tamura S, Ishida N, Miyazu T, Onoue S, Tani S, Yamade M, Hamaya Y, Iwaizumi M, Osawa S, Furuta T, Sugimoto K. Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation. Sci Rep 2020;10:21353. [PMID: 33288852 DOI: 10.1038/s41598-020-78603-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
267 Sugimoto K, Ikeya K, Bamba S, Andoh A, Yamasaki H, Mitsuyama K, Nasuno M, Tanaka H, Matsuura A, Kato M, Ishida N, Tamura S, Takano R, Tani S, Osawa S, Nishihira J, Hanai H. Highly Bioavailable Curcumin Derivative Ameliorates Crohn's Disease Symptoms: A Randomized, Double-Blind, Multicenter Study. J Crohns Colitis 2020;14:1693-701. [PMID: 32412598 DOI: 10.1093/ecco-jcc/jjaa097] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
268 El-Matary W, Carroll MW, Debruyn JC, Huynh H, Wine E, Lawrence S, Chandrakumar A, Morel T, Jacobson K. Discontinuation of Immunosuppressive Medications in Children With Inflammatory Bowel Disease on Combination Therapy. J Pediatr Gastroenterol Nutr 2020;71:740-3. [PMID: 32740529 DOI: 10.1097/MPG.0000000000002857] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
269 Bendix M, Dige A, Jørgensen SP, Dahlerup JF, Bibby BM, Deleuran B, Agnholt J. Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn's Disease Patients Treated with High-Dose Vitamin Alone or Combined with Infliximab. Nutrients 2020;12:E3699. [PMID: 33266022 DOI: 10.3390/nu12123699] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
270 Sankarasubramanian J, Ahmad R, Avuthu N, Singh AB, Guda C. Gut Microbiota and Metabolic Specificity in Ulcerative Colitis and Crohn's Disease. Front Med (Lausanne) 2020;7:606298. [PMID: 33330572 DOI: 10.3389/fmed.2020.606298] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
271 Bernasconi R, Favara N, Fouladvari N, Invernizzi M, Levi M, Pane S, Magagnin L. Nanostructured polypyrrole layers implementation on magnetically navigable 3D printed microdevices for targeted gastrointestinal drug delivery. Multifunct Mater 2020;3:045003. [DOI: 10.1088/2399-7532/abc735] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
272 Shi JH, Luo L, Chen XL, Pan YP, Zhang Z, Fang H, Chen Y, Chen WD, Cao Q. Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn’s disease in China. World J Gastroenterol 2020; 26(41): 6455-6474 [PMID: 33244205 DOI: 10.3748/wjg.v26.i41.6455] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
273 Pan J, Fu D, Li Y, Wang Y, Lian G, Liu X. Body weight, serum albumin and food intolerance were linked to upper gastrointestinal Crohn's disease: a 7-year retrospective analysis. Ann Transl Med 2020;8:1370. [PMID: 33313115 DOI: 10.21037/atm-20-2212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
274 Chen M, Zhu H, Mao YJ, Cao N, Yu YL, Li LY, Zhao Q, Wu M, Ye M. Regulation of IL12B Expression in Human Macrophages by TALEN-mediated Epigenome Editing. Curr Med Sci 2020;40:900-9. [PMID: 33123904 DOI: 10.1007/s11596-020-2249-2] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
275 Ruiz MA, Junior RLK, Piron-Ruiz L, Saran PS, Castiglioni L, Quadros LG, Pinho TS, Burt RK. Medical, ethical, and legal aspects of hematopoietic stem cell transplantation for Crohn’s disease in Brazil. World J Stem Cells 2020; 12(10): 1113-1123 [PMID: 33178395 DOI: 10.4252/wjsc.v12.i10.1113] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
276 Mishra R, Dhawan P, Srivastava AS, Singh AB. Inflammatory bowel disease: Therapeutic limitations and prospective of the stem cell therapy. World J Stem Cells 2020; 12(10): 1050-1066 [PMID: 33178391 DOI: 10.4252/wjsc.v12.i10.1050] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
277 Bakhshi Z, Yadav S, Salonen BR, Bonnes SL, Varayil JE, Harmsen WS, Hurt RT, Tremaine WJ, Loftus EV Jr. Incidence and Outcomes of Home Parenteral Nutrition in Patients With Crohn Disease in Olmsted County, Minnesota. Crohns Colitis 360 2020;2:otaa083. [PMID: 34142084 DOI: 10.1093/crocol/otaa083] [Reference Citation Analysis]
278 De Vries LCS, Ghiboub M, van Hamersveld PHP, Welting O, Verseijden C, Bell MJ, Rioja I, Prinjha RK, Koelink PJ, Strobl B, Müller M, D'Haens GR, Wildenberg ME, De Jonge WJ. Tyrosine Kinase 2 Signalling Drives Pathogenic T cells in Colitis. J Crohns Colitis 2021;15:617-30. [PMID: 33005945 DOI: 10.1093/ecco-jcc/jjaa199] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
279 Ruder B, Becker C. At the Forefront of the Mucosal Barrier: The Role of Macrophages in the Intestine. Cells 2020;9:E2162. [PMID: 32987848 DOI: 10.3390/cells9102162] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
280 Rehman M, Cancarevic I, Iskander B, Lalani S, Malik BH. Biologics Targeting in the Treatment of Inflammatory Bowel Disease: A Conundrum. Cureus 2020;12:e10621. [PMID: 33123434 DOI: 10.7759/cureus.10621] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
281 Ananthakrishnan AN. Microbiome-Based Biomarkers for IBD. Inflamm Bowel Dis 2020;26:1463-9. [PMID: 32311010 DOI: 10.1093/ibd/izaa071] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
282 Irving P, Barrett K, Tang D, Nijher M, de Lusignan S. Common infections, mental health problems and healthcare use in people with inflammatory bowel disease: a cohort study protocol. Evid Based Ment Health 2021;24:82-7. [PMID: 32943436 DOI: 10.1136/ebmental-2020-300167] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
283 Duan Y, Liu Y, Li Y. Previous Intestinal Resection Is Associated with Postoperative Complications in Crohn's Disease: A Cohort Study. Gastroenterol Res Pract. 2020;2020:2194382. [PMID: 33014037 DOI: 10.1155/2020/2194382] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
284 Kono T, Fichera A. Surgical Treatment for Crohn's Disease: A Role of Kono-S Anastomosis in the West. Clin Colon Rectal Surg 2020;33:335-43. [PMID: 33162837 DOI: 10.1055/s-0040-1714236] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
285 Ng CH, Chin YH, Lin SY, Koh JWH, Lieske B, Koh FH, Chong CS, Foo FJ. Kono-S anastomosis for Crohn's disease: a systemic review, meta-analysis, and meta-regression. Surg Today 2021;51:493-501. [PMID: 32894346 DOI: 10.1007/s00595-020-02130-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
286 Vardi I, Chermesh I, Werner L, Barel O, Freund T, McCourt C, Fisher Y, Pinsker M, Javasky E, Weiss B, Rechavi G, Hagin D, Snapper SB, Somech R, Konnikova L, Shouval DS. Monogenic Inflammatory Bowel Disease: It's Never Too Late to Make a Diagnosis. Front Immunol 2020;11:1775. [PMID: 33013830 DOI: 10.3389/fimmu.2020.01775] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
287 Lo CH, Lochhead P, Khalili H, Song M, Tabung FK, Burke KE, Richter JM, Giovannucci EL, Chan AT, Ananthakrishnan AN. Dietary Inflammatory Potential and Risk of Crohn's Disease and Ulcerative Colitis. Gastroenterology 2020;159:873-883.e1. [PMID: 32389666 DOI: 10.1053/j.gastro.2020.05.011] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 18.3] [Reference Citation Analysis]
288 Reif S, Elbaum-Shiff Y, Koroukhov N, Shilo I, Musseri M, Golan-Gerstl R. Cow and Human Milk-Derived Exosomes Ameliorate Colitis in DSS Murine Model. Nutrients 2020;12:E2589. [PMID: 32858892 DOI: 10.3390/nu12092589] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 10.0] [Reference Citation Analysis]
289 Arai K, Kunisaki R, Kakuta F, Hagiwara SI, Murakoshi T, Yanagi T, Shimizu T, Kato S, Ishige T, Aomatsu T, Inoue M, Saito T, Iwama I, Kawashima H, Kumagai H, Tajiri H, Iwata N, Mochizuki T, Noguchi A, Kashiwabara T, Shimizu H, Suzuki Y, Hirano Y, Fujiwara T. Phenotypic characteristics of pediatric inflammatory bowel disease in Japan: results from a multicenter registry. Intest Res 2020;18:412-20. [PMID: 32806870 DOI: 10.5217/ir.2019.00130] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
290 Guo D, Yang J, Ling F, Tu L, Li J, Chen Y, Zou K, Zhu L, Hou X. Elemental Diet Enriched with Amino Acids Alleviates Mucosal Inflammatory Response and Prevents Colonic Epithelial Barrier Dysfunction in Mice with DSS-Induced Chronic Colitis. J Immunol Res 2020;2020:9430763. [PMID: 32855978 DOI: 10.1155/2020/9430763] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
291 Labarile N, Ghosh S, Ng SC, Walters J, Iacucci M. Tests that now deserve to be more widely adopted in IBD clinical practice. Therap Adv Gastroenterol 2020;13:1756284820944088. [PMID: 32782481 DOI: 10.1177/1756284820944088] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
292 Wu X, Jiang J, Gu Z, Zhang J, Chen Y, Liu X. Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress. Stem Cell Res Ther 2020;11:345. [PMID: 32771052 DOI: 10.1186/s13287-020-01855-9] [Cited by in Crossref: 67] [Cited by in F6Publishing: 74] [Article Influence: 22.3] [Reference Citation Analysis]
293 Candia R, Bravo-Soto GA, Monrroy H, Hernandez C, Nguyen GC. Colonoscopy-guided therapy for the prevention of post-operative recurrence of Crohn's disease. Cochrane Database Syst Rev 2020;8:CD012328. [PMID: 32746500 DOI: 10.1002/14651858.CD012328.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
294 Bahrami G, Malekshahi H, Miraghaee S, Madani H, Babaei A, Mohammadi B, Hatami R. Protective and Therapeutic Effects of Aloe Vera Gel on Ulcerative Colitis Induced by Acetic Acid in Rats. Clin Nutr Res 2020;9:223-34. [PMID: 32789152 DOI: 10.7762/cnr.2020.9.3.223] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
295 Malesza IJ, Malesza M, Krela-Kaźmierczak I, Zielińska A, Souto EB, Dobrowolska A, Eder P. Primary Humoral Immune Deficiencies: Overlooked Mimickers of Chronic Immune-Mediated Gastrointestinal Diseases in Adults. Int J Mol Sci 2020;21:E5223. [PMID: 32718006 DOI: 10.3390/ijms21155223] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
296 Li H, Lyu W. Intestinal NK/T cell lymphoma: A case report. WJG 2020;26:3985-93. [DOI: 10.3748/wjg.v26.i27.3985] [Reference Citation Analysis]
297 Li H, Lyu W. Intestinal NK/T cell lymphoma: A case report. World J Gastroenterol 2020; 26(27): 3989-3997 [PMID: 32774072 DOI: 10.3748/wjg.v26.i27.3989] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
298 Duan L, Huang H, Zhao X, Zhou M, Chen S, Wang C, Han Z, Han ZC, Guo Z, Li Z, Cao X. Extracellular vesicles derived from human placental mesenchymal stem cells alleviate experimental colitis in mice by inhibiting inflammation and oxidative stress. Int J Mol Med 2020;46:1551-61. [PMID: 32945344 DOI: 10.3892/ijmm.2020.4679] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
299 Buttó LF, Pelletier A, More SK, Zhao N, Osme A, Hager CL, Ghannoum MA, Sekaly RP, Cominelli F, Dave M. Intestinal Stem Cell Niche Defects Result in Impaired 3D Organoid Formation in Mouse Models of Crohn's Disease-like Ileitis. Stem Cell Reports 2020;15:389-407. [PMID: 32679063 DOI: 10.1016/j.stemcr.2020.06.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
300 Hamminger P, Rica R, Ellmeier W. Histone deacetylases as targets in autoimmune and autoinflammatory diseases. Adv Immunol 2020;147:1-59. [PMID: 32981634 DOI: 10.1016/bs.ai.2020.06.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
301 Cruz-Lebrón A, D'argenio Garcia L, Talla A, Joussef-Piña S, Quiñones-Mateu ME, Sékaly RP, de Carvalho KIL, Levine AD. Decreased Enteric Bacterial Composition and Diversity in South American Crohn's Disease Vary With the Choice of Treatment Strategy and Time Since Diagnosis. J Crohns Colitis 2020;14:791-800. [PMID: 31758685 DOI: 10.1093/ecco-jcc/jjz189] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
302 Reinisch W, Gecse K, Halfvarson J, Irving PM, Jahnsen J, Peyrin-Biroulet L, Rogler G, Schreiber S, Danese S. Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease. Inflamm Bowel Dis 2021;27:106-22. [PMID: 32634212 DOI: 10.1093/ibd/izaa078] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
303 Shukla A, Surapaneni S, Sobel JD. Desquamative Inflammatory Vaginitis as an Extraintestinal Manifestation of Crohn’s Disease. Curr Infect Dis Rep 2020;22. [DOI: 10.1007/s11908-020-00733-y] [Reference Citation Analysis]
304 Salwen-deremer JK, Siegel CA, Smith MT. Cognitive Behavioral Therapy for Insomnia: A Promising Treatment for Insomnia, Pain, and Depression in Patients With IBD. Crohn's & Colitis 360 2020;2. [DOI: 10.1093/crocol/otaa052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
305 Bertani L, Fornai M, Fornili M, Antonioli L, Benvenuti L, Tapete G, Baiano Svizzero G, Ceccarelli L, Mumolo MG, Baglietto L, de Bortoli N, Bellini M, Marchi S, Costa F, Blandizzi C. Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab. Aliment Pharmacol Ther 2020;52:284-91. [PMID: 32506635 DOI: 10.1111/apt.15870] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
306 Huo JH, Wang XY, Gong L, Gu X. Role of regulatory B cells in autoimmune diseases of the digestive system. Shijie Huaren Xiaohua Zazhi 2020; 28(12): 486-492 [DOI: 10.11569/wcjd.v28.i12.486] [Reference Citation Analysis]
307 Dotimas J, Das M, Martin D. Cutaneous T-cell lymphoma in the setting of anti-tumor necrosis factor and immunomodulator therapy: A case report and literature review. SAGE Open Med Case Rep 2020;8:2050313X20937223. [PMID: 32655868 DOI: 10.1177/2050313X20937223] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
308 Principi M, Labarile N, Bianchi FP, Contaldo A, Tafuri S, Ierardi E, Di Leo A. The Cost of Inflammatory Bowel Disease Management Matches with Clinical Course: A Single Outpatient Centre Analysis. Int J Environ Res Public Health 2020;17:E4549. [PMID: 32599816 DOI: 10.3390/ijerph17124549] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
309 Zibandeh N, Genc D, Duran Y, Banzragch M, Sokwala S, Goker K, Atug O, Akkoç T. Human dental follicle mesenchymal stem cells alleviate T cell response in inflamed tissue of Crohn's patients. Turk J Gastroenterol 2020;31:400-9. [PMID: 32519960 DOI: 10.5152/tjg.2020.19358] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
310 Gareb B, Otten AT, Frijlink HW, Dijkstra G, Kosterink JGW. Review: Local Tumor Necrosis Factor-α Inhibition in Inflammatory Bowel Disease. Pharmaceutics 2020;12:E539. [PMID: 32545207 DOI: 10.3390/pharmaceutics12060539] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
311 Crowley E, Warner N, Pan J, Khalouei S, Elkadri A, Fiedler K, Foong J, Turinsky AL, Bronte-Tinkew D, Zhang S, Hu J, Tian D, Li D, Horowitz J, Siddiqui I, Upton J, Roifman CM, Church PC, Wall DA, Ramani AK, Kotlarz D, Klein C, Uhlig H, Snapper SB, Gonzaga-Jauregui C, Paterson AD, McGovern DPB, Brudno M, Walters TD, Griffiths AM, Muise AM. Prevalence and Clinical Features of Inflammatory Bowel Diseases Associated With Monogenic Variants, Identified by Whole-Exome Sequencing in 1000 Children at a Single Center. Gastroenterology 2020;158:2208-20. [PMID: 32084423 DOI: 10.1053/j.gastro.2020.02.023] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 15.0] [Reference Citation Analysis]
312 Papoutsopoulou S, Satsangi J, Campbell BJ, Probert CS. Review article: impact of cigarette smoking on intestinal inflammation-direct and indirect mechanisms. Aliment Pharmacol Ther 2020;51:1268-85. [PMID: 32372449 DOI: 10.1111/apt.15774] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 8.3] [Reference Citation Analysis]
313 von Martels JZH, Bourgonje AR, Klaassen MAY, Alkhalifah HAA, Sadaghian Sadabad M, Vich Vila A, Gacesa R, Gabriëls RY, Steinert RE, Jansen BH, Bulthuis MLC, van Dullemen HM, Visschedijk MC, Festen EAM, Weersma RK, de Vos P, van Goor H, Faber KN, Harmsen HJM, Dijkstra G. Riboflavin Supplementation in Patients with Crohn's Disease [the RISE-UP study]. J Crohns Colitis 2020;14:595-607. [PMID: 31873717 DOI: 10.1093/ecco-jcc/jjz208] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 11.7] [Reference Citation Analysis]
314 Besednova NN, Zaporozhets TS, Kuznetsova TA, Makarenkova ID, Kryzhanovsky SP, Fedyanina LN, Ermakova SP. Extracts and Marine Algae Polysaccharides in Therapy and Prevention of Inflammatory Diseases of the Intestine. Mar Drugs 2020;18:E289. [PMID: 32486405 DOI: 10.3390/md18060289] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
315 Decara J, Rivera P, López-Gambero AJ, Serrano A, Pavón FJ, Baixeras E, Rodríguez de Fonseca F, Suárez J. Peroxisome Proliferator-Activated Receptors: Experimental Targeting for the Treatment of Inflammatory Bowel Diseases. Front Pharmacol 2020;11:730. [PMID: 32536865 DOI: 10.3389/fphar.2020.00730] [Cited by in Crossref: 28] [Cited by in F6Publishing: 35] [Article Influence: 9.3] [Reference Citation Analysis]
316 Jin Y, Blikslager AT. The Regulation of Intestinal Mucosal Barrier by Myosin Light Chain Kinase/Rho Kinases. Int J Mol Sci 2020;21:E3550. [PMID: 32443411 DOI: 10.3390/ijms21103550] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 11.0] [Reference Citation Analysis]
317 Becker HEF, Jamin C, Bervoets L, Xu P, Pierik MJ, Stassen FRM, Savelkoul PHM, Penders J, Jonkers DMAE. Higher prevalence of Bacteroides fragilis in Crohn’s disease exacerbations and strain-dependent increase of epithelial resistance.. [DOI: 10.1101/2020.05.16.099358] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
318 Townsend CM, Nguyen TM, Cepek J, Abbass M, Parker CE, MacDonald JK, Khanna R, Jairath V, Feagan BG. Adalimumab for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2020;5:CD012877. [PMID: 32413933 DOI: 10.1002/14651858.CD012877.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
319 Elleisy N, Rohde S, Huth A, Gittel N, Glass Ä, Möller S, Lamprecht G, Schäffler H, Jaster R. Genetic association analysis of CLEC5A and CLEC7A gene single-nucleotide polymorphisms and Crohn’s disease. World J Gastroenterol 2020; 26(18): 2194-2202 [PMID: 32476786 DOI: 10.3748/wjg.v26.i18.2194] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
320 Martinez-Medina M, Strozzi F, Castillo BRD, Serrano-Morillas N, Bustins NF, Martínez-Martínez L. Antimicrobial Resistance Profiles of Adherent Invasive Escherichia coli Show Increased Resistance to β-Lactams. Antibiotics (Basel) 2020;9:E251. [PMID: 32414140 DOI: 10.3390/antibiotics9050251] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
321 Nardone OM, Shivaji UN, Ferruzza V, Ghosh S, Iacucci M. Soluble Blood Markers of Mucosal Healing in Inflammatory Bowel Disease: The Future of Noninvasive Monitoring. Inflamm Bowel Dis 2020;26:961-9. [PMID: 31587036 DOI: 10.1093/ibd/izz226] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
322 Kim HS, Chung S, Song MY, Lim C, Shin H, Hur J, Kwon H, Suh YG, Kim EH, Shin D, Kim SH. Efficient and Divergent Enantioselective Syntheses of DHPVs and Anti-Inflammatory Effect on IEC-6 Cells. Molecules 2020;25:E2215. [PMID: 32397326 DOI: 10.3390/molecules25092215] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
323 Troncone E, Marafini I, Del Vecchio Blanco G, Di Grazia A, Monteleone G. Novel Therapeutic Options for People with Ulcerative Colitis: An Update on Recent Developments with Janus Kinase (JAK) Inhibitors. Clin Exp Gastroenterol 2020;13:131-9. [PMID: 32440190 DOI: 10.2147/CEG.S208020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
324 Sahrmann P, Gilli F, Wiedemeier DB, Attin T, Schmidlin PR, Karygianni L. The Microbiome of Peri-Implantitis: A Systematic Review and Meta-Analysis. Microorganisms 2020;8:E661. [PMID: 32369987 DOI: 10.3390/microorganisms8050661] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 9.7] [Reference Citation Analysis]
325 Painchart C, Brabant S, Duveau N, Nachury M, Desreumaux P, Branche J, Gérard R, Prevost CLD, Wils P, Lambin T, Boualit M, Labalette M, Pariente B. Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn's Disease. Dig Dis Sci 2020;65:1445-52. [PMID: 31599389 DOI: 10.1007/s10620-019-05865-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
326 Bastida G, Garrido A, Valero E, del Pozo P. Enfermedad de Crohn. Medicine - Programa de Formación Médica Continuada Acreditado 2020;13:603-612. [DOI: 10.1016/j.med.2020.06.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
327 Bai X, Bai G, Tang L, Liu L, Li Y, Jiang W. Changes in MMP-2, MMP-9, inflammation, blood coagulation and intestinal mucosal permeability in patients with active ulcerative colitis. Exp Ther Med 2020;20:269-74. [PMID: 32536995 DOI: 10.3892/etm.2020.8710] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
328 Oliveira MC, Elias JB, Moraes DA, Simões BP, Rodrigues M, Ribeiro AAF, Piron-Ruiz L, Ruiz MA, Hamerschlak N. A review of hematopoietic stem cell transplantation for autoimmune diseases: multiple sclerosis, systemic sclerosis and Crohn's disease. Position paper of the Brazilian Society of Bone Marrow Transplantation. Hematol Transfus Cell Ther 2021;43:65-86. [PMID: 32418777 DOI: 10.1016/j.htct.2020.03.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
329 Kayama H, Tani H, Kitada S, Opasawatchai A, Okumura R, Motooka D, Nakamura S, Takeda K. BATF2 prevents T-cell-mediated intestinal inflammation through regulation of the IL-23/IL-17 pathway. Int Immunol 2019;31:371-83. [PMID: 30753547 DOI: 10.1093/intimm/dxz014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
330 Taylor KM, Hanscombe KB, Prescott NJ, Iniesta R, Traylor M, Taylor NS, Fong S, Powell N, Irving PM, Anderson SH, Mathew CG, Lewis CM, Sanderson JD. Genetic and Inflammatory Biomarkers Classify Small Intestine Inflammation in Asymptomatic First-degree Relatives of Patients With Crohn's Disease. Clin Gastroenterol Hepatol 2020;18:908-916.e13. [PMID: 31202982 DOI: 10.1016/j.cgh.2019.05.061] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
331 Jess T, Jensen BW, Andersson M, Villumsen M, Allin KH. Inflammatory Bowel Diseases Increase Risk of Type 2 Diabetes in a Nationwide Cohort Study. Clinical Gastroenterology and Hepatology 2020;18:881-888.e1. [DOI: 10.1016/j.cgh.2019.07.052] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 10.7] [Reference Citation Analysis]
332 Alahdab YO, Demirtas CO, Kani HT, Tuney D, Seker L, Tolu T, Atug O. Clinical significance of isolated abnormal intestinal findings in magnetic resonance enterography in patients with suspected small bowel disease. Abdom Radiol (NY) 2020;45:1036-43. [PMID: 31686178 DOI: 10.1007/s00261-019-02297-5] [Reference Citation Analysis]
333 Postovalova EA, Makarova OV, Kosyreva AM, Dzhalilova DS. Hypoxia is a key mechanism for regulating inflammation in ulcerative colitis. Russ Open Med J 2020;9. [DOI: 10.15275/rusomj.2020.0101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
334 Wu MY, Liu L, Wang EJ, Xiao HT, Cai CZ, Wang J, Su H, Wang Y, Tan J, Zhang Z, Wang J, Yao M, Ouyang DF, Yue Z, Li M, Chen Y, Bian ZX, Lu JH. PI3KC3 complex subunit NRBF2 is required for apoptotic cell clearance to restrict intestinal inflammation. Autophagy 2021;17:1096-111. [PMID: 32160108 DOI: 10.1080/15548627.2020.1741332] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
335 Lopens S, Krawczyk M, Papp M, Milkiewicz P, Schierack P, Liu Y, Wunsch E, Conrad K, Roggenbuck D. The search for the Holy Grail: autoantigenic targets in primary sclerosing cholangitis associated with disease phenotype and neoplasia. Auto Immun Highlights 2020;11:6. [PMID: 32178720 DOI: 10.1186/s13317-020-00129-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
336 Gwon Y, Mo M, Chen MH, Chi Z, Li J, Xia AH, Ibrahim JG. Network meta-regression for ordinal outcomes: Applications in comparing Crohn's disease treatments. Stat Med 2020. [PMID: 32166784 DOI: 10.1002/sim.8518] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
337 Andersen V, Möller S, Jensen PB, Møller FT, Green A. Caesarean Delivery and Risk of Chronic Inflammatory Diseases (Inflammatory Bowel Disease, Rheumatoid Arthritis, Coeliac Disease, and Diabetes Mellitus): A Population Based Registry Study of 2,699,479 Births in Denmark During 1973-2016. Clin Epidemiol 2020;12:287-93. [PMID: 32210632 DOI: 10.2147/CLEP.S229056] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 10.0] [Reference Citation Analysis]
338 Leber A, Hontecillas R, Zoccoli-Rodriguez V, Colombel JF, Chauhan J, Ehrich M, Farinola N, Bassaganya-Riera J. The Safety, Tolerability, and Pharmacokinetics Profile of BT-11, an Oral, Gut-Restricted Lanthionine Synthetase C-Like 2 Agonist Investigational New Drug for Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial. Inflamm Bowel Dis 2020;26:643-52. [PMID: 31077582 DOI: 10.1093/ibd/izz094] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
339 Sohn J, Sun Y, Genco RJ, Kirkwood KL. The Periodontal Microenvironment: a Potential Reservoir for Intestinal Pathobionts in Crohn’s Disease. Curr Oral Health Rep 2020;7:37-44. [DOI: 10.1007/s40496-020-00251-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
340 Pisani LF, Moriggi M, Gelfi C, Vecchi M, Pastorelli L. Proteomic insights on the metabolism in inflammatory bowel disease. World J Gastroenterol 2020; 26(7): 696-705 [PMID: 32116417 DOI: 10.3748/wjg.v26.i7.696] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
341 Sayed IM, Suarez K, Lim E, Singh S, Pereira M, Ibeawuchi SR, Katkar G, Dunkel Y, Mittal Y, Chattopadhyay R, Guma M, Boland BS, Dulai PS, Sandborn WJ, Ghosh P, Das S. Host engulfment pathway controls inflammation in inflammatory bowel disease. FEBS J 2020;287:3967-88. [PMID: 32003126 DOI: 10.1111/febs.15236] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]
342 Bertani L, Baglietto L, Antonioli L, Fornai M, Tapete G, Albano E, Ceccarelli L, Mumolo MG, Pellegrini C, Lucenteforte E, de Bortoli N, Bellini M, Marchi S, Blandizzi C, Costa F. Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients. Br J Clin Pharmacol 2020;86:1296-305. [PMID: 32027388 DOI: 10.1111/bcp.14235] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
343 Wang S, Dai Y, Zhang J, Ou D, Ouyang C, Lu F. Intestinal ulcers as an initial finding in EBV-associated lymphoproliferative disorder: A case report. Medicine (Baltimore) 2020;99:e18764. [PMID: 32011464 DOI: 10.1097/MD.0000000000018764] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
344 Vermeire S, Lukáš M, Magro F, Adsul S, Lindner D, Rosario M, Roth J, Danese S. Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis. J Crohns Colitis 2020;14:1066-73. [PMID: 32060515 DOI: 10.1093/ecco-jcc/jjaa027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
345 Wohnhaas CT, Schmid R, Rolser M, Kaaru E, Langgartner D, Rieber K, Strobel B, Eisele C, Wiech F, Jakob I, Gantner F, Herichova I, Vinisko R, Böcher WO, Visvanathan S, Shen F, Panzenbeck M, Raymond E, Reber SO, Delić D, Baum P. Fecal MicroRNAs Show Promise as Noninvasive Crohn's Disease Biomarkers. Crohns Colitis 360 2020;2:otaa003. [PMID: 32551441 DOI: 10.1093/crocol/otaa003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
346 Durayski E, Watte G, Pacini GS, Roman DH, Machado MB, Marchiori E, Hochhegger B, Baldisserotto M. Diffusion-weighted imaging and apparent diffusion coefficient values for evaluating terminal ileitis in patients with Crohn's disease. Radiol Bras 2019;52:361-7. [PMID: 32047329 DOI: 10.1590/0100-3984.2019.0011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
347 Keir M, Yi Y, Lu T, Ghilardi N. The role of IL-22 in intestinal health and disease. J Exp Med 2020;217:e20192195. [PMID: 32997932 DOI: 10.1084/jem.20192195] [Cited by in Crossref: 96] [Cited by in F6Publishing: 102] [Article Influence: 32.0] [Reference Citation Analysis]
348 Pang JXQ, Kheirkhahrahimabadi H, Bindra S, Bindra G, Panaccione R, Eksteen B, Kaplan GG, Nasser Y, Beck PL, Jijon HB. Differential Effect of Genetic Burden on Disease Phenotypes in Crohn's Disease and Ulcerative Colitis in a Canadian Cohort. J Can Assoc Gastroenterol 2021;4:65-72. [PMID: 33855263 DOI: 10.1093/jcag/gwaa002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
349 Unger LW, Argeny S, Stift A, Yang Y, Karall A, Freilinger T, Müller C, Bergmann M, Stift J, Riss S. Mesenteric granulomas independently predict long-term risk of surgical recurrence in Crohn's disease. Colorectal Dis 2020;22:170-7. [PMID: 31393663 DOI: 10.1111/codi.14814] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
350 Ho SSC, Keenan JI, Day AS. The Role of Gastrointestinal-Related Fatty Acid-Binding Proteins as Biomarkers in Gastrointestinal Diseases. Dig Dis Sci 2020;65:376-90. [PMID: 31529416 DOI: 10.1007/s10620-019-05841-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
351 Flemming S, Luissint AC, Kusters DHM, Raya-Sandino A, Fan S, Zhou DW, Hasegawa M, Garcia-Hernandez V, García AJ, Parkos CA, Nusrat A. Desmocollin-2 promotes intestinal mucosal repair by controlling integrin-dependent cell adhesion and migration. Mol Biol Cell 2020;31:407-18. [PMID: 31967937 DOI: 10.1091/mbc.E19-12-0692] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 5.7] [Reference Citation Analysis]
352 Bobo TR, Fitzpatrick LR, Whitcomb TL, Cooper TK, Raiciulescu S, Smith JP. Role of the δ-Opioid Receptor in 2 Murine Models of Colitis. Comp Med 2020;70:25-34. [PMID: 31969211 DOI: 10.30802/AALAS-CM-19-000024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
353 Vich Vila A, Collij V, Sanna S, Sinha T, Imhann F, Bourgonje AR, Mujagic Z, Jonkers DMAE, Masclee AAM, Fu J, Kurilshikov A, Wijmenga C, Zhernakova A, Weersma RK. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nat Commun. 2020;11:362. [PMID: 31953381 DOI: 10.1038/s41467-019-14177-z] [Cited by in Crossref: 228] [Cited by in F6Publishing: 246] [Article Influence: 76.0] [Reference Citation Analysis]
354 Shao BZ, Wang SL, Pan P, Yao J, Wu K, Li ZS, Bai Y, Linghu EQ. Targeting NLRP3 Inflammasome in Inflammatory Bowel Disease: Putting out the Fire of Inflammation. Inflammation. 2019;42:1147-1159. [PMID: 30937839 DOI: 10.1007/s10753-019-01008-y] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 15.3] [Reference Citation Analysis]
355 Griffiths OR, Landon J, Coxon RE, Morris K, James P, Adams R. Inflammatory bowel disease and targeted oral anti-TNFα therapy. Adv Protein Chem Struct Biol 2020;119:157-98. [PMID: 31997768 DOI: 10.1016/bs.apcsb.2019.08.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
356 Yu Y, Yin YH, Min L, Zhu ST, Li P, Zhang ST. Challenge in the new era: Translational medicine in gastrointestinal endoscopy and early cancer. Chronic Dis Transl Med 2019;5:234-42. [PMID: 32055782 DOI: 10.1016/j.cdtm.2019.12.002] [Reference Citation Analysis]
357 Poyato-Borrego M, Segura-Sampedro JJ, Martín-González J, Torres-Domínguez Y, Velasco-Ortega E, Segura-Egea JJ. High Prevalence of Apical Periodontitis in Patients With Inflammatory Bowel Disease: An Age- and Gender- matched Case-control Study. Inflamm Bowel Dis 2020;26:273-9. [PMID: 31247107 DOI: 10.1093/ibd/izz128] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
358 Alam MT, Amos GCA, Murphy ARJ, Murch S, Wellington EMH, Arasaradnam RP. Microbial imbalance in inflammatory bowel disease patients at different taxonomic levels. Gut Pathog 2020;12:1. [PMID: 31911822 DOI: 10.1186/s13099-019-0341-6] [Cited by in Crossref: 124] [Cited by in F6Publishing: 128] [Article Influence: 41.3] [Reference Citation Analysis]
359 Fang ZN, Li XH, Lin JJ, Huang SY, Cao QH, Chen ZH, Sun CH, Zhang ZW, Rieder F, Rimola J, Chen MH, Li ZP, Mao R, Feng ST. Magnetisation transfer imaging adds information to conventional MRIs to differentiate inflammatory from fibrotic components of small intestinal strictures in Crohn's disease. Eur Radiol 2020;30:1938-47. [PMID: 31900705 DOI: 10.1007/s00330-019-06594-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
360 Bisseling T, van der Marel S, Boleij A, Bruggeling C, van Meeteren MW. Maag-, darm- en leverziekten. Handboek leefstijlgeneeskunde 2020. [DOI: 10.1007/978-90-368-2324-1_7] [Reference Citation Analysis]
361 Fricke U, Hein L, Schwabe U. Neue Arzneimittel 2019. Arzneiverordnungs-Report 2020 2020. [DOI: 10.1007/978-3-662-62168-4_2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
362 Ma C, Liu X. Histologic evaluation of disease activity in inflammatory bowel disease. Atlas of Endoscopy Imaging in Inflammatory Bowel Disease 2020. [DOI: 10.1016/b978-0-12-814811-2.00015-3] [Reference Citation Analysis]
363 Kayama H, Takeda K. Mucosal Regulatory System for Balanced Immunity in the Gut. Mucosal Vaccines 2020. [DOI: 10.1016/b978-0-12-811924-2.00015-8] [Reference Citation Analysis]
364 Arnhold J. Cell and Tissue Destruction in Selected Disorders. Cell and Tissue Destruction 2020. [DOI: 10.1016/b978-0-12-816388-7.00009-7] [Reference Citation Analysis]
365 Kiernan MG, Coffey JC, Sahebally SM, Tibbitts P, Lyons EM, O'leary E, Owolabi F, Dunne CP. Systemic Molecular Mediators of Inflammation Differentiate Between Crohn's Disease and Ulcerative Colitis, Implicating Threshold Levels of IL-10 and Relative Ratios of Pro-inflammatory Cytokines in Therapy. J Crohns Colitis 2020;14:118-29. [PMID: 31241755 DOI: 10.1093/ecco-jcc/jjz117] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
366 Offermanns S. Pharmaka bei chronisch entzündlichen Darmerkrankungen. Pharmakologie und Toxikologie 2020. [DOI: 10.1007/978-3-662-58304-3_47] [Reference Citation Analysis]
367 Wang T, Liu K, Wen L, Yang Y, Yin X, Liu K, Chen Y, He Y, Yang M, Wei Y, Wang B, Chen D. Autophagy and Gastrointestinal Diseases. Adv Exp Med Biol 2020;1207:529-56. [PMID: 32671773 DOI: 10.1007/978-981-15-4272-5_38] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
368 Chen H, Shi J, Pan Y, Zhang Z, Fang H, Chen Y, Chen W, Cao Q. Cost-Effectiveness of Reimbursing Infliximab for Moderate to Severe Crohn's Disease in China. Adv Ther 2020;37:431-49. [PMID: 31797196 DOI: 10.1007/s12325-019-01150-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
369 Bernardi L, Santos CHMD, Pinheiro VAZ, Oliveira RJ, Antoniolli-Silva ACMB. TRANSPLANTATION OF ADIPOSE-DERIVED MESENCHYMAL STEM CELLS IN REFRACTORY CROHN'S DISEASE: SYSTEMATIC REVIEW. Arq Bras Cir Dig 2019;32:e1465. [PMID: 31859918 DOI: 10.1590/0102-672020190001e1465] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
370 Moroi R, Shiga H, Endo K, Yamamoto K, Kuroha M, Kanazawa Y, Kakuta Y, Kinouchi Y, Masamune A. Long-Term Prognosis of Japanese Patients with Crohn's Disease Treated by Switching Anti-Tumor Necrosis Factor-α Antibodies. Inflamm Intest Dis 2020;5:11-9. [PMID: 32232050 DOI: 10.1159/000504803] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
371 Bokemeyer A, Tepasse PR, Quill L, Lenz P, Rijcken E, Vieth M, Ding N, Ketelhut S, Rieder F, Kemper B, Bettenworth D. Quantitative Phase Imaging Using Digital Holographic Microscopy Reliably Assesses Morphology and Reflects Elastic Properties of Fibrotic Intestinal Tissue. Sci Rep 2019;9:19388. [PMID: 31852983 DOI: 10.1038/s41598-019-56045-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
372 Artom M, Czuber-Dochan W, Sturt J, Proudfoot H, Roberts D, Norton C. Cognitive-behavioural therapy for the management of inflammatory bowel disease-fatigue: a feasibility randomised controlled trial. Pilot Feasibility Stud 2019;5:145. [PMID: 31890258 DOI: 10.1186/s40814-019-0538-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
373 Dulai PS, Singh S, Vande Casteele N, Boland BS, Rivera-Nieves J, Ernst PB, Eckmann L, Barrett KE, Chang JT, Sandborn WJ. Should We Divide Crohn's Disease Into Ileum-Dominant and Isolated Colonic Diseases? Clin Gastroenterol Hepatol 2019;17:2634-43. [PMID: 31009791 DOI: 10.1016/j.cgh.2019.04.040] [Cited by in Crossref: 57] [Cited by in F6Publishing: 36] [Article Influence: 14.3] [Reference Citation Analysis]
374 Seishima J, Iida N, Kitamura K, Yutani M, Wang Z, Seki A, Yamashita T, Sakai Y, Honda M, Yamashita T, Kagaya T, Shirota Y, Fujinaga Y, Mizukoshi E, Kaneko S. Gut-derived Enterococcus faecium from ulcerative colitis patients promotes colitis in a genetically susceptible mouse host. Genome Biol 2019;20:252. [PMID: 31767028 DOI: 10.1186/s13059-019-1879-9] [Cited by in Crossref: 42] [Cited by in F6Publishing: 49] [Article Influence: 10.5] [Reference Citation Analysis]
375 Gill N, Pietrosanu M, Gniadecki R. Risk of Inflammatory Bowel Disease in Psoriasis Patients Treated with Anti-Interleukin-17 Agents: A Bayesian Metaanalysis.. [DOI: 10.1101/19012179] [Reference Citation Analysis]
376 Abbass M, Cepek J, Parker CE, Nguyen TM, MacDonald JK, Feagan BG, Khanna R, Jairath V. Adalimumab for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2019;2019. [PMID: 31742665 DOI: 10.1002/14651858.CD012878.pub2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
377 Leber A, Hontecillas R, Zoccoli-Rodriguez V, Bienert C, Chauhan J, Bassaganya-Riera J. Activation of NLRX1 by NX-13 Alleviates Inflammatory Bowel Disease through Immunometabolic Mechanisms in CD4+ T Cells. J Immunol 2019;203:3407-15. [PMID: 31694910 DOI: 10.4049/jimmunol.1900364] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
378 Farokhi S, Bahrami G, Babaie A, Farzaei M, Students Research Committee, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran, Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran, Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran, Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran. Protective and Therapeutic Effect of Oleoresin of Pistacia atlantica in Acetic Acid-induced Colitis in Rat. J Med Plants 2019;4:135-148. [DOI: 10.29252/jmp.4.72.135] [Reference Citation Analysis]
379 Ma C, Almutairdi A, Tanyingoh D, Seow CH, Novak KL, Lu C, Panaccione R, Kaplan GG, Kotze PG. Reduction in surgical stoma rates in Crohn's disease: a population-based time trend analysis. Colorectal Dis 2019;21:1279-87. [PMID: 31206974 DOI: 10.1111/codi.14731] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
380 Takahashi K, Nakagawasai O, Nemoto W, Odaira T, Sakuma W, Onogi H, Nishijima H, Furihata R, Nemoto Y, Iwasa H, Tan-No K, Tadano T. Effect of Enterococcus faecalis 2001 on colitis and depressive-like behavior in dextran sulfate sodium-treated mice: involvement of the brain-gut axis. J Neuroinflammation 2019;16:201. [PMID: 31672153 DOI: 10.1186/s12974-019-1580-7] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 8.5] [Reference Citation Analysis]
381 Celentano V, O'Leary DP, Caiazzo A, Flashman KG, Sagias F, Conti J, Senapati A, Khan J. Longer small bowel segments are resected in emergency surgery for ileocaecal Crohn's disease with a higher ileostomy and complication rate. Tech Coloproctol 2019;23:1085-91. [PMID: 31664551 DOI: 10.1007/s10151-019-02104-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
382 Nayyar AS, Patel S, Parikh H, Doshi A, Kumar B, Shankar TA. Aggressive periodontitis in a setting of established crohn’s disease: a complex interplay of etiological factors affecting disease outcome. GHOA 2019;10:262-266. [DOI: 10.15406/ghoa.2019.10.00393] [Reference Citation Analysis]
383 Chiu B, Chan J, Das S, Alshamma Z, Sergi C. Pediatric Sarcoidosis: A Review with Emphasis on Early Onset and High-Risk Sarcoidosis and Diagnostic Challenges. Diagnostics (Basel) 2019;9:E160. [PMID: 31731423 DOI: 10.3390/diagnostics9040160] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
384 Derijks LJJ, Wong DR, Hommes DW, van Bodegraven AA. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease. Clin Pharmacokinet 2018;57:1075-106. [PMID: 29512050 DOI: 10.1007/s40262-018-0639-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
385 Chaparro M, Aterido A, Guerra I, Iborra M, Cabriada JL, Bujanda L, Taxonera C, García-Sánchez V, Marín-Jiménez I, Barreiro-de Acosta M, Vera I, Martín-Arranz MD, Hernández-Breijo B, Mesonero F, Sempere L, Gomollón F, Hinojosa J, Bermejo F, Beltrán B, Rodríguez-Pescador A, Banales JM, Olivares D, Aguilar-Melero P, Menchén L, Ferreiro-Iglesias R, Blazquez Gómez I, Benitez García B, Guijarro LG, Marin AC, Bernardo D, Marsal S, Julia A, Gisbert JP. Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease. Therap Adv Gastroenterol 2019;12:1756284819867848. [PMID: 31598133 DOI: 10.1177/1756284819867848] [Reference Citation Analysis]
386 Benmoussa A, Diallo I, Salem M, Michel S, Gilbert C, Sévigny J, Provost P. Concentrates of two subsets of extracellular vesicles from cow's milk modulate symptoms and inflammation in experimental colitis. Sci Rep 2019;9:14661. [PMID: 31601878 DOI: 10.1038/s41598-019-51092-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 6.5] [Reference Citation Analysis]
387 Kim J, Kim SH, Kim TO. Evaluation of CT enterography findings for endoscopic complete remission after anti-TNF-α therapy in patients with Crohn's disease. Acta Radiol 2019;60:1200-8. [PMID: 30628841 DOI: 10.1177/0284185118820062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
388 Liu J, Andrews JM, Sammour T, Bryant RV, Grafton R, Simpson E, Putrus E, Nixon C. Benefits of Exclusive Enteral Nutrition in Adults With Complex Active Crohn’s Disease: A Case Series of 13 Consecutive Patients. Crohn's & Colitis 360 2019;1. [DOI: 10.1093/crocol/otz044] [Reference Citation Analysis]
389 de Groof EJ, Stevens TW, Eshuis EJ, Gardenbroek TJ, Bosmans JE, van Dongen JM, Mol B, Buskens CJ, Stokkers PCF, Hart A, D'Haens GR, Bemelman WA, Ponsioen CY; LIR!C study group. Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn's disease: the LIR!C Trial. Gut 2019;68:1774-80. [PMID: 31233395 DOI: 10.1136/gutjnl-2018-317539] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 8.8] [Reference Citation Analysis]
390 Silva I, Pinto R, Mateus V. Preclinical Study in Vivo for New Pharmacological Approaches in Inflammatory Bowel Disease: A Systematic Review of Chronic Model of TNBS-Induced Colitis. J Clin Med 2019;8:E1574. [PMID: 31581545 DOI: 10.3390/jcm8101574] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
391 M B, A A, L M, N T. Isolated ano-perianal tuberculosis: challenging diagnosis. GHOA 2019;10:254-256. [DOI: 10.15406/ghoa.2019.10.00391] [Reference Citation Analysis]
392 Löwenberg M, Vermeire S, Mostafavi N, Hoentjen F, Franchimont D, Bossuyt P, Hindryckx P, Rispens T, de Vries A, van der Woude CJ, Berends S, Ambarus CA, Mathot R, Clasquin E, Baert F, D'Haens G. Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease. Gastroenterology 2019;157:997-1006.e6. [PMID: 31175865 DOI: 10.1053/j.gastro.2019.05.067] [Cited by in Crossref: 62] [Cited by in F6Publishing: 64] [Article Influence: 15.5] [Reference Citation Analysis]
393 Klaassen MAY, Imhann F, Collij V, Fu J, Wijmenga C, Zhernakova A, Dijkstra G, Festen EAM, Gacesa R, Vich Vila A, Weersma RK. Anti-inflammatory Gut Microbial Pathways Are Decreased During Crohn's Disease Exacerbations. J Crohns Colitis 2019;13:1439-49. [PMID: 31066440 DOI: 10.1093/ecco-jcc/jjz077] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
394 Berkowitz L, Pardo-Roa C, Salazar GA, Salazar-Echegarai F, Miranda JP, Ramírez G, Chávez JL, Kalergis AM, Bueno SM, Álvarez-Lobos M. Mucosal Exposure to Cigarette Components Induces Intestinal Inflammation and Alters Antimicrobial Response in Mice. Front Immunol 2019;10:2289. [PMID: 31608070 DOI: 10.3389/fimmu.2019.02289] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
395 Panpetch W, Hiengrach P, Nilgate S, Tumwasorn S, Somboonna N, Wilantho A, Chatthanathon P, Prueksapanich P, Leelahavanichkul A. Additional Candida albicans administration enhances the severity of dextran sulfate solution induced colitis mouse model through leaky gut-enhanced systemic inflammation and gut-dysbiosis but attenuated by Lactobacillus rhamnosus L34. Gut Microbes 2020;11:465-80. [PMID: 31530137 DOI: 10.1080/19490976.2019.1662712] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 12.5] [Reference Citation Analysis]
396 Berkowitz L, Pardo-Roa C, Ramírez G, Vallejos OP, Sebastián VP, Riedel CA, Álvarez-Lobos M, Bueno SM. The absence of interleukin 10 affects the morphology, differentiation, granule content and the production of cryptidin-4 in Paneth cells in mice. PLoS One 2019;14:e0221618. [PMID: 31509557 DOI: 10.1371/journal.pone.0221618] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
397 Singhvi N, Gupta V, Gaur M, Sharma V, Puri A, Singh Y, Dubey GP, Lal R. Interplay of Human Gut Microbiome in Health and Wellness. Indian J Microbiol 2020;60:26-36. [PMID: 32089571 DOI: 10.1007/s12088-019-00825-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
398 Coy CSR, Kotze PG. SURGICAL STRATEGIES IN MULTIDISCIPLINARY MANAGEMENT OF CROHN'S DISEASE. Revista Médica Clínica Las Condes 2019;30:349-356. [DOI: 10.1016/j.rmclc.2019.07.007] [Reference Citation Analysis]
399 Galazzo G, Tedjo DI, Wintjens DSJ, Savelkoul PHM, Masclee AAM, Bodelier AGL, Pierik MJ, Jonkers DMAE, Penders J. Faecal Microbiota Dynamics and their Relation to Disease Course in Crohn's Disease. J Crohns Colitis 2019;13:1273-82. [PMID: 30810207 DOI: 10.1093/ecco-jcc/jjz049] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
400 Yamazaki H, So R, Matsuoka K, Kobayashi T, Shinzaki S, Matsuura M, Okabayashi S, Kataoka Y, Tsujimoto Y, Furukawa TA, Watanabe N. Certolizumab pegol for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2019;8:CD012893. [PMID: 31476018 DOI: 10.1002/14651858.CD012893.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
401 Sun F, Liang W, Tang K, Hong M, Qian J. Profiling the lncRNA-miRNA-mRNA ceRNA network to reveal potential crosstalk between inflammatory bowel disease and colorectal cancer. PeerJ 2019;7:e7451. [PMID: 31523496 DOI: 10.7717/peerj.7451] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
402 Bavaro DF, Ingravallo G, Signorile F, Fortarezza F, Di Gennaro F, Angarano G, Saracino A. Splenic abscesses as a first manifestation of Crohn's disease: a case report. BMC Gastroenterol 2019;19:144. [PMID: 31416435 DOI: 10.1186/s12876-019-1066-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
403 Rahme E, Nedjar H, Afif W. Cost of Refractory Crohn's Disease Before and After Ustekinumab Utilization. J Can Assoc Gastroenterol 2020;3:257-65. [PMID: 33241178 DOI: 10.1093/jcag/gwz025] [Reference Citation Analysis]
404 Soontararak S, Chow L, Johnson V, Coy J, Webb C, Wennogle S, Dow S. Humoral immune responses against gut bacteria in dogs with inflammatory bowel disease. PLoS One 2019;14:e0220522. [PMID: 31369623 DOI: 10.1371/journal.pone.0220522] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
405 Schön MP. Adaptive and Innate Immunity in Psoriasis and Other Inflammatory Disorders. Front Immunol 2019;10:1764. [PMID: 31402919 DOI: 10.3389/fimmu.2019.01764] [Cited by in Crossref: 68] [Cited by in F6Publishing: 73] [Article Influence: 17.0] [Reference Citation Analysis]
406 Xu S, Xu ZX, Yan S, Le J, Chen H, Ming L, Xu SG, Lin T. Curcumin suppresses intestinal microvascular endothelial cells invasion and angiogenesis induced by activated platelets. Exp Ther Med 2019;18:1099-106. [PMID: 31316605 DOI: 10.3892/etm.2019.7662] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
407 Schäfer AO. [Perianal inflammatory diseases : Classification and imaging]. Radiologe 2018;58:344-54. [PMID: 29464273 DOI: 10.1007/s00117-018-0368-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
408 Romagnoni A, Jégou S, Van Steen K, Wainrib G, Hugot JP; International Inflammatory Bowel Disease Genetics Consortium (IIBDGC). Comparative performances of machine learning methods for classifying Crohn Disease patients using genome-wide genotyping data. Sci Rep 2019;9:10351. [PMID: 31316157 DOI: 10.1038/s41598-019-46649-z] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 13.3] [Reference Citation Analysis]
409 Huang C, Shi G. Smoking and microbiome in oral, airway, gut and some systemic diseases. J Transl Med. 2019;17:225. [PMID: 31307469 DOI: 10.1186/s12967-019-1971-7] [Cited by in Crossref: 90] [Cited by in F6Publishing: 97] [Article Influence: 22.5] [Reference Citation Analysis]
410 Niu YW, Qu CQ, Wang GH, Yan GY. RWHMDA: Random Walk on Hypergraph for Microbe-Disease Association Prediction. Front Microbiol 2019;10:1578. [PMID: 31354672 DOI: 10.3389/fmicb.2019.01578] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
411 Bunte K, Beikler T. Th17 Cells and the IL-23/IL-17 Axis in the Pathogenesis of Periodontitis and Immune-Mediated Inflammatory Diseases. Int J Mol Sci. 2019;20. [PMID: 31295952 DOI: 10.3390/ijms20143394] [Cited by in Crossref: 160] [Cited by in F6Publishing: 176] [Article Influence: 40.0] [Reference Citation Analysis]
412 Kinnucan J, Binion D, Cross R, Evans E, Harlen K, Matarese L, Mullins A, O'Neal B, Reiss M, Scott FI, Weaver A, Rosenberg J. Inflammatory Bowel Disease Care Referral Pathway. Gastroenterology 2019;157:242-254.e6. [PMID: 30980795 DOI: 10.1053/j.gastro.2019.03.064] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
413 Bakouny Z, Yared F, El Rassy E, Jabbour R, Hallit R, Khoury N, Honein K, Bou Jaoude J. Comparative Efficacy of Anti-TNF Therapies For The Prevention of Postoperative Recurrence of Crohn's Disease: A Systematic Review and Network Meta-Analysis of Prospective Trials. J Clin Gastroenterol 2019;53:409-17. [PMID: 29517709 DOI: 10.1097/MCG.0000000000001006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
414 Figueroa C. Epidemiología de la enfermedad inflamatoria intestinal. Revista Médica Clínica Las Condes 2019;30:257-61. [DOI: 10.1016/j.rmclc.2019.06.003] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
415 Pagnini C, Pizarro TT, Cominelli F. Novel Pharmacological Therapy in Inflammatory Bowel Diseases: Beyond Anti-Tumor Necrosis Factor. Front Pharmacol. 2019;10:671. [PMID: 31316377 DOI: 10.3389/fphar.2019.00671] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 10.5] [Reference Citation Analysis]
416 Gao C, Liu L, Zhou Y, Bian Z, Wang S, Wang Y. Novel drug delivery systems of Chinese medicine for the treatment of inflammatory bowel disease. Chin Med 2019;14:23. [PMID: 31236131 DOI: 10.1186/s13020-019-0245-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
417 Avivar-Valderas A, Martín-Martín C, Ramírez C, Del Río B, Menta R, Mancheño-Corvo P, Ortiz-Virumbrales M, Herrero-Méndez Á, Panés J, García-Olmo D, Castañer JL, Palacios I, Lombardo E, Dalemans W, DelaRosa O. Dissecting Allo-Sensitization After Local Administration of Human Allogeneic Adipose Mesenchymal Stem Cells in Perianal Fistulas of Crohn's Disease Patients. Front Immunol 2019;10:1244. [PMID: 31258526 DOI: 10.3389/fimmu.2019.01244] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
418 Yang FC, Chiu PY, Chen Y, Mak TW, Chen NJ. TREM-1-dependent M1 macrophage polarization restores intestinal epithelium damaged by DSS-induced colitis by activating IL-22-producing innate lymphoid cells. J Biomed Sci 2019;26:46. [PMID: 31189465 DOI: 10.1186/s12929-019-0539-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
419 Gong W, Guo K, Zheng T, Fang M, Xie H, Li W, Hong Z, Ren H, Gu G, Wang G, Wu X, Wang Z, Ren J, Li J. Correlation between endoscopic and histological validated scoring indices in Crohn's disease. Dig Liver Dis 2019;51:812-7. [PMID: 30718202 DOI: 10.1016/j.dld.2019.01.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
420 2015 European Society of Coloproctology (ESCP) collaborating group. Patients with Crohn’s disease have longer post-operative in-hospital stay than patients with colon cancer but no difference in complications’ rate. World J Gastrointest Surg 2019; 11(5): 261-270 [PMID: 31171957 DOI: 10.4240/wjgs.v11.i5.261] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
421 Garber A, Regueiro M. Extraintestinal Manifestations of Inflammatory Bowel Disease: Epidemiology, Etiopathogenesis, and Management. Curr Gastroenterol Rep. 2019;21:31. [PMID: 31098819 DOI: 10.1007/s11894-019-0698-1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 8.5] [Reference Citation Analysis]
422 Uyeda JW. Utility of MR Imaging in Abdominopelvic Emergencies. Radiol Clin North Am 2019;57:705-15. [PMID: 31076027 DOI: 10.1016/j.rcl.2019.02.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
423 Battat R, Dulai PS, Jairath V, Vande Casteele N. A product review of vedolizumab in inflammatory bowel disease. Hum Vaccin Immunother 2019;15:2482-90. [PMID: 30897022 DOI: 10.1080/21645515.2019.1591139] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
424 Plevris N, Lyons M, Jenkinson PW, Chuah CS, Merchant LM, Pattenden RJ, Watson EF, Ho GT, Noble CL, Shand AG, Din S, Arnott ID, Jones GR, Lees CW. Higher Adalimumab Drug Levels During Maintenance Therapy for Crohn's Disease Are Associated With Biologic Remission. Inflamm Bowel Dis 2019;25:1036-43. [PMID: 30335139 DOI: 10.1093/ibd/izy320] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
425 Borecki K, Zawada I, Salkić NN, Karakiewicz B, Adler G. Relationship between the IL23R SNPs and Crohn's Disease Susceptibility and Phenotype in the Polish and Bosnian Populations: A Case-Control Study. Int J Environ Res Public Health 2019;16:E1551. [PMID: 31052515 DOI: 10.3390/ijerph16091551] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
426 Kristensen MS, Kjærulff TM, Ersbøll AK, Green A, Hallas J, Thygesen LC. The Influence of Antidepressants on the Disease Course Among Patients With Crohn's Disease and Ulcerative Colitis-A Danish Nationwide Register-Based Cohort Study. Inflamm Bowel Dis 2019;25:886-93. [PMID: 30551218 DOI: 10.1093/ibd/izy367] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
427 Lovisa S, Genovese G, Danese S. Role of Epithelial-to-Mesenchymal Transition in Inflammatory Bowel Disease. J Crohns Colitis 2019;13:659-68. [PMID: 30520951 DOI: 10.1093/ecco-jcc/jjy201] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 8.8] [Reference Citation Analysis]
428 Ateş Bulut E, Törüner M. The influence of disease type and activity to sexual life and health quality in inflammatory bowel disease. Turk J Gastroenterol 2019;30:33-9. [PMID: 30644362 DOI: 10.5152/tjg.2018.18250] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
429 Gutiérrez A, Rivero M, Martín-Arranz MD, García Sánchez V, Castro M, Barrio J, de Francisco R, Barreiro-de Acosta M, Juliá B, Cea-Calvo L, Romero C, Borruel Sainz N, Domènech E. Perioperative management and early complications after intestinal resection with ileocolonic anastomosis in Crohn's disease: analysis from the PRACTICROHN study. Gastroenterol Rep (Oxf) 2019;7:168-75. [PMID: 31217980 DOI: 10.1093/gastro/goz010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
430 Ruder B, Atreya R, Becker C. Tumour Necrosis Factor Alpha in Intestinal Homeostasis and Gut Related Diseases. Int J Mol Sci 2019;20:E1887. [PMID: 30995806 DOI: 10.3390/ijms20081887] [Cited by in Crossref: 64] [Cited by in F6Publishing: 72] [Article Influence: 16.0] [Reference Citation Analysis]
431 Cogger-ward R, Collins A, Mclean D, Dehinsilu J, Huett A. A conserved protein, BcmA, mediates motility, biofilm formation, and host colonisation in Adherent InvasiveEscherichia coli.. [DOI: 10.1101/606798] [Reference Citation Analysis]
432 Belarif L, Danger R, Kermarrec L, Nerrière-Daguin V, Pengam S, Durand T, Mary C, Kerdreux E, Gauttier V, Kucik A, Thepenier V, Martin JC, Chang C, Rahman A, Guen NS, Braudeau C, Abidi A, David G, Malard F, Takoudju C, Martinet B, Gérard N, Neveu I, Neunlist M, Coron E, MacDonald TT, Desreumaux P, Mai HL, Le Bas-Bernardet S, Mosnier JF, Merad M, Josien R, Brouard S, Soulillou JP, Blancho G, Bourreille A, Naveilhan P, Vanhove B, Poirier N. IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease. J Clin Invest 2019;129:1910-25. [PMID: 30939120 DOI: 10.1172/JCI121668] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 12.0] [Reference Citation Analysis]
433 Baumgart DC, Misery L, Naeyaert S, Taylor PC. Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities? Front Pharmacol 2019;10:279. [PMID: 30983996 DOI: 10.3389/fphar.2019.00279] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 15.0] [Reference Citation Analysis]
434 Bai J, Yu J, Wang J, Xue B, He N, Tian Y, Yang L, Wang Y, Wang Y, Tang Q. DNA Methylation of miR-122 Aggravates Oxidative Stress in Colitis Targeting SELENBP1 Partially by p65NF-κB Signaling. Oxid Med Cell Longev 2019;2019:5294105. [PMID: 31019652 DOI: 10.1155/2019/5294105] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
435 Liu M, Lin X, Wang L, He Y, Chen M, Mao R. Thalidomide-induced sinus bradycardia in Crohn's disease: case report and literature review. J Int Med Res 2019;47:2228-33. [PMID: 30832535 DOI: 10.1177/0300060519833293] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
436 Scarberry K, Brady JT, Scarberry K, Stein SL, Steinhagen E. Surgery for Crohn’s Disease Affects Male Sexual Function. Ann Colorectal Res 2019;In Press. [DOI: 10.5812/acr.85458] [Reference Citation Analysis]
437 Zhen Y, Zhang H. NLRP3 Inflammasome and Inflammatory Bowel Disease. Front Immunol. 2019;10:276. [PMID: 30873162 DOI: 10.3389/fimmu.2019.00276] [Cited by in Crossref: 250] [Cited by in F6Publishing: 246] [Article Influence: 62.5] [Reference Citation Analysis]
438 Simčič S, Berlec A, Stopinšek S, Štrukelj B, Orel R. Engineered and wild-type L. lactis promote anti-inflammatory cytokine signalling in inflammatory bowel disease patient's mucosa. World J Microbiol Biotechnol 2019;35:45. [PMID: 30810891 DOI: 10.1007/s11274-019-2615-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
439 Maehata Y, Nagata Y, Moriyama T, Matsuno Y, Hirano A, Umeno J, Torisu T, Manabe T, Kitazono T, Esaki M. Risk of surgery in patients with stricturing type of Crohn's disease at the initial diagnosis: a single center experience. Intest Res 2019;17:357-64. [PMID: 30781932 DOI: 10.5217/ir.2018.00107] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
440 Rolandsdotter H, Jönsson-Videsäter K, L Fagerberg U, Finkel Y, Eberhardson M. Exclusive Enteral Nutrition: Clinical Effects and Changes in Mucosal Cytokine Profile in Pediatric New Inflammatory Bowel Disease. Nutrients 2019;11:E414. [PMID: 30781421 DOI: 10.3390/nu11020414] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
441 Khanna R, Feagan BG. The Role of Biomarkers in Treatment Algorithms for Ulcerative Colitis (UC). Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases 2019. [DOI: 10.1002/9781119289234.ch2] [Reference Citation Analysis]
442 Vande Casteele N, Sandborn WJ. Pharmacokinetics-Based Dosing for Therapeutic Monoclonal Antibodies in Inflammatory Bowel Disease. Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases 2019. [DOI: 10.1002/9781119289234.ch11] [Reference Citation Analysis]
443 Han Y, Zhang L, Li W, Liu X, Xiao J, Chen G, Li N. Natural CAC chemopreventive agents from Ilex rotunda Thunb. J Nat Med 2019;73:456-67. [PMID: 30758715 DOI: 10.1007/s11418-019-01281-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
444 Hindryckx P, Laukens D, D'Amico F, Danese S. Unmet Needs in IBD: the Case of Fatigue. Clin Rev Allergy Immunol. 2018;55:368-378. [PMID: 28852978 DOI: 10.1007/s12016-017-8641-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
445 Pérez-Jeldres T, Tyler CJ, Boyer JD, Karuppuchamy T, Bamias G, Dulai PS, Boland BS, Sandborn WJ, Patel DR, Rivera-Nieves J. Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts. Inflamm Bowel Dis 2019;25:270-82. [PMID: 30165490 DOI: 10.1093/ibd/izy269] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 8.0] [Reference Citation Analysis]
446 Sun Y, Li L, Xia Y, Li W, Wang K, Wang L, Miao Y, Ma S. The gut microbiota heterogeneity and assembly changes associated with the IBD. Sci Rep 2019;9:440. [PMID: 30679676 DOI: 10.1038/s41598-018-37143-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
447 Huang H, Xu S, Huang F, Wang X, Chen Y, Xu Z. A Meta-Analysis of Efficacy and Safety of Infliximab for Prevention of Postoperative Recurrence in Patients with Crohn's Disease. Biomed Res Int 2018;2018:2615978. [PMID: 30643797 DOI: 10.1155/2018/2615978] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
448 Deepak P, Fowler KJ, Fletcher JG, Bruining DH. Novel Imaging Approaches in Inflammatory Bowel Diseases. Inflamm Bowel Dis 2019;25:248-60. [PMID: 30010908 DOI: 10.1093/ibd/izy239] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
449 Zarei-Kordshouli F, Geramizadeh B, Khodakaram-Tafti A. Prevalence of Mycobacterium avium subspecies paratuberculosis IS 900 DNA in biopsy tissues from patients with Crohn's disease: histopathological and molecular comparison with Johne's disease in Fars province of Iran. BMC Infect Dis 2019;19:23. [PMID: 30616527 DOI: 10.1186/s12879-018-3619-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
450 Lindenbaum GA, Marks JA, Price TP, Costa SA. Causes of Short Bowel Syndrome in Adults. Contemporary Pancreas and Small Bowel Transplantation 2019. [DOI: 10.1007/978-3-319-05257-1_24] [Reference Citation Analysis]
451 Barnes TG, Mortensen NJ. Intraoperative Detection of Upper Gastrointestinal Strictures. Mastery of IBD Surgery 2019. [DOI: 10.1007/978-3-030-16755-4_20] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
452 Muise AM. Very Early Onset Inflammatory Bowel Disease (VEOIBD). Textbook of Autoinflammation 2019. [DOI: 10.1007/978-3-319-98605-0_21] [Reference Citation Analysis]
453 Hedayat KM, Lapraz J. Inflammatory bowel diseases. The Theory of Endobiogeny 2019. [DOI: 10.1016/b978-0-12-816964-3.00011-0] [Reference Citation Analysis]
454 Böhmig M. Mechanisms of Disease, Etiology and Clinical Manifestations. Inflammatory Bowel Disease Nursing Manual 2019. [DOI: 10.1007/978-3-319-75022-4_3] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
455 Versini M, Jeandel P, Rosenthal E, Shoenfeld Y. Obesity in Autoimmune Diseases. Mosaic of Autoimmunity 2019. [DOI: 10.1016/b978-0-12-814307-0.00035-9] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
456 Vu NB, Van Pham P. Current Status of Stem Cell Transplantation for Autoimmune Diseases. Stem Cell Transplantation for Autoimmune Diseases and Inflammation 2019. [DOI: 10.1007/978-3-030-23421-8_1] [Reference Citation Analysis]
457 Treister N, Saavedra A, Villa A. Clinical Immunology in Diagnoses of Maxillofacial Disease. Contemporary Oral Medicine 2019. [DOI: 10.1007/978-3-319-72303-7_5] [Reference Citation Analysis]
458 Albeituni S, Stiban J. Roles of Ceramides and Other Sphingolipids in Immune Cell Function and Inflammation. Adv Exp Med Biol 2019;1161:169-91. [PMID: 31562630 DOI: 10.1007/978-3-030-21735-8_15] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 10.0] [Reference Citation Analysis]
459 Zhang L, Liu B. Targeting Autophagy with Small-Molecule Modulators in Immune-Related Diseases. Adv Exp Med Biol 2019;1209:181-203. [PMID: 31728871 DOI: 10.1007/978-981-15-0606-2_11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
460 Althoff P, Schmiegel W, Lang G, Nicolas V, Brechmann T. Creeping Fat Assessed by Small Bowel MRI Is Linked to Bowel Damage and Abdominal Surgery in Crohn's Disease. Dig Dis Sci 2019;64:204-12. [PMID: 30276568 DOI: 10.1007/s10620-018-5303-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
461 Kiernan MG, Coffey JC, McDermott K, Cotter PD, Cabrera-Rubio R, Kiely PA, Dunne CP. The Human Mesenteric Lymph Node Microbiome Differentiates Between Crohn's Disease and Ulcerative Colitis. J Crohns Colitis 2019;13:58-66. [PMID: 30239655 DOI: 10.1093/ecco-jcc/jjy136] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
462 Pratap Mouli V, Ahuja V. Biologics and Inflammatory Bowel Disease. GI Surgery Annual 2019. [DOI: 10.1007/978-981-13-3227-2_3] [Reference Citation Analysis]
463 Marigorta UM. Genetic Risk Prediction in IBD. Molecular Genetics of Inflammatory Bowel Disease 2019. [DOI: 10.1007/978-3-030-28703-0_7] [Reference Citation Analysis]
464 Manthey CF, Sebode M, Hayward-koennecke H, Lutterotti A, Huber S. Drugs for Soft Tissue Autoimmune Disorders. Nijkamp and Parnham's Principles of Immunopharmacology 2019. [DOI: 10.1007/978-3-030-10811-3_35] [Reference Citation Analysis]
465 Yarani R, Mirza AH, Kaur S, Pociot F. The emerging role of lncRNAs in inflammatory bowel disease. Exp Mol Med 2018;50:1-14. [PMID: 30523244 DOI: 10.1038/s12276-018-0188-9] [Cited by in Crossref: 65] [Cited by in F6Publishing: 70] [Article Influence: 13.0] [Reference Citation Analysis]
466 Pellegrini C, Fornai M, Colucci R, Benvenuti L, D’Antongiovanni V, Natale G, Fulceri F, Giorgis M, Marini E, Gastaldi S, Bertinaria M, Blandizzi C, Antonioli L. A Comparative Study on the Efficacy of NLRP3 Inflammasome Signaling Inhibitors in a Pre-clinical Model of Bowel Inflammation. Front Pharmacol 2018;9:1405. [PMID: 30559669 DOI: 10.3389/fphar.2018.01405] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
467 Moroi R, Endo K, Yamamoto K, Naito T, Onodera M, Kuroha M, Kanazawa Y, Kimura T, Kakuta Y, Masamune A, Kinouchi Y, Shimosegawa T. Long-term prognosis of Japanese patients with biologic-naïve Crohn's disease treated with anti-tumor necrosis factor-α antibodies. Intest Res 2019;17:94-106. [PMID: 30508475 DOI: 10.5217/ir.2018.00048] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
468 Dotti I, Salas A. Potential Use of Human Stem Cell-Derived Intestinal Organoids to Study Inflammatory Bowel Diseases. Inflamm Bowel Dis 2018;24:2501-9. [PMID: 30169820 DOI: 10.1093/ibd/izy275] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
469 Lenti MV, Levison S, Eliadou E, Willert R, Kemp K, Carter A, Stansfield C, Assadsangabi A, Singh S, Crooks B, Tattersall S, Fairhurst F, Kenneth C, Subramanian S, Probert C, Storey D, Gregg B, Smith P, Liu E, Limdi JK, Johnston A, Hamlin PJ, Selinger CP. A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: The Cross Pennine study. Dig Liver Dis 2018;50:1299-304. [PMID: 30077465 DOI: 10.1016/j.dld.2018.07.007] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 6.2] [Reference Citation Analysis]
470 Fröhling M, Tepasse P, Intemann J, Sambale M, Sherwood J, Paruzel P, Tiemeyer NM, Nowacki TM, Brückner M, Mennigen R, Lügering A, Echtermeyer F, Pap T, Stratis A, Bettenworth D. Syndecan-4 Modulates Epithelial Gut Barrier Function and Epithelial Regeneration in Experimental Colitis. Inflamm Bowel Dis 2018;24:2579-89. [PMID: 30053064 DOI: 10.1093/ibd/izy248] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
471 Pauwen NY, Louis E, Siegel C, Colombel JF, Macq J. Integrated Care for Crohn's Disease: A Plea for the Development of Clinical Decision Support Systems. J Crohns Colitis 2018;12:1499-504. [PMID: 30496446 DOI: 10.1093/ecco-jcc/jjy128] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
472 Zhu Y, Xiang J, Liu W, Cao Q, Zhou W. Laparoscopy Combined with Enhanced Recovery Pathway in Ileocecal Resection for Crohn's Disease: A Randomized Study. Gastroenterol Res Pract 2018;2018:9648674. [PMID: 30534152 DOI: 10.1155/2018/9648674] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
473 El-Matary W, Deora V, Grover K. Barriers to clinical research in children with inflammatory bowel disease: The patients' perspective. PLoS One 2018;13:e0206965. [PMID: 30408097 DOI: 10.1371/journal.pone.0206965] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
474 Pallotta N, Vincoli G, Pezzotti P, Giovannone M, Gigliozzi A, Badiali D, Vernia P, Corazziari ES. A risk score system to timely manage treatment in Crohn's disease: a cohort study. BMC Gastroenterol 2018;18:164. [PMID: 30400823 DOI: 10.1186/s12876-018-0889-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
475 Visvanathan S, Baum P, Salas A, Vinisko R, Schmid R, Grebe KM, Davis JW, Wallace K, Böcher WO, Padula SJ, Fine JS, Panés J. Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn's Disease: Results From a Randomised Phase II Biopsy Sub-study. J Crohns Colitis 2018;12:1170-9. [PMID: 30032288 DOI: 10.1093/ecco-jcc/jjy099] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
476 Ruemmele FM, Rosh J, Faubion WA, Dubinsky MC, Turner D, Lazar A, Eichner S, Maa JF, Alperovich G, Robinson AM, Hyams JS. Efficacy of Adalimumab for Treatment of Perianal Fistula in Children with Moderately to Severely Active Crohn's Disease: Results from IMAgINE 1 and IMAgINE 2. J Crohns Colitis 2018;12:1249-54. [PMID: 29939254 DOI: 10.1093/ecco-jcc/jjy087] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
477 Kavanagh RG, O'Grady J, Carey BW, McLaughlin PD, O'Neill SB, Maher MM, O'Connor OJ. Low-Dose Computed Tomography for the Optimization of Radiation Dose Exposure in Patients with Crohn's Disease. Gastroenterol Res Pract 2018;2018:1768716. [PMID: 30515203 DOI: 10.1155/2018/1768716] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
478 Leroux LP, Nasr M, Valanparambil R, Tam M, Rosa BA, Siciliani E, Hill DE, Zarlenga DS, Jaramillo M, Weinstock JV, Geary TG, Stevenson MM, Urban JF Jr, Mitreva M, Jardim A. Analysis of the Trichuris suis excretory/secretory proteins as a function of life cycle stage and their immunomodulatory properties. Sci Rep 2018;8:15921. [PMID: 30374177 DOI: 10.1038/s41598-018-34174-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
479 Ruiz MA, Kaiser Junior RL, Piron-Ruiz L, Peña-Arciniegas T, Saran PS, De Quadros LG. Hematopoietic stem cell transplantation for Crohn’s disease: Gaps, doubts and perspectives. World J Stem Cells 2018; 10(10): 134-137 [PMID: 30397423 DOI: 10.4252/wjsc.v10.i10.134] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
480 Flemming S, Luissint AC, Nusrat A, Parkos CA. Analysis of leukocyte transepithelial migration using an in vivo murine colonic loop model. JCI Insight 2018;3:99722. [PMID: 30333307 DOI: 10.1172/jci.insight.99722] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
481 Dobre M, Milanesi E, Mănuc TE, Arsene DE, Ţieranu CG, Maj C, Becheanu G, Mănuc M. Differential Intestinal Mucosa Transcriptomic Biomarkers for Crohn's Disease and Ulcerative Colitis. J Immunol Res 2018;2018:9208274. [PMID: 30417021 DOI: 10.1155/2018/9208274] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
482 Narula N, Millson B, Charland K, Donepudi K, Gaetano T, McHugh K, Latour MG, Gazel S, Laliberté MC, Marshall JK. Impact of Adalimumab Patient Support Program's Care Coach Calls on Clinical Outcomes in Patients with Crohn's Disease in Canada: An Observational Retrospective Cohort Study. J Can Assoc Gastroenterol 2018;1:191-8. [PMID: 31294360 DOI: 10.1093/jcag/gwy059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
483 Lindström U, Olofsson T, Wedrén S, Qirjazo I, Askling J. Impact of extra-articular spondyloarthritis manifestations and comorbidities on drug retention of a first TNF-inhibitor in ankylosing spondylitis: a population-based nationwide study. RMD Open 2018;4:e000762. [PMID: 30402269 DOI: 10.1136/rmdopen-2018-000762] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
484 Liu TC, Kern JT, VanDussen KL, Xiong S, Kaiko GE, Wilen CB, Rajala MW, Caruso R, Holtzman MJ, Gao F, McGovern DP, Nunez G, Head RD, Stappenbeck TS. Interaction between smoking and ATG16L1T300A triggers Paneth cell defects in Crohn's disease. J Clin Invest 2018;128:5110-22. [PMID: 30137026 DOI: 10.1172/JCI120453] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 7.6] [Reference Citation Analysis]
485 Chen YJ, Mao R, Li XH, Cao QH, Chen ZH, Liu BX, Chen SL, Chen BL, He Y, Zeng ZR, Ben-Horin S, Rimola J, Rieder F, Xie XY, Chen MH. Real-Time Shear Wave Ultrasound Elastography Differentiates Fibrotic from Inflammatory Strictures in Patients with Crohn's Disease. Inflamm Bowel Dis 2018;24:2183-90. [PMID: 29718309 DOI: 10.1093/ibd/izy115] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
486 Sandborn WJ, Lee SD, Tarabar D, Louis E, Klopocka M, Klaus J, Reinisch W, Hébuterne X, Park DI, Schreiber S, Nayak S, Ahmad A, Banerjee A, Brown LS, Cataldi F, Gorelick KJ, Cheng JB, Hassan-Zahraee M, Clare R, D'Haens GR. Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study. Gut 2018;67:1824-35. [PMID: 28982740 DOI: 10.1136/gutjnl-2016-313457] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 12.6] [Reference Citation Analysis]
487 Aggeletopoulou I, Assimakopoulos SF, Konstantakis C, Triantos C. Interleukin 12/interleukin 23 pathway: Biological basis and therapeutic effect in patients with Crohn's disease. World J Gastroenterol 2018;24:4093-103. [PMID: 30271076 DOI: 10.3748/wjg.v24.i36.4093] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
488 Timmer A, de Sordi D, Menke E, Peplies J, Claßen M, Koletzko S, Otto-Sobotka F. Modeling determinants of satisfaction with health care in youth with inflammatory bowel disease: a cross-sectional survey. Clin Epidemiol 2018;10:1289-305. [PMID: 30310323 DOI: 10.2147/CLEP.S165554] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
489 Yu Y, Zhu S, Li P, Min L, Zhang S. Helicobacter pylori infection and inflammatory bowel disease: a crosstalk between upper and lower digestive tract. Cell Death Dis 2018;9:961. [PMID: 30237392 DOI: 10.1038/s41419-018-0982-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
490 Coppell KJ, Galts CP, Huizing FY, Norton JK, Gray AR, Schultz K, Hobbs CE, Aluzaite K, Schultz M. Annual Incidence and Phenotypic Presentation of IBD in Southern New Zealand: An 18-Year Epidemiological Analysis. Inflamm Intest Dis 2018;3:32-9. [PMID: 30505840 DOI: 10.1159/000492615] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
491 Sebastián VP, Salazar GA, Coronado-Arrázola I, Schultz BM, Vallejos OP, Berkowitz L, Álvarez-Lobos MM, Riedel CA, Kalergis AM, Bueno SM. Heme Oxygenase-1 as a Modulator of Intestinal Inflammation Development and Progression. Front Immunol 2018;9:1956. [PMID: 30258436 DOI: 10.3389/fimmu.2018.01956] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 7.8] [Reference Citation Analysis]
492 Krela-Kazmierczak I, Szymczak-Tomczak A, Tomczak M, Lykowska-Szuber L, Eder P, Kucharski MA, Stawczyk-Eder K, Waszak K, Karczewski J, Dobrowolska A. Is there a relation between vitamin D, interleukin-17, and bone mineral density in patients with inflammatory bowel disease? Arch Med Sci 2021;17:662-74. [PMID: 34025836 DOI: 10.5114/aoms.2018.78009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
493 Catalano O, Kilcoyne A, Signore A, Mahmood U, Rosen B. Lower Gastrointestinal Tract Applications of PET/Computed Tomography and PET/MR Imaging. Radiol Clin North Am 2018;56:821-34. [PMID: 30119776 DOI: 10.1016/j.rcl.2018.05.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
494 Hansson-Hedblom A, Almond C, Borgström F, Sly I, Enkusson D, Troelsgaard Buchholt A, Karlsson L. Cost-effectiveness of ustekinumab in moderate to severe Crohn's disease in Sweden. Cost Eff Resour Alloc 2018;16:28. [PMID: 30123097 DOI: 10.1186/s12962-018-0114-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
495 Kasembeli MM, Bharadwaj U, Robinson P, Tweardy DJ. Contribution of STAT3 to Inflammatory and Fibrotic Diseases and Prospects for its Targeting for Treatment. Int J Mol Sci 2018;19:E2299. [PMID: 30081609 DOI: 10.3390/ijms19082299] [Cited by in Crossref: 73] [Cited by in F6Publishing: 81] [Article Influence: 14.6] [Reference Citation Analysis]
496 Schreiber S, Siegel CA, Friedenberg KA, Younes ZH, Seidler U, Bhandari BR, Wang K, Wendt E, McKevitt M, Zhao S, Sundy JS, Lee SD, Loftus EV. A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn's Disease. J Crohns Colitis 2018;12:1014-20. [PMID: 29846530 DOI: 10.1093/ecco-jcc/jjy070] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
497 Taguchi N, Oda S, Kobayashi T, Naoe H, Sasaki Y, Imuta M, Nakaura T, Yamashita Y. Advanced parametric imaging for evaluation of Crohn's disease using dual-energy computed tomography enterography. Radiol Case Rep 2018;13:709-12. [PMID: 30050596 DOI: 10.1016/j.radcr.2018.04.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
498 Li H, Shi FH, Huang SY, Zhang SG, Gu ZC, Wei JF. Clinical adverse effects of natalizumab: Protocol for a meta-analysis of randomized double-blind placebo-controlled clinical trails. Medicine (Baltimore) 2018;97:e11507. [PMID: 29995817 DOI: 10.1097/MD.0000000000011507] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
499 Kim MS, Kim JY. Ginger attenuates inflammation in a mouse model of dextran sulfate sodium-induced colitis. Food Sci Biotechnol 2018;27:1493-501. [PMID: 30319860 DOI: 10.1007/s10068-018-0438-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
500 Cai X, Shen W, Guo Z, Li Y, Cao L, Gong J, Zhu W. Thickness of Subcutaneous Fat Is a Predictive Factor of Incisional Surgical Site Infection in Crohn's Disease Surgery: A Retrospective Study. Gastroenterol Res Pract 2018;2018:1546075. [PMID: 30140279 DOI: 10.1155/2018/1546075] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
501 Pagnini C, Siakavellas SI, Bamias G. Systematic Review with Network Meta-Analysis: Efficacy of Induction Therapy with a Second Biological Agent in Anti-TNF-Experienced Crohn's Disease Patients. Gastroenterol Res Pract 2018;2018:6317057. [PMID: 30116266 DOI: 10.1155/2018/6317057] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
502 Barnhoorn M, de Jonge-Muller E, Molendijk I, van Gulijk M, Lebbink O, Janson S, Schoonderwoerd M, van der Helm D, van der Meulen-de Jong A, Hawinkels L, Verspaget H. Endoscopic Administration of Mesenchymal Stromal Cells Reduces Inflammation in Experimental Colitis. Inflamm Bowel Dis 2018;24:1755-67. [PMID: 29796655 DOI: 10.1093/ibd/izy130] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
503 Bo L, Fu H, Yang J. Comprehensive analysis of gene expression profiles provides insight into the pathogenesis of Crohn's disease. Mol Med Rep 2018;18:2643-50. [PMID: 30015893 DOI: 10.3892/mmr.2018.9267] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
504 Kameyama H, Nagahashi M, Shimada Y, Tajima Y, Ichikawa H, Nakano M, Sakata J, Kobayashi T, Narayanan S, Takabe K, Wakai T. Genomic characterization of colitis-associated colorectal cancer. World J Surg Oncol 2018;16:121. [PMID: 29966533 DOI: 10.1186/s12957-018-1428-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
505 Zhang M, Merlin D. Nanoparticle-Based Oral Drug Delivery Systems Targeting the Colon for Treatment of Ulcerative Colitis. Inflamm Bowel Dis 2018;24:1401-15. [PMID: 29788186 DOI: 10.1093/ibd/izy123] [Cited by in Crossref: 64] [Cited by in F6Publishing: 65] [Article Influence: 12.8] [Reference Citation Analysis]
506 Vande Casteele N, Mould DR, Coarse J, Hasan I, Gils A, Feagan B, Sandborn WJ. Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's Disease. Clin Pharmacokinet 2017;56:1513-23. [PMID: 28353055 DOI: 10.1007/s40262-017-0535-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
507 Gollifer RM, Menys A, Makanyanga J, Puylaert CA, Vos FM, Stoker J, Atkinson D, Taylor SA. Relationship between MRI quantified small bowel motility and abdominal symptoms in Crohn's disease patients-a validation study. Br J Radiol 2018;91:20170914. [PMID: 29888980 DOI: 10.1259/bjr.20170914] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
508 Bokemeyer A, Tentrop N, Barth PJ, Lenze F, Hengst K, Kleinheinz J, Bettenworth D. Successful treatment of oral Crohn's disease by anti-TNF-alpha dose escalation - a case report. BMC Gastroenterol 2018;18:88. [PMID: 29914414 DOI: 10.1186/s12876-018-0818-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
509 Holko P, Kawalec P, Pilc A. Impact of Biologic Treatment of Crohn's Disease on the Rate of Surgeries and Other Healthcare Resources: An Analysis of a Nationwide Database From Poland. Front Pharmacol 2018;9:621. [PMID: 29942260 DOI: 10.3389/fphar.2018.00621] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
510 Feng Y, Liao Y, Huang W, Lai X, Luo J, Du C, Lin J, Zhang Z, Qiu D, Liu Q, Shen H, Xiang AP, Zhang Q. Mesenchymal stromal cells-derived matrix Gla protein contribute to the alleviation of experimental colitis. Cell Death Dis. 2018;9:691. [PMID: 29880866 DOI: 10.1038/s41419-018-0734-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
511 Vetter M, Neurath MF. Treatment Perspectives in Crohn's Disease. Digestion 2018;98:135-42. [PMID: 29870990 DOI: 10.1159/000488449] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
512 Mao R, Tang RH, Qiu Y, Chen BL, Guo J, Zhang SH, Li XH, Feng R, He Y, Li ZP, Zeng ZR, Eliakim R, Ben-Horin S, Chen MH. Different clinical outcomes in Crohn's disease patients with esophagogastroduodenal, jejunal, and proximal ileal disease involvement: is L4 truly a single phenotype? Therap Adv Gastroenterol. 2018;11:1756284818777938. [PMID: 29899757 DOI: 10.1177/1756284818777938] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
513 Shaikhkhalil AK, Boyle B, Smith J, Dotson JL, Donegan A, Kim SC, Maltz RM, Crandall W. Using Quality Improvement to Increase Utilization of Enteral Therapy in Pediatric Crohn Disease: Results and Outcomes. J Pediatr Gastroenterol Nutr 2018;66:909-14. [PMID: 29315161 DOI: 10.1097/MPG.0000000000001879] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
514 Tontini GE, Mudter J, Vieth M, Günther C, Milani V, Atreya R, Rath T, Nägel A, Hatem G, Sturniolo GC, Vecchi M, Neurath MF, Galle PR, Buda A, Neumann H. Prediction of clinical outcomes in Crohn's disease by using confocal laser endomicroscopy: results from a prospective multicenter study. Gastrointest Endosc 2018;87:1505-1514.e3. [PMID: 29108979 DOI: 10.1016/j.gie.2017.10.033] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
515 Li C. The Role of Endoplasmic Reticulum Stress in the Development of Fibrosis in Crohn’s Disease. Exploratory Research and Hypothesis in Medicine 2018;3:33-41. [DOI: 10.14218/erhm.2018.00003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
516 Bortlík M. Conventional and biological therapy for inflammatory bowel disease. Vnitr Lek 2018;64:642-653. [DOI: 10.36290/vnl.2018.088] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
517 Rosario M, Dirks NL, Milch C, Parikh A, Bargfrede M, Wyant T, Fedyk E, Fox I. A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab. Clin Pharmacokinet 2017;56:1287-301. [PMID: 28523450 DOI: 10.1007/s40262-017-0546-0] [Cited by in Crossref: 91] [Cited by in F6Publishing: 95] [Article Influence: 18.2] [Reference Citation Analysis]
518 Babic M, Romagnani C. The Role of Natural Killer Group 2, Member D in Chronic Inflammation and Autoimmunity. Front Immunol 2018;9:1219. [PMID: 29910814 DOI: 10.3389/fimmu.2018.01219] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
519 Folkerts J, Stadhouders R, Redegeld FA, Tam SY, Hendriks RW, Galli SJ, Maurer M. Effect of Dietary Fiber and Metabolites on Mast Cell Activation and Mast Cell-Associated Diseases. Front Immunol 2018;9:1067. [PMID: 29910798 DOI: 10.3389/fimmu.2018.01067] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
520 Nielsen OH, Rejnmark L, Moss AC. Role of Vitamin D in the Natural History of Inflammatory Bowel Disease. J Crohns Colitis 2018;12:742-52. [PMID: 29529167 DOI: 10.1093/ecco-jcc/jjy025] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 8.8] [Reference Citation Analysis]
521 Rivas MA, Avila BE, Koskela J, Huang H, Stevens C, Pirinen M, Haritunians T, Neale BM, Kurki M, Ganna A, Graham D, Glaser B, Peter I, Atzmon G, Barzilai N, Levine AP, Schiff E, Pontikos N, Weisburd B, Lek M, Karczewski KJ, Bloom J, Minikel EV, Petersen BS, Beaugerie L, Seksik P, Cosnes J, Schreiber S, Bokemeyer B, Bethge J, Heap G, Ahmad T, Plagnol V, Segal AW, Targan S, Turner D, Saavalainen P, Farkkila M, Kontula K, Palotie A, Brant SR, Duerr RH, Silverberg MS, Rioux JD, Weersma RK, Franke A, Jostins L, Anderson CA, Barrett JC, MacArthur DG, Jalas C, Sokol H, Xavier RJ, Pulver A, Cho JH, McGovern DPB, Daly MJ; International IBD Genetics Consortium., NIDDK IBD Genetics Consortium., T2D-GENES Consortium. Insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population. PLoS Genet 2018;14:e1007329. [PMID: 29795570 DOI: 10.1371/journal.pgen.1007329] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 9.6] [Reference Citation Analysis]
522 Catalan-Serra I, Brenna Ø. Immunotherapy in inflammatory bowel disease: Novel and emerging treatments. Hum Vaccin Immunother 2018;14:2597-611. [PMID: 29624476 DOI: 10.1080/21645515.2018.1461297] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
523 Zewde M, Kiyotani K, Park JH, Fang H, Yap KL, Yew PY, Alachkar H, Kato T, Mai TH, Ikeda Y, Matsuda T, Liu X, Ren L, Deng B, Harada M, Nakamura Y. The era of immunogenomics/immunopharmacogenomics. J Hum Genet 2018;63:865-75. [PMID: 29785006 DOI: 10.1038/s10038-018-0468-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
524 Xiao N, Liu F, Zhou G, Sun M, Ai F, Liu Z. Food-specific IgGs Are Highly Increased in the Sera of Patients with Inflammatory Bowel Disease and Are Clinically Relevant to the Pathogenesis. Intern Med 2018;57:2787-98. [PMID: 29780153 DOI: 10.2169/internalmedicine.9377-17] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
525 Shim HH, Ma C, Kotze PG, Seow CH, Al-Farhan H, Al-Darmaki AK, Pang JXQ, Fedorak RN, Devlin SM, Dieleman LA, Kaplan GG, Novak KL, Kroeker KI, Halloran BP, Panaccione R. Preoperative Ustekinumab Treatment Is Not Associated With Increased Postoperative Complications in Crohn's Disease: A Canadian Multi-Centre Observational Cohort Study. J Can Assoc Gastroenterol 2018;1:115-23. [PMID: 31294352 DOI: 10.1093/jcag/gwy013] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
526 Bossuyt P, Debeuckelaere C, Ferrante M, Vanbeckevoort D, Billiet T, Wolthuis A, van Assche G, D'Hoore A, Vermeire S. The operative risk and natural history after the diagnosis of ileal penetrating Crohn's disease. Eur J Gastroenterol Hepatol 2018;30:539-45. [PMID: 29462028 DOI: 10.1097/MEG.0000000000001091] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
527 Adedokun OJ, Xu Z, Gasink C, Jacobstein D, Szapary P, Johanns J, Gao LL, Davis HM, Hanauer SB, Feagan BG, Ghosh S, Sandborn WJ. Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease. Gastroenterology 2018;154:1660-71. [PMID: 29409871 DOI: 10.1053/j.gastro.2018.01.043] [Cited by in Crossref: 131] [Cited by in F6Publishing: 131] [Article Influence: 26.2] [Reference Citation Analysis]
528 Lopes S, Andrade P, Afonso J, Cunha R, Rodrigues-Pinto E, Ramos I, Macedo G, Magro F. Monitoring Crohn's disease activity: endoscopy, fecal markers and computed tomography enterography. Therap Adv Gastroenterol 2018;11:1756284818769075. [PMID: 29760785 DOI: 10.1177/1756284818769075] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
529 Yu HC, Chen TP, Chang YC. Inflammatory bowel disease as a risk factor for periodontitis under Taiwanese National Health Insurance Research database. J Dent Sci 2018;13:242-7. [PMID: 30895127 DOI: 10.1016/j.jds.2018.03.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
530 Holm TL, Tornehave D, Søndergaard H, Kvist PH, Sondergaard BC, Hansen L, Hermit MB, Holgersen K, Vergo S, Frederiksen KS, Haase C, Lundsgaard D. Evaluating IL-21 as a Potential Therapeutic Target in Crohn's Disease. Gastroenterol Res Pract 2018;2018:5962624. [PMID: 29849593 DOI: 10.1155/2018/5962624] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
531 Chandan JS, Thomas T. The impact of inflammatory bowel disease on oral health. Br Dent J 2017;222:549-53. [PMID: 28387295 DOI: 10.1038/sj.bdj.2017.318] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
532 Pockley AG, Lindsay JO, Foulds GA, Rutella S, Gribben JG, Alexander T, Snowden JA. Immune Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Crohn's Disease: Current Status and Future Directions. A Review on Behalf of the EBMT Autoimmune Diseases Working Party and the Autologous Stem Cell Transplantation In Refractory CD-Low Intensity Therapy Evaluation Study Investigators. Front Immunol 2018;9:646. [PMID: 29670622 DOI: 10.3389/fimmu.2018.00646] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
533 Schäffler H, Herlemann DP, Klinitzke P, Berlin P, Kreikemeyer B, Jaster R, Lamprecht G. Vitamin D administration leads to a shift of the intestinal bacterial composition in Crohn's disease patients, but not in healthy controls. J Dig Dis 2018;19:225-34. [PMID: 29573237 DOI: 10.1111/1751-2980.12591] [Cited by in Crossref: 66] [Cited by in F6Publishing: 66] [Article Influence: 13.2] [Reference Citation Analysis]
534 Schöllnast H. Radiologische Charakterisierung chronisch-entzündlicher Darmerkrankungen. Radiologe 2018;58:312-319. [DOI: 10.1007/s00117-018-0372-x] [Reference Citation Analysis]
535 Holko P, Kawalec P, Stawowczyk E. Prevalence and drug treatment practices of inflammatory bowel diseases in Poland in the years 2012-2014: an analysis of nationwide databases. Eur J Gastroenterol Hepatol 2018;30:456-64. [PMID: 29256907 DOI: 10.1097/MEG.0000000000001047] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
536 Roy S, Esmaeilniakooshkghazi A, Patnaik S, Wang Y, George SP, Ahrorov A, Hou JK, Herron AJ, Sesaki H, Khurana S. Villin-1 and Gelsolin Regulate Changes in Actin Dynamics That Affect Cell Survival Signaling Pathways and Intestinal Inflammation. Gastroenterology 2018;154:1405-1420.e2. [PMID: 29274870 DOI: 10.1053/j.gastro.2017.12.016] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
537 Cougnoux A, Movassaghi M, Picache JA, Iben JR, Navid F, Salman A, Martin K, Farhat NY, Cluzeau C, Tseng WC, Burkert K, Sojka C, Wassif CA, Cawley NX, Bonnet R, Porter FD. Gastrointestinal Tract Pathology in a BALB/c Niemann-Pick Disease Type C1 Null Mouse Model. Dig Dis Sci 2018;63:870-80. [PMID: 29357083 DOI: 10.1007/s10620-018-4914-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
538 Zhu C, Song K, Shen Z, Quan Y, Tan B, Luo W, Wu S, Tang K, Yang Z, Wang X. Roseburia intestinalis inhibits interleukin‑17 excretion and promotes regulatory T cells differentiation in colitis. Mol Med Rep 2018;17:7567-74. [PMID: 29620246 DOI: 10.3892/mmr.2018.8833] [Cited by in Crossref: 21] [Cited by in F6Publishing: 40] [Article Influence: 4.2] [Reference Citation Analysis]
539 Chen G, Ran X, Li B, Li Y, He D, Huang B, Fu S, Liu J, Wang W. Sodium Butyrate Inhibits Inflammation and Maintains Epithelium Barrier Integrity in a TNBS-induced Inflammatory Bowel Disease Mice Model. EBioMedicine. 2018;30:317-325. [PMID: 29627390 DOI: 10.1016/j.ebiom.2018.03.030] [Cited by in Crossref: 163] [Cited by in F6Publishing: 178] [Article Influence: 32.6] [Reference Citation Analysis]
540 Stamatiades GA, Ioannou P, Petrikkos G, Tsioutis C. Fungal infections in patients with inflammatory bowel disease: A systematic review. Mycoses 2018;61:366-76. [PMID: 29453860 DOI: 10.1111/myc.12753] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 5.6] [Reference Citation Analysis]
541 Schäffler H, Rohde M, Rohde S, Huth A, Gittel N, Hollborn H, Koczan D, Glass Ä, Lamprecht G, Jaster R. NOD2- and disease-specific gene expression profiles of peripheral blood mononuclear cells from Crohn’s disease patients. World J Gastroenterol 2018; 24(11): 1196-1205 [PMID: 29568200 DOI: 10.3748/wjg.v24.i11.1196] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
542 Galvis L, Sánchez ÁY, Jurado LF, Murcia MI. Tuberculosis associated with tumor necrosis factor-α antagonists, case description and analysis of reported cases in Colombia. biomedica 2018;38:7. [DOI: 10.7705/biomedica.v38i0.3273] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
543 Suarez K, Lim E, Singh S, Pereira M, Joosen LP, Ibeawuchi S, Dunkel Y, Mittal Y, Ho SB, Chattopadhyay R, Guma M, Boland BS, Dulai PS, Sandborn WJ, Ghosh P, Das S. Dysregulation of the engulfment pathway in the gut fuels Inflammatory Bowel Disease.. [DOI: 10.1101/280172] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
544 Bendix M, Greisen S, Dige A, Hvas CL, Bak N, Jørgensen SP, Dahlerup JF, Deleuran B, Agnholt J. Vitamin D increases programmed death receptor-1 expression in Crohn's disease. Oncotarget 2017;8:24177-86. [PMID: 28412753 DOI: 10.18632/oncotarget.15489] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
545 Sundblad V, Quintar AA, Morosi LG, Niveloni SI, Cabanne A, Smecuol E, Mauriño E, Mariño KV, Bai JC, Maldonado CA, Rabinovich GA. Galectins in Intestinal Inflammation: Galectin-1 Expression Delineates Response to Treatment in Celiac Disease Patients. Front Immunol 2018;9:379. [PMID: 29545799 DOI: 10.3389/fimmu.2018.00379] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
546 Li Y, Ge Y, Zhu W, Gong J, Cao L, Guo Z, Gu L, Li J. Increased enteric glial cells in proximal margin of resection is associated with postoperative recurrence of Crohn's disease. J Gastroenterol Hepatol 2018;33:638-44. [PMID: 28873259 DOI: 10.1111/jgh.13973] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
547 Schöffel N, Brüggmann D, Klingelhöfer D, Bendels MHK, Groneberg DA. Crohn's Disease: A Critical Approach to Publication Procedures and Citation Behavior of the Global Research Network. J Clin Gastroenterol 2018;52:246-54. [PMID: 29420359 DOI: 10.1097/MCG.0000000000000798] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
548 Bourgonje AR, von Martels JZH, de Vos P, Faber KN, Dijkstra G. Increased fecal calprotectin levels in Crohn's disease correlate with elevated serum Th1- and Th17-associated cytokines. PLoS One 2018;13:e0193202. [PMID: 29466406 DOI: 10.1371/journal.pone.0193202] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
549 Ciccocioppo R, Dos Santos CC, Baumgart DC, Cangemi GC, Cardinale V, Ciacci C, De Coppi P, Haldar D, Klersy C, Nostro MC, Ott M, Piemonti L, Tomei AA, Uygun B, Vetrano S, Orlando G. Proceedings of the signature series event of the international society for cellular therapy: "Advancements in cellular therapies and regenerative medicine in digestive diseases," London, United Kingdom, May 3, 2017. Cytotherapy 2018;20:461-76. [PMID: 29398624 DOI: 10.1016/j.jcyt.2017.12.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
550 Kotze PG, Ma C, Almutairdi A, Panaccione R. Clinical utility of ustekinumab in Crohn's disease. J Inflamm Res. 2018;11:35-47. [PMID: 29445293 DOI: 10.2147/jir.s157358] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
551 Berkowitz L, Schultz BM, Salazar GA, Pardo-Roa C, Sebastián VP, Álvarez-Lobos MM, Bueno SM. Impact of Cigarette Smoking on the Gastrointestinal Tract Inflammation: Opposing Effects in Crohn's Disease and Ulcerative Colitis. Front Immunol 2018;9:74. [PMID: 29441064 DOI: 10.3389/fimmu.2018.00074] [Cited by in Crossref: 81] [Cited by in F6Publishing: 87] [Article Influence: 16.2] [Reference Citation Analysis]
552 Le V, Crouser ED. Potential immunotherapies for sarcoidosis. Expert Opin Biol Ther 2018;18:399-407. [PMID: 29327613 DOI: 10.1080/14712598.2018.1427727] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
553 Bosca-Watts MM, Minguez M, Planelles D, Navarro S, Rodriguez A, Santiago J, Tosca J, Mora F. HLA-DQ: Celiac disease vs inflammatory bowel disease. World J Gastroenterol 2018; 24(1): 96-103 [PMID: 29358886 DOI: 10.3748/wjg.v24.i1.96] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
554 Lee S, Massie I, Meran L, Li VS. Extracellular Matrix Remodeling in Intestinal Homeostasis and Disease. Intestinal Stem Cell Niche 2018. [DOI: 10.1016/bs.asn.2018.01.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
555 Page AJ, Li H. Gastrointestinal mechanosensory function in health and disease. Mechanobiology in Health and Disease 2018. [DOI: 10.1016/b978-0-12-812952-4.00013-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
556 Gurram B. Diarrhea. Nelson Pediatric Symptom-Based Diagnosis 2018. [DOI: 10.1016/b978-0-323-39956-2.00011-x] [Reference Citation Analysis]
557 Schäffler H, Schmidt M, Huth A, Reiner J, Glass Ä, Lamprecht G. Clinical factors are associated with vitamin D levels in IBD patients: A retrospective analysis. J Dig Dis 2018;19:24-32. [PMID: 29232067 DOI: 10.1111/1751-2980.12565] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
558 Takeuchi K, Miyamura M, Arai T, Ishikawa R, Yamada A, Suzuki Y. Current Progress of Endoscopy in Inflammatory Bowel Disease: CT Enterography and CT Colonography in Inflammatory Bowel Disease. Advances in Endoscopy in Inflammatory Bowel Disease 2018. [DOI: 10.1007/978-4-431-56018-0_5] [Reference Citation Analysis]
559 D'Haens G, Vermeire S, Vogelsang H, Allez M, Desreumaux P, Van Gossum A, Sandborn WJ, Baumgart DC, Ransohoff RM, Comer GM, Ahmad A, Cataldi F, Cheng J, Clare R, Gorelick KJ, Kaminski A, Pradhan V, Rivers S, Sikpi MO, Zhang Y, Hassan-Zahraee M, Reinisch W, Stuve O. Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn's Disease: Report of the TOSCA Study. J Crohns Colitis 2018;12:188-96. [PMID: 28961770 DOI: 10.1093/ecco-jcc/jjx128] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
560 Shim HH, Seow CH. Cessation of Biologics: Can It Be Done? Treatment of Inflammatory Bowel Disease with Biologics 2018. [DOI: 10.1007/978-3-319-60276-9_10] [Reference Citation Analysis]
561 Lindenbaum GA, Marks JA, Price TP, Costa SA. Causes of Short Bowel Syndrome in Adults. Contemporary Small Bowel Transplantation 2018. [DOI: 10.1007/978-3-319-05547-3_24-1] [Reference Citation Analysis]
562 Bouhnik Y, Carbonnel F, Laharie D, Stefanescu C, Hébuterne X, Abitbol V, Nachury M, Brixi H, Bourreille A, Picon L, Bourrier A, Allez M, Peyrin-Biroulet L, Moreau J, Savoye G, Fumery M, Nancey S, Roblin X, Altwegg R, Bouguen G, Bommelaer G, Danese S, Louis E, Zappa M, Mary JY; GETAID CREOLE Study Group. Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. Gut 2018;67:53-60. [PMID: 28119352 DOI: 10.1136/gutjnl-2016-312581] [Cited by in Crossref: 146] [Cited by in F6Publishing: 112] [Article Influence: 29.2] [Reference Citation Analysis]
563 Catalano OA, Kilcoyne A, Lauri C, Signore A. PET/MRI in Inflammatory Diseases. PET/MR Imaging: Current and Emerging Applications 2018. [DOI: 10.1007/978-3-319-69641-6_9] [Reference Citation Analysis]
564 Park SH. The importance of immunization in immune-mediated inflammatory disease cannot be overstated. Intest Res 2018;16:325. [DOI: 10.5217/ir.2018.16.3.325] [Reference Citation Analysis]
565 Henson MA, Phalak P. Microbiota dysbiosis in inflammatory bowel diseases: in silico investigation of the oxygen hypothesis. BMC Syst Biol 2017;11:145. [PMID: 29282051 DOI: 10.1186/s12918-017-0522-1] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 7.5] [Reference Citation Analysis]
566 Ananthakrishnan AN, Luo C, Yajnik V, Khalili H, Garber JJ, Stevens BW, Cleland T, Xavier RJ. Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases. Cell Host Microbe 2017; 21: 603-610. e3. [PMID: 28494241 DOI: 10.1016/j.chom.2017.04.010] [Cited by in Crossref: 210] [Cited by in F6Publishing: 218] [Article Influence: 35.0] [Reference Citation Analysis]
567 Yamazaki H, So R, Matsuoka K, Kobayashi T, Shinzaki S, Matsuura M, Okabayashi S, Kataoka Y, Tsujimoto Y, Furukawa TA, Watanabe N. Certolizumab pegol for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2017. [DOI: 10.1002/14651858.cd012893] [Reference Citation Analysis]
568 Bähler C, Vavricka SR, Schoepfer AM, Brüngger B, Reich O. Trends in prevalence, mortality, health care utilization and health care costs of Swiss IBD patients: a claims data based study of the years 2010, 2012 and 2014. BMC Gastroenterol 2017;17:138. [PMID: 29197335 DOI: 10.1186/s12876-017-0681-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 5.8] [Reference Citation Analysis]
569 Kobayashi T, Hishida A, Tanaka H, Nuki Y, Bamba S, Yamada A, Fujii T, Shinzaki S, Yokoyama Y, Yoshida A, Ozeki K, Ashizuka S, Kamata N, Nanjo S, Kakimoto K, Nakamura M, Matsui A, Yamauchi R, Takahashi S, Tomizawa T, Yoshino T, Hibi T. Real-world Experience of Anti-tumor Necrosis Factor Therapy for Internal Fistulas in Crohn's Disease: A Retrospective Multicenter Cohort Study. Inflamm Bowel Dis 2017;23:2245-51. [PMID: 29084079 DOI: 10.1097/MIB.0000000000001276] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
570 Tse CS, Deepak P, Smyrk TC, Raffals LE. Isolated Acute Terminal Ileitis Without Preexisting Inflammatory Bowel Disease Rarely Progresses to Crohn's Disease. Dig Dis Sci 2017;62:3557-62. [PMID: 29064015 DOI: 10.1007/s10620-017-4803-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
571 Wang Y, Mao Y, Zhang J, Shi G, Cheng L, Lin Y, Li Y, Zhang X, Zhang Y, Chen X, Deng J, Su X, Dai L, Yang Y, Zhang S, Yu D, Wei Y, Deng H. IL-35 recombinant protein reverses inflammatory bowel disease and psoriasis through regulation of inflammatory cytokines and immune cells. J Cell Mol Med 2018;22:1014-25. [PMID: 29193791 DOI: 10.1111/jcmm.13428] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
572 Zhang AF, Miao YL. Strategies for remission induction of inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2017; 25(33): 2938-2944 [DOI: 10.11569/wcjd.v25.i33.2938] [Reference Citation Analysis]
573 Sun CM, Wu J, Zhang H, Shi G, Chen ZT. Circulating miR-125a but not miR-125b is decreased in active disease status and negatively correlates with disease severity as well as inflammatory cytokines in patients with Crohn’s disease. World J Gastroenterol 2017; 23(44): 7888-7898 [PMID: 29209130 DOI: 10.3748/wjg.v23.i44.7888] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
574 Borecki K, Zawada I, Pawinska-Matecka A, Salkic NN, Karakiewicz B, Adler G. ABCB1 3435C>T and 2677G>T/A polymorphisms in Polish and Bosnian patients with Crohn's disease - A preliminary report. Bosn J Basic Med Sci 2017;17:323-7. [PMID: 28759738 DOI: 10.17305/bjbms.2017.2172] [Reference Citation Analysis]
575 Abbass M, Cepek J, Parker CE, Nguyen TM, Macdonald JK, Feagan BG, Khanna R, Jairath V. Adalimumab for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2017. [DOI: 10.1002/14651858.cd012878] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
576 Rasmussen SC. Karen J. Brewer (1961-2014). Ruthenium Complexes 2017. [DOI: 10.1002/9783527695225.ch1] [Reference Citation Analysis]
577 Cepek J, Abbass M, Nguyen TM, Parker CE, Macdonald JK, Feagan BG, Jairath V, Khanna R. Adalimumab for maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2017. [DOI: 10.1002/14651858.cd012877] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
578 Pecoraro A, Nappi L, Crescenzi L, D'Armiento FP, Genovese A, Spadaro G. Chronic Diarrhea in Common Variable Immunodeficiency: a Case Series and Review of the Literature. J Clin Immunol. 2018;38:67-76. [PMID: 29138951 DOI: 10.1007/s10875-017-0461-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
579 Wang H, Zuo L, Zhao J, Dong J, Li Y, Gu L, Gong J, Liu Q, Zhu W. Impact of Preoperative Exclusive Enteral Nutrition on Postoperative Complications and Recurrence After Bowel Resection in Patients with Active Crohn's Disease. World J Surg 2016;40:1993-2000. [PMID: 26940580 DOI: 10.1007/s00268-016-3488-z] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
580 Allez M, Skolnick BE, Wisniewska-Jarosinska M, Petryka R, Overgaard RV. Anti-NKG2D monoclonal antibody (NNC0142-0002) in active Crohn's disease: a randomised controlled trial. Gut 2017;66:1918-25. [PMID: 27489241 DOI: 10.1136/gutjnl-2016-311824] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
581 Hoffmann M, Schwertassek U, Seydel A, Weber K, Hauschildt S, Lehmann J. Therapeutic efficacy of a combined sage and bitter apple phytopharmaceutical in chronic DSS-induced colitis. Sci Rep 2017;7:14214. [PMID: 29079781 DOI: 10.1038/s41598-017-13985-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
582 Ruiz MA, Kaiser Junior RL, de Quadros LG, Caseiro GHX, Oliveira AF, Peña-Arciniegas T, Piron-Ruiz L, Kaiser FSL, Oliveira VL. Hematopoietic stem cell transplantation in a severe refractory Crohn's disease patient with intestinal stoma: a case report. Int Med Case Rep J 2017;10:353-9. [PMID: 29123428 DOI: 10.2147/IMCRJ.S139552] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
583 Al-Saffar AK, Meijer CH, Gannavarapu VR, Hall G, Li Y, Diaz Tartera HO, Lördal M, Ljung T, Hellström PM, Webb DL. Parallel Changes in Harvey-Bradshaw Index, TNFα, and Intestinal Fatty Acid Binding Protein in Response to Infliximab in Crohn's Disease. Gastroenterol Res Pract 2017;2017:1745918. [PMID: 29201046 DOI: 10.1155/2017/1745918] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
584 Bjerrum JT, Steenholdt C, Ainsworth M, Nielsen OH, Reed MA, Atkins K, Günther UL, Hao F, Wang Y. Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease. BMC Med 2017;15:184. [PMID: 29032767 DOI: 10.1186/s12916-017-0949-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
585 Phillips BE, Garciafigueroa Y, Trucco M, Giannoukakis N. Clinical Tolerogenic Dendritic Cells: Exploring Therapeutic Impact on Human Autoimmune Disease. Front Immunol 2017;8:1279. [PMID: 29075262 DOI: 10.3389/fimmu.2017.01279] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 9.0] [Reference Citation Analysis]
586 Ruiz MA, Kaiser RL Jr, de Quadros LG, Piron-Ruiz L, Peña-Arciniegas T, Faria MAG, Siqueira RC, Pirozzi FF, Kaiser FSL, Burt RK. Low toxicity and favorable clinical and quality of life impact after non-myeloablative autologous hematopoietic stem cell transplant in Crohn's disease. BMC Res Notes 2017;10:495. [PMID: 28985769 DOI: 10.1186/s13104-017-2824-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
587 Rafia R, Scope A, Harnan S, Stevens JW, Stevenson M, Lobo A. Vedolizumab for Treating Moderately to Severely Active Crohn's Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics 2016;34:1241-53. [PMID: 27480631 DOI: 10.1007/s40273-016-0436-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
588 Hwang SW, Kim JH, Im JP, Ye BD, Koo HS, Huh KC, Cheon JH, Kim YS, Kim YH, Han DS, Kim WH, Kim JS; Crohn's disease clinical network and cohort (CONNECT) study. Influence of age at diagnosis on the clinical characteristics of Crohn's disease in Korea: Results from the CONNECT study. J Gastroenterol Hepatol 2017;32:1716-22. [PMID: 28251684 DOI: 10.1111/jgh.13775] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
589 Seo H, Ye BD, Song EM, Lee SH, Chang K, Lee HS, Hwang SW, Park SH, Yang DH, Kim KJ, Byeon JS, Myung SJ, Yang SK. Long-Term Outcomes of Adalimumab Treatment in 254 Patients with Crohn's Disease: A Hospital-Based Cohort Study from Korea. Dig Dis Sci 2017;62:2882-93. [PMID: 28822006 DOI: 10.1007/s10620-017-4715-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
590 Soendergaard C, Kvist PH, Thygesen P, Reslow M, Nielsen OH, Kopchick JJ, Holm TL. Characterization of Growth Hormone Resistance in Experimental and Ulcerative Colitis. Int J Mol Sci. 2017;18:2046. [PMID: 28946616 DOI: 10.3390/ijms18102046] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
591 Dudley-Brown S. Optimizing Inflammatory Bowel Disease Management: An Overview for the Gastroenterology Nurse. Gastroenterol Nurs 2017;40 Suppl 1S:S1-S14. [PMID: 27922458 DOI: 10.1097/SGA.0000000000000277] [Reference Citation Analysis]
592 Ardesia M, Costantino G, Mondello P, Alibrandi A, Fries W. Serology of Viral Infections and Tuberculosis Screening in an IBD Population Referred to a Tertiary Centre of Southern Italy. Gastroenterol Res Pract 2017;2017:4139656. [PMID: 29075289 DOI: 10.1155/2017/4139656] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
593 Higueras MÁ, Jiménez-García L, Herranz S, Hortelano S, Luque A. Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response. J Vis Exp 2017. [PMID: 28994756 DOI: 10.3791/55824] [Reference Citation Analysis]
594 Wang L, Yu Z, Wan S, Wu F, Chen W, Zhang B, Lin D, Liu J, Xie H, Sun X, Wu Z. Exosomes Derived from Dendritic Cells Treated with Schistosoma japonicum Soluble Egg Antigen Attenuate DSS-Induced Colitis. Front Pharmacol 2017;8:651. [PMID: 28959207 DOI: 10.3389/fphar.2017.00651] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 8.3] [Reference Citation Analysis]
595 Cooper J, Blake I, Lindsay JO, Hawkey CJ. Living with Crohn's disease: an exploratory cross-sectional qualitative study into decision-making and expectations in relation to autologous haematopoietic stem cell treatment (the DECIDES study). BMJ Open 2017;7:e015201. [PMID: 28893742 DOI: 10.1136/bmjopen-2016-015201] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
596 Hughes ER, Winter MG, Duerkop BA, Spiga L, Furtado de Carvalho T, Zhu W, Gillis CC, Büttner L, Smoot MP, Behrendt CL, Cherry S, Santos RL, Hooper LV, Winter SE. Microbial Respiration and Formate Oxidation as Metabolic Signatures of Inflammation-Associated Dysbiosis. Cell Host Microbe 2017;21:208-19. [PMID: 28182951 DOI: 10.1016/j.chom.2017.01.005] [Cited by in Crossref: 172] [Cited by in F6Publishing: 172] [Article Influence: 28.7] [Reference Citation Analysis]
597 Vetter M, Neurath MF. Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges. Therap Adv Gastroenterol 2017;10:773-90. [PMID: 29051788 DOI: 10.1177/1756283X17727388] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
598 Langbrandtner J, Hüppe A, Jessen P, Büning J, Nikolaus S, Raspe H, Bokemeyer B. Quality of care in inflammatory bowel disease: results of a prospective controlled cohort study in Germany (NETIBD). Clin Exp Gastroenterol 2017;10:215-27. [PMID: 28919797 DOI: 10.2147/CEG.S135346] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
599 Feldbrügge L, Moss AC, Yee EU, Csizmadia E, Mitsuhashi S, Longhi MS, Sandhu B, Stephan H, Wu Y, Cheifetz AS, Müller CE, Sévigny J, Robson SC, Jiang ZG. Expression of Ecto-nucleoside Triphosphate Diphosphohydrolases-2 and -3 in the Enteric Nervous System Affects Inflammation in Experimental Colitis and Crohn's Disease. J Crohns Colitis 2017;11:1113-23. [PMID: 28472257 DOI: 10.1093/ecco-jcc/jjx058] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
600 de Barros KSC, Flores C, Harlacher L, Francesconi CFM. Evolution of Clinical Behavior in Crohn's Disease: Factors Associated with Complicated Disease and Surgery. Dig Dis Sci 2017;62:2481-8. [PMID: 28748409 DOI: 10.1007/s10620-017-4685-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
601 Li J, Ueno A, Iacucci M, Fort Gasia M, Jijon HB, Panaccione R, Kaplan GG, Beck PL, Luider J, Barkema HW, Qian J, Gui X, Ghosh S. Crossover Subsets of CD4(+) T Lymphocytes in the Intestinal Lamina Propria of Patients with Crohn's Disease and Ulcerative Colitis. Dig Dis Sci 2017;62:2357-68. [PMID: 28573508 DOI: 10.1007/s10620-017-4596-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
602 Schäffler H, Huth A, Lamprecht G, Anders O. Vedolizumab Treatment for Ulcerative Colitis in an Elderly Multimorbid Patient with Hemophilia A. Case Rep Gastroenterol 2017;11:774-9. [PMID: 29606934 DOI: 10.1159/000485372] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
603 Battat R, Kopylov U, Bessissow T, Bitton A, Cohen A, Jain A, Martel M, Seidman E, Afif W. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease. Clin Gastroenterol Hepatol 2017;15:1427-1434.e2. [PMID: 28365485 DOI: 10.1016/j.cgh.2017.03.032] [Cited by in Crossref: 148] [Cited by in F6Publishing: 86] [Article Influence: 24.7] [Reference Citation Analysis]
604 Troncoso LL, Biancardi AL, de Moraes Jr HV, Zaltman C. Ophthalmic manifestations in patients with inflammatory bowel disease: A review. World J Gastroenterol 2017; 23(32): 5836-5848 [PMID: 28932076 DOI: 10.3748/wjg.v23.i32.5836] [Cited by in CrossRef: 62] [Cited by in F6Publishing: 61] [Article Influence: 10.3] [Reference Citation Analysis]
605 Zwicker S, Lira-Junior R, Höög C, Almer S, Boström EA. Systemic Chemokine Levels with "Gut-Specific" Vedolizumab in Patients with Inflammatory Bowel Disease-A Pilot Study. Int J Mol Sci 2017;18:E1827. [PMID: 28829369 DOI: 10.3390/ijms18081827] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
606 Rabbi MF, Eissa N, Munyaka PM, Kermarrec L, Elgazzar O, Khafipour E, Bernstein CN, Ghia JE. Reactivation of Intestinal Inflammation Is Suppressed by Catestatin in a Murine Model of Colitis via M1 Macrophages and Not the Gut Microbiota. Front Immunol 2017;8:985. [PMID: 28871257 DOI: 10.3389/fimmu.2017.00985] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
607 Taylor KM, Hanscombe KB, Iniesta R, Traylor M, Taylor NS, Powell N, Irving PM, Anderson SH, Prescott NJ, Mathew CG, Lewis CM, Sanderson JD. Predictors of intestinal inflammation in asymptomatic first-degree relatives of patients with Crohn’s disease.. [DOI: 10.1101/173492] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
608 Choi M, Lim S, Choi MG, Shim KN, Lee SH. Effectiveness of Capsule Endoscopy Compared with Other Diagnostic Modalities in Patients with Small Bowel Crohn's Disease: A Meta-Analysis. Gut Liver 2017;11:62-72. [PMID: 27728963 DOI: 10.5009/gnl16015] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
609 Bähler C, Schoepfer AM, Vavricka SR, Brüngger B, Reich O. Chronic comorbidities associated with inflammatory bowel disease: prevalence and impact on healthcare costs in Switzerland. Eur J Gastroenterol Hepatol 2017;29:916-25. [PMID: 28471826 DOI: 10.1097/MEG.0000000000000891] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 8.2] [Reference Citation Analysis]
610 More S, Bøtner A, Butterworth A, Calistri P, Depner K, Edwards S, Garin-Bastuji B, Good M, Gortázar Schmidt C, Michel V, Miranda MA, Nielsen SS, Raj M, Sihvonen L, Spoolder H, Stegeman JA, Thulke HH, Velarde A, Willeberg P, Winckler C, Baldinelli F, Broglia A, Zancanaro G, Beltrán-Beck B, Kohnle L, Morgado J, Bicout D; EFSA Panel on Animal Health and Welfare (AHAW). Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): paratuberculosis. EFSA J 2017;15:e04960. [PMID: 32625604 DOI: 10.2903/j.efsa.2017.4960] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
611 Wang R, Gu X, Dai W, Ye J, Lu F, Chai Y, Fan G, Gonzalez FJ, Duan G, Qi Y. A lipidomics investigation into the intervention of celastrol in experimental colitis. Mol Biosyst 2016;12:1436-44. [PMID: 27021137 DOI: 10.1039/c5mb00864f] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
612 Feng JR, Qiu X, Wang F, Chen PF, Gao Q, Peng YN, Lin X, Liu Q, Liu J, Zhao Q, Li J. Diagnostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Crohn's Disease. Gastroenterol Res Pract 2017;2017:3526460. [PMID: 28798770 DOI: 10.1155/2017/3526460] [Cited by in Crossref: 23] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
613 Li J, Doty AL, Tang Y, Berrie D, Iqbal A, Tan SA, Clare-Salzler MJ, Wallet SM, Glover SC. Enrichment of IL-17A+ IFN-γ+ and IL-22+ IFN-γ+ T cell subsets is associated with reduction of NKp44+ ILC3s in the terminal ileum of Crohn's disease patients. Clin Exp Immunol 2017;190:143-53. [PMID: 28586085 DOI: 10.1111/cei.12996] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
614 Zhu Y, Zhou W, Qi W, Liu W, Chen M, Zhu H, Xiang J, Xie Q, Chen P. Body mass index is a practical preoperative nutritional index for postoperative infectious complications after intestinal resection in patients with Crohn's disease.Medicine (Baltimore). 2017;96:e7113. [PMID: 28591060 DOI: 10.1097/MD.0000000000007113] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
615 Mahlich J, Matsuoka K, Nakamura Y, Sruamsiri R. The relationship between socio-demographic factors, health status, treatment type, and employment outcome in patients with inflammatory bowel disease in Japan. BMC Public Health 2017;17:623. [PMID: 28676039 DOI: 10.1186/s12889-017-4516-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
616 Fuchs F, Schillinger D, Atreya R, Hirschmann S, Fischer S, Neufert C, Atreya I, Neurath MF, Zundler S. Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles. Front Immunol 2017;8:764. [PMID: 28717358 DOI: 10.3389/fimmu.2017.00764] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 5.5] [Reference Citation Analysis]
617 Melhem H, Spalinger MR, Cosin-Roger J, Atrott K, Lang S, Wojtal KA, Vavricka SR, Rogler G, Frey-Wagner I. Prdx6 Deficiency Ameliorates DSS Colitis: Relevance of Compensatory Antioxidant Mechanisms. J Crohns Colitis 2017;11:871-84. [PMID: 28199527 DOI: 10.1093/ecco-jcc/jjx016] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
618 Sands BE, Chen J, Feagan BG, Penney M, Rees WA, Danese S, Higgins PDR, Newbold P, Faggioni R, Patra K, Li J, Klekotka P, Morehouse C, Pulkstenis E, Drappa J, van der Merwe R, Gasser RA Jr. Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study. Gastroenterology 2017;153:77-86.e6. [PMID: 28390867 DOI: 10.1053/j.gastro.2017.03.049] [Cited by in Crossref: 171] [Cited by in F6Publishing: 175] [Article Influence: 28.5] [Reference Citation Analysis]
619 Sandborn WJ, Rutgeerts P, Colombel JF, Ghosh S, Petryka R, Sands BE, Mitra P, Luo A. Eldelumab [anti-interferon-γ-inducible protein-10 antibody] Induction Therapy for Active Crohn's Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study. J Crohns Colitis 2017;11:811-9. [PMID: 28333187 DOI: 10.1093/ecco-jcc/jjx005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
620 Cohen L, Fathallah N, Pommaret E, de Parades V, Cosnes J. L’association maladie de Crohn et maladie de Verneuil : une crise annoncée ? La Presse Médicale 2017;46:777-778. [DOI: 10.1016/j.lpm.2017.05.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
621 Tian T, Wang Z, Zhang J. Pathomechanisms of Oxidative Stress in Inflammatory Bowel Disease and Potential Antioxidant Therapies. Oxid Med Cell Longev 2017;2017:4535194. [PMID: 28744337 DOI: 10.1155/2017/4535194] [Cited by in Crossref: 213] [Cited by in F6Publishing: 246] [Article Influence: 35.5] [Reference Citation Analysis]
622 Jeengar MK, Thummuri D, Magnusson M, Naidu VGM, Uppugunduri S. Uridine Ameliorates Dextran Sulfate Sodium (DSS)-Induced Colitis in Mice. Sci Rep 2017;7:3924. [PMID: 28634361 DOI: 10.1038/s41598-017-04041-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 6.7] [Reference Citation Analysis]
623 Oh K, Oh EH, Baek S, Song EM, Kim GU, Seo M, Hwang SW, Park SH, Yang DH, Kim KJ, Byeon JS, Myung SJ, Yang SK, Ye BD. Elevated C-reactive protein level during clinical remission can predict poor outcomes in patients with Crohn's disease. PLoS One. 2017;12:e0179266. [PMID: 28622356 DOI: 10.1371/journal.pone.0179266] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
624 Spadaccini M, D'Alessio S, Peyrin-Biroulet L, Danese S. PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue. Int J Mol Sci. 2017;18. [PMID: 28617319 DOI: 10.3390/ijms18061276] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
625 Krug SM, Bojarski C, Fromm A, Lee IM, Dames P, Richter JF, Turner JR, Fromm M, Schulzke JD. Tricellulin is regulated via interleukin-13-receptor α2, affects macromolecule uptake, and is decreased in ulcerative colitis. Mucosal Immunol 2018;11:345-56. [PMID: 28612843 DOI: 10.1038/mi.2017.52] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 6.0] [Reference Citation Analysis]
626 Nahum A, Filice G, Malhotra A. A Complicated Thread: Abdominal Actinomycosis in a Young Woman with Crohn Disease. Case Rep Gastroenterol 2017;11:377-81. [PMID: 28690491 DOI: 10.1159/000475917] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
627 Hensel KO, Abellan Schneyder FE, Wilke L, Heusch A, Wirth S, Jenke AC. Speckle Tracking Stress Echocardiography Uncovers Early Subclinical Cardiac Involvement in Pediatric Patients with Inflammatory Bowel Diseases. Sci Rep 2017;7:2966. [PMID: 28592829 DOI: 10.1038/s41598-017-03255-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
628 Qiu Y, Li MY, Feng T, Feng R, Mao R, Chen BL, He Y, Zeng ZR, Zhang SH, Chen MH. Systematic review with meta-analysis: the efficacy and safety of stem cell therapy for Crohn's disease. Stem Cell Res Ther 2017;8:136. [PMID: 28583202 DOI: 10.1186/s13287-017-0570-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
629 Suh SY, An WG. Systems Pharmacological Approach of Pulsatillae Radix on Treating Crohn's Disease. Evid Based Complement Alternat Med 2017;2017:4198035. [PMID: 28659988 DOI: 10.1155/2017/4198035] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
630 Wirtz S, Popp V, Kindermann M, Gerlach K, Weigmann B, Fichtner-Feigl S, Neurath MF. Chemically induced mouse models of acute and chronic intestinal inflammation. Nat Protoc. 2017;12:1295-1309. [PMID: 28569761 DOI: 10.1038/nprot.2017.044] [Cited by in Crossref: 538] [Cited by in F6Publishing: 562] [Article Influence: 89.7] [Reference Citation Analysis]
631 Panés J, Sandborn WJ, Schreiber S, Sands BE, Vermeire S, D'Haens G, Panaccione R, Higgins PDR, Colombel JF, Feagan BG, Chan G, Moscariello M, Wang W, Niezychowski W, Marren A, Healey P, Maller E. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. Gut 2017;66:1049-59. [PMID: 28209624 DOI: 10.1136/gutjnl-2016-312735] [Cited by in Crossref: 216] [Cited by in F6Publishing: 185] [Article Influence: 36.0] [Reference Citation Analysis]
632 Oh EH, Oh K, Han M, Seo H, Chang K, Lee SH, Kim GU, Song EM, Seo M, Lee HS, Hwang SW, Park SH, Yang DH, Kim KJ, Byeon JS, Myung SJ, Yang SK, Ye BD. Early anti-TNF/immunomodulator therapy is associated with better long-term clinical outcomes in Asian patients with Crohn's disease with poor prognostic factors. PLoS One 2017;12:e0177479. [PMID: 28542298 DOI: 10.1371/journal.pone.0177479] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
633 Bourgain C. Agir sur les gènes est- ce suffisant ? Archives de philosophie du droit 2017;Tome 59:39-52. [DOI: 10.3917/apd.591.0076] [Reference Citation Analysis]
634 Liu L, Zhao C, Yang Y, Kong X, Shao T, Ren L, Zhuang X, Yin B, Dryden G, McClain C, Luan W, Feng W. Fibroblast Growth Factor 21 Deficiency Attenuates Experimental Colitis-Induced Adipose Tissue Lipolysis. Gastroenterol Res Pract 2017;2017:3089378. [PMID: 28584524 DOI: 10.1155/2017/3089378] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
635 Lu JT, Xu AT, Shen J, Ran ZH. Crosstalk between intestinal epithelial cell and adaptive immune cell in intestinal mucosal immunity. J Gastroenterol Hepatol 2017;32:975-80. [PMID: 28072910 DOI: 10.1111/jgh.13723] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
636 Neurath MF. Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol 2017;14:269-78. [PMID: 28144028 DOI: 10.1038/nrgastro.2016.208] [Cited by in Crossref: 315] [Cited by in F6Publishing: 287] [Article Influence: 52.5] [Reference Citation Analysis]
637 Truffinet O, Martinez-Vinson C, Guerriero E, Hugot JP, Viala J. Tacrolimus Exerts Only a Transient Effectiveness in Refractory Pediatric Crohn Disease: A Case Series. J Pediatr Gastroenterol Nutr 2017;64:721-5. [PMID: 27429426 DOI: 10.1097/MPG.0000000000001338] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
638 Loktionov A, Chhaya V, Bandaletova T, Poullis A. Inflammatory bowel disease detection and monitoring by measuring biomarkers in non-invasively collected colorectal mucus. J Gastroenterol Hepatol 2017;32:992-1002. [PMID: 27787913 DOI: 10.1111/jgh.13627] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
639 Galeone C, Pelucchi C, Barbera G, Citterio C, La Vecchia C, Franchi A. Crohn's disease in Italy: A critical review of the literature using different data sources. Dig Liver Dis 2017;49:459-66. [PMID: 28109766 DOI: 10.1016/j.dld.2016.12.033] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
640 Chandan JS, Thomas T. Inflammatory bowel disease and oral health. BDJ Team 2017;4:17083. [DOI: 10.1038/bdjteam.2017.83] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
641 Resnick IB, Metodiev K, Lazarova P. Hematopoietic Cell Transplantation for Autoimmune Diseases: A Review of History, Current State, and Future Issues. Immunotherapy - Myths, Reality, Ideas, Future 2017. [DOI: 10.5772/67604] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
642 Valenti S, Gallizzi R, De Vivo D, Romano C. Intestinal Behçet and Crohn's disease: two sides of the same coin. Pediatr Rheumatol Online J 2017;15:33. [PMID: 28427473 DOI: 10.1186/s12969-017-0162-4] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 7.0] [Reference Citation Analysis]
643 Robinson AM, Rahman AA, Miller S, Stavely R, Sakkal S, Nurgali K. The neuroprotective effects of human bone marrow mesenchymal stem cells are dose-dependent in TNBS colitis. Stem Cell Res Ther 2017;8:87. [PMID: 28420434 DOI: 10.1186/s13287-017-0540-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
644 Vermeire S, Loftus EV Jr, Colombel JF, Feagan BG, Sandborn WJ, Sands BE, Danese S, D'Haens GR, Kaser A, Panaccione R, Rubin DT, Shafran I, McAuliffe M, Kaviya A, Sankoh S, Mody R, Abhyankar B, Smyth M. Long-term Efficacy of Vedolizumab for Crohn's Disease. J Crohns Colitis 2017;11:412-24. [PMID: 27683798 DOI: 10.1093/ecco-jcc/jjw176] [Cited by in Crossref: 27] [Cited by in F6Publishing: 52] [Article Influence: 4.5] [Reference Citation Analysis]
645 Deepak P, Park SH, Ehman EC, Hansel SL, Fidler JL, Bruining DH, Fletcher JG. Crohn's disease diagnosis, treatment approach, and management paradigm: what the radiologist needs to know. Abdom Radiol (NY) 2017;42:1068-86. [PMID: 28210767 DOI: 10.1007/s00261-017-1068-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
646 Uzzan M, Galicier L, Gornet JM, Oksenhendler E, Fieschi C, Allez M, Bouhnik Y, Kirchgesner J, Boutboul D, Treton X, Gérard L, Mahévas M, Cosnes J, Amiot A. Autoimmune cytopenias associated with inflammatory bowel diseases: Insights from a multicenter retrospective cohort. Dig Liver Dis 2017;49:397-404. [PMID: 28063954 DOI: 10.1016/j.dld.2016.12.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
647 Kucharzik T, Wittig BM, Helwig U, Börner N, Rössler A, Rath S, Maaser C; TRUST study group. Use of Intestinal Ultrasound to Monitor Crohn's Disease Activity. Clin Gastroenterol Hepatol 2017;15:535-542.e2. [PMID: 27856365 DOI: 10.1016/j.cgh.2016.10.040] [Cited by in Crossref: 114] [Cited by in F6Publishing: 88] [Article Influence: 19.0] [Reference Citation Analysis]
648 Ye L, Zhang YP, Yu N, Jia YX, Wan SJ, Wang FY. Serum platelet factor 4 is a reliable activity parameter in adult patients with inflammatory bowel disease: A pilot study. Medicine (Baltimore) 2017;96:e6323. [PMID: 28296751 DOI: 10.1097/MD.0000000000006323] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
649 Liu TC, Naito T, Liu Z, VanDussen KL, Haritunians T, Li D, Endo K, Kawai Y, Nagasaki M, Kinouchi Y, McGovern DP, Shimosegawa T, Kakuta Y, Stappenbeck TS. LRRK2 but not ATG16L1 is associated with Paneth cell defect in Japanese Crohn's disease patients. JCI Insight 2017;2:e91917. [PMID: 28352666 DOI: 10.1172/jci.insight.91917] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 5.8] [Reference Citation Analysis]
650 Battat R, Deol N, Nguyen TM, Parker CE, Khanna R, Feagan BG, Jairath V. Infliximab for maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2017. [DOI: 10.1002/14651858.cd012609] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
651 Lin C, Zhang J. Inflammasomes in Inflammation-Induced Cancer. Front Immunol 2017;8:271. [PMID: 28360909 DOI: 10.3389/fimmu.2017.00271] [Cited by in Crossref: 53] [Cited by in F6Publishing: 63] [Article Influence: 8.8] [Reference Citation Analysis]
652 Zundler S, Fischer A, Schillinger D, Binder MT, Atreya R, Rath T, Lopez-Pósadas R, Voskens CJ, Watson A, Atreya I, Neufert C, Neurath MF. The α4β1 Homing Pathway Is Essential for Ileal Homing of Crohn's Disease Effector T Cells In Vivo. Inflamm Bowel Dis 2017;23:379-91. [PMID: 28221249 DOI: 10.1097/MIB.0000000000001029] [Cited by in Crossref: 69] [Cited by in F6Publishing: 59] [Article Influence: 11.5] [Reference Citation Analysis]
653 Kmieć Z, Cyman M, Ślebioda TJ. Cells of the innate and adaptive immunity and their interactions in inflammatory bowel disease. Adv Med Sci 2017;62:1-16. [PMID: 28126697 DOI: 10.1016/j.advms.2016.09.001] [Cited by in Crossref: 65] [Cited by in F6Publishing: 58] [Article Influence: 10.8] [Reference Citation Analysis]
654 Oh EH, Ko DH, Seo H, Chang K, Kim GU, Song EM, Seo M, Lee HS, Hwang SW, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK, Park SH. Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease. World J Gastroenterol 2017; 23(8): 1489-1496 [PMID: 28293096 DOI: 10.3748/wjg.v23.i8.1489] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
655 Mantarro A, Scalise P, Guidi E, Neri E. Magnetic resonance enterography in Crohn’s disease: How we do it and common imaging findings. World J Radiol 2017; 9(2): 46-54 [PMID: 28298964 DOI: 10.4329/wjr.v9.i2.46] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
656 Lu ZJ, Wu JJ, Jiang WL, Xiao JH, Tao KZ, Ma L, Zheng P, Wan R, Wang XP. MicroRNA-155 promotes the pathogenesis of experimental colitis by repressing SHIP-1 expression. World J Gastroenterol 2017; 23(6): 976-985 [PMID: 28246471 DOI: 10.3748/wjg.v23.i6.976] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 38] [Article Influence: 6.3] [Reference Citation Analysis]
657 Petersen BS, Fredrich B, Hoeppner MP, Ellinghaus D, Franke A. Opportunities and challenges of whole-genome and -exome sequencing. BMC Genet 2017;18:14. [PMID: 28193154 DOI: 10.1186/s12863-017-0479-5] [Cited by in Crossref: 117] [Cited by in F6Publishing: 125] [Article Influence: 19.5] [Reference Citation Analysis]
658 van Erp S, Ercan E, Breedveld P, Brakenhoff L, Ghariq E, Schmid S, Osch MV, van Buchem M, Emmer B, van der Grond J, Wolterbeek R, Hommes D, Fidder H, van der Wee N, Huizinga T, van der Heijde D, Middelkoop H, Ronen I, van der Meulen-de Jong A. Cerebral magnetic resonance imaging in quiescent Crohn’s disease patients with fatigue. World J Gastroenterol 2017; 23(6): 1018-1029 [PMID: 28246475 DOI: 10.3748/wjg.v23.i6.1018] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
659 Chen Y, Salem M, Boyd M, Bornholdt J, Li Y, Coskun M, Seidelin JB, Sandelin A, Nielsen OH. Relation between NOD2 genotype and changes in innate signaling in Crohn's disease on mRNA and miRNA levels. NPJ Genom Med 2017;2:3. [PMID: 29263823 DOI: 10.1038/s41525-016-0001-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
660 Darr U, Khan N. Treat to Target in Inflammatory Bowel Disease: An Updated Review of Literature. Curr Treat Options Gastroenterol. 2017;15:116-125. [PMID: 28161818 DOI: 10.1007/s11938-017-0130-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
661 Nemati S, Teimourian S. An Overview of Inflammatory Bowel Disease: General Consideration and Genetic Screening Approach in Diagnosis of Early Onset Subsets. Middle East J Dig Dis. 2017;9:69-80. [PMID: 28638582 DOI: 10.15171/mejdd.2017.54] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
662 Kotze PG, Saab MP, Saab B, da Silva Kotze LM, Olandoski M, Pinheiro LV, Martinez CA, Ayrizono ML, Magro DO, Coy CS. Tumor Necrosis Factor Alpha Inhibitors Did Not Influence Postoperative Morbidity After Elective Surgical Resections in Crohn's Disease. Dig Dis Sci 2017;62:456-64. [PMID: 27933472 DOI: 10.1007/s10620-016-4400-2] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 7.3] [Reference Citation Analysis]
663 Stappenbeck TS, McGovern DPB. Paneth Cell Alterations in the Development and Phenotype of Crohn's Disease. Gastroenterology 2017;152:322-6. [PMID: 27729212 DOI: 10.1053/j.gastro.2016.10.003] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
664 Yajnik V, Khan N, Dubinsky M, Axler J, James A, Abhyankar B, Lasch K. Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age. Adv Ther 2017;34:542-59. [PMID: 28070861 DOI: 10.1007/s12325-016-0467-6] [Cited by in Crossref: 59] [Cited by in F6Publishing: 60] [Article Influence: 9.8] [Reference Citation Analysis]
665 Coretti L, Natale A, Cuomo M, Florio E, Keller S, Lembo F, Chiariotti L, Pero R. The Interplay between Defensins and Microbiota in Crohn's Disease. Mediators Inflamm 2017;2017:8392523. [PMID: 28246439 DOI: 10.1155/2017/8392523] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
666 Rumman A, Candia R, Sam JJ, Croitoru K, Silverberg MS, Steinhart AH, Nguyen GC. Public versus Private Drug Insurance and Outcomes of Patients Requiring Biologic Therapies for Inflammatory Bowel Disease. Can J Gastroenterol Hepatol 2017;2017:7365937. [PMID: 28239601 DOI: 10.1155/2017/7365937] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
667 Földes A, Kádár K, Kerémi B, Zsembery Á, Gyires K, S Zádori Z, Varga G. Mesenchymal Stem Cells of Dental Origin-Their Potential for Antiinflammatory and Regenerative Actions in Brain and Gut Damage. Curr Neuropharmacol 2016;14:914-34. [PMID: 26791480 DOI: 10.2174/1570159x14666160121115210] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
668 Hampshire T, Menys A, Jaffer A, Bhatnagar G, Punwani S, Atkinson D, Halligan S, Hawkes DJ, Taylor SA. A Probabilistic Method for Estimation of Bowel Wall Thickness in MR Colonography. PLoS One 2017;12:e0168317. [PMID: 28072831 DOI: 10.1371/journal.pone.0168317] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
669 Alves de Almeida AC, de-Faria FM, Dunder RJ, Manzo LP, Souza-Brito AR, Luiz-Ferreira A. Recent Trends in Pharmacological Activity of Alkaloids in Animal Colitis: Potential Use for Inflammatory Bowel Disease. Evid Based Complement Alternat Med 2017;2017:8528210. [PMID: 28191024 DOI: 10.1155/2017/8528210] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
670 Hedjoudje A, Cheurfa C, Briquez C, Zhang A, Koch S, Vuitton L. rs2476601 polymorphism in PTPN22 is associated with Crohn's disease but not with ulcerative colitis: a meta-analysis of 16,838 cases and 13,356 controls. Ann Gastroenterol 2017;30:197-208. [PMID: 28243041 DOI: 10.20524/aog.2017.0121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
671 Zamani S, Zali MR, Aghdaei HA, Sechi LA, Niegowska M, Caggiu E, Keshavarz R, Mosavari N, Feizabadi MM. Mycobacterium avium subsp. paratuberculosis and associated risk factors for inflammatory bowel disease in Iranian patients. Gut Pathog 2017;9:1. [PMID: 28053669 DOI: 10.1186/s13099-016-0151-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
672 Treister N, Saavedra A, Villa A. Clinical Immunology in Diagnoses of Maxillofacial Disease. Contemporary Oral Medicine 2017. [DOI: 10.1007/978-3-319-28100-1_5-1] [Reference Citation Analysis]
673 Biancheri P, Macdonald TT. Matrix Metalloproteinases. Crohn's Disease and Ulcerative Colitis 2017. [DOI: 10.1007/978-3-319-33703-6_13] [Reference Citation Analysis]
674 Macartney K, Crawford N. Management and Prevention of Infectious Diseases in IBD Patients. Crohn's Disease and Ulcerative Colitis 2017. [DOI: 10.1007/978-3-319-33703-6_59] [Reference Citation Analysis]
675 Kanai T. Leukocytapheresis Therapy of Inflammatory Bowel Disease. Crohn's Disease and Ulcerative Colitis 2017. [DOI: 10.1007/978-3-319-33703-6_49] [Reference Citation Analysis]
676 Bettenworth D, Gustavsson A, Atreja A, Lopez R, Tysk C, van Assche G, Rieder F. A Pooled Analysis of Efficacy, Safety, and Long-term Outcome of Endoscopic Balloon Dilation Therapy for Patients with Stricturing Crohn's Disease. Inflamm Bowel Dis 2017;23:133-42. [PMID: 28002130 DOI: 10.1097/MIB.0000000000000988] [Cited by in Crossref: 134] [Cited by in F6Publishing: 101] [Article Influence: 22.3] [Reference Citation Analysis]
677 Danese S, Bonovas S, Peyrin-Biroulet L. Biosimilars in IBD: from theory to practice. Nat Rev Gastroenterol Hepatol 2017;14:22-31. [PMID: 27729659 DOI: 10.1038/nrgastro.2016.155] [Cited by in Crossref: 66] [Cited by in F6Publishing: 54] [Article Influence: 11.0] [Reference Citation Analysis]
678 Bevins CL. The Immune System in IBD: Antimicrobial Peptides. Crohn's Disease and Ulcerative Colitis 2017. [DOI: 10.1007/978-3-319-33703-6_5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
679 Sands BE, Sandborn WJ, Van Assche G, Lukas M, Xu J, James A, Abhyankar B, Lasch K. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy. Inflamm Bowel Dis 2017;23:97-106. [PMID: 27930408 DOI: 10.1097/MIB.0000000000000979] [Cited by in Crossref: 113] [Cited by in F6Publishing: 98] [Article Influence: 18.8] [Reference Citation Analysis]
680 Van Pham P. Stem Cell Therapy for Autoimmune Disease. Stem Cell Biology and Regenerative Medicine 2017. [DOI: 10.1007/978-3-319-29149-9_11] [Reference Citation Analysis]
681 Kienle P. Crohn’s Disease. Coloproctology 2017. [DOI: 10.1007/978-3-662-53210-2_15] [Reference Citation Analysis]
682 Geboes K. Crohn’s Disease. Encyclopedia of Pathology 2017. [DOI: 10.1007/978-3-319-40560-5_1450] [Reference Citation Analysis]
683 Popp V, Gerlach K, Mott S, Turowska A, Garn H, Atreya R, Lehr HA, Ho IC, Renz H, Weigmann B, Neurath MF. Rectal Delivery of a DNAzyme That Specifically Blocks the Transcription Factor GATA3 and Reduces Colitis in Mice. Gastroenterology 2017;152:176-192.e5. [PMID: 27639807 DOI: 10.1053/j.gastro.2016.09.005] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 7.8] [Reference Citation Analysis]
684 Becker F, Vowinkel T. Platelets in Inflammatory Bowel Disease. Platelets in Thrombotic and Non-Thrombotic Disorders 2017. [DOI: 10.1007/978-3-319-47462-5_80] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
685 Budanur T, Şirin M, Sepet E, Ünür M, Güllüoğlu M, Cantez S, Uğurcan D. Orofacial Crohn’s disease: A case report. Balkan J Dent Med 2017;21:123-126. [DOI: 10.1515/bjdm-2017-0021] [Reference Citation Analysis]
686 Baumgart DC. Immunobiology of Human Dendritic Cells in Inflammatory Bowel Disease. Crohn's Disease and Ulcerative Colitis 2017. [DOI: 10.1007/978-3-319-33703-6_7] [Reference Citation Analysis]
687 Mao EJ, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther 2017;45:3-13. [PMID: 27862107 DOI: 10.1111/apt.13847] [Cited by in Crossref: 141] [Cited by in F6Publishing: 101] [Article Influence: 23.5] [Reference Citation Analysis]
688 Buttó LF, Haller D. Intestinal Microbiology and Ecology in Crohn’s Disease and Ulcerative Colitis. Crohn's Disease and Ulcerative Colitis 2017. [DOI: 10.1007/978-3-319-33703-6_4] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
689 Kumar M, Kissoon-Singh V, Coria AL, Moreau F, Chadee K. Probiotic mixture VSL#3 reduces colonic inflammation and improves intestinal barrier function in Muc2 mucin-deficient mice. Am J Physiol Gastrointest Liver Physiol 2017;312:G34-45. [PMID: 27856417 DOI: 10.1152/ajpgi.00298.2016] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 9.3] [Reference Citation Analysis]
690 Fortinsky KJ, Kevans D, Qiang J, Xu W, Bellolio F, Steinhart H, Milgrom R, Greenberg G, Cohen Z, Macrae H, Stempak J, McLeod R, Silverberg MS. Rates and Predictors of Endoscopic and Clinical Recurrence After Primary Ileocolic Resection for Crohn's Disease. Dig Dis Sci 2017;62:188-96. [PMID: 27778204 DOI: 10.1007/s10620-016-4351-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
691 Stevens BW, Borren NZ, Velonias G, Conway G, Cleland T, Andrews E, Khalili H, Garber JG, Xavier RJ, Yajnik V, Ananthakrishnan AN. Vedolizumab Therapy Is Associated with an Improvement in Sleep Quality and Mood in Inflammatory Bowel Diseases. Dig Dis Sci 2017;62:197-206. [PMID: 27796768 DOI: 10.1007/s10620-016-4356-2] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 6.7] [Reference Citation Analysis]
692 Blanco I. Other Diseases Associated With Alpha-1 Antitrypsin Deficiency. Blanco's Overview of Alpha-1 Antitrypsin Deficiency 2017. [DOI: 10.1016/b978-0-12-809530-0.00012-x] [Reference Citation Analysis]
693 Roth-walter F, Berger S, Luckschander-zeller N. Inflammatory Bowel Disease in Humans, Pets, and Horses. Comparative Medicine 2017. [DOI: 10.1007/978-3-319-47007-8_4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
694 Campos-vega R, Dave Oomah B, Vergara-castañeda HA. In VivoandIn VitroStudies on Dietary Fiber and Gut Health. Dietary Fiber Functionality in Food and Nutraceuticals 2016. [DOI: 10.1002/9781119138105.ch6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
695 Timmermans WM, van Laar JA, van Hagen PM, van Zelm MC. Immunopathogenesis of granulomas in chronic autoinflammatory diseases. Clin Transl Immunology 2016;5:e118. [PMID: 28090320 DOI: 10.1038/cti.2016.75] [Cited by in Crossref: 47] [Cited by in F6Publishing: 53] [Article Influence: 6.7] [Reference Citation Analysis]
696 Zou Y, Lin J, Li W, Wu Z, He Z, Huang G, Wang J, Ye C, Cheng X, Ding C, Zheng X, Chi H. Huangqin-tang ameliorates dextran sodium sulphate-induced colitis by regulating intestinal epithelial cell homeostasis, inflammation and immune response. Sci Rep. 2016;6:39299. [PMID: 27982094 DOI: 10.1038/srep39299] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 3.7] [Reference Citation Analysis]
697 Uzzan M, Ko HM, Mehandru S, Cunningham-Rundles C. Gastrointestinal Disorders Associated with Common Variable Immune Deficiency (CVID) and Chronic Granulomatous Disease (CGD). Curr Gastroenterol Rep 2016;18:17. [PMID: 26951230 DOI: 10.1007/s11894-016-0491-3] [Cited by in Crossref: 61] [Cited by in F6Publishing: 46] [Article Influence: 8.7] [Reference Citation Analysis]
698 Wu P, Jia F, Zhang B, Zhang P. Risk of cardiovascular disease in inflammatory bowel disease. Exp Ther Med 2017;13:395-400. [PMID: 28352306 DOI: 10.3892/etm.2016.3966] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 5.9] [Reference Citation Analysis]
699 Caneparo V, Pastorelli L, Pisani LF, Bruni B, Prodam F, Boldorini R, Roggenbuck D, Vecchi M, Landolfo S, Gariglio M, De Andrea M. Distinct Anti-IFI16 and Anti-GP2 Antibodies in Inflammatory Bowel Disease and Their Variation with Infliximab Therapy. Inflamm Bowel Dis 2016;22:2977-87. [PMID: 27636380 DOI: 10.1097/MIB.0000000000000926] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
700 Slevin SM, Dennedy MC, Connaughton EP, Ribeiro A, Ceredig R, Griffin MD, Egan LJ. Infliximab Selectively Modulates the Circulating Blood Monocyte Repertoire in Crohn's Disease. Inflamm Bowel Dis 2016;22:2863-78. [PMID: 27824651 DOI: 10.1097/MIB.0000000000000964] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
701 Uzzan M, Colombel JF, Cerutti A, Treton X, Mehandru S. B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases. Dig Dis Sci 2016;61:3407-24. [PMID: 27655102 DOI: 10.1007/s10620-016-4317-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
702 Zwicker S, Bureik D, Bosma M, Martinez GL, Almer S, Boström EA. Receptor-Type Protein-Tyrosine Phosphatase ζ and Colony Stimulating Factor-1 Receptor in the Intestine: Cellular Expression and Cytokine- and Chemokine Responses by Interleukin-34 and Colony Stimulating Factor-1. PLoS One 2016;11:e0167324. [PMID: 27898738 DOI: 10.1371/journal.pone.0167324] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
703 Loganes C, Valencic E, Pin A, Marini E, Martelossi S, Naviglio S, De Leo L, Not T, Monasta L, Tommasini A, Marcuzzi A. Ex vivo response to mucosal bacteria and muramyl dipeptide in inflammatory bowel disease. World J Gastroenterol 2016; 22(44): 9734-9743 [PMID: 27956797 DOI: 10.3748/wjg.v22.i44.9734] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
704 Weigmann B, Neurath MF. Th9 cells in inflammatory bowel diseases. Semin Immunopathol. 2017;39:89-95. [PMID: 27837255 DOI: 10.1007/s00281-016-0603-z] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]
705 Chan HC, Ng SC. Emerging biologics in inflammatory bowel disease. J Gastroenterol. 2017;52:141-150. [PMID: 27832357 DOI: 10.1007/s00535-016-1283-0] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 7.0] [Reference Citation Analysis]
706 Ciccocioppo R, Racca F, Scudeller L, Piralla A, Formagnana P, Pozzi L, Betti E, Vanoli A, Riboni R, Kruzliak P, Baldanti F, Corazza GR. Differential cellular localization of Epstein-Barr virus and human cytomegalovirus in the colonic mucosa of patients with active or quiescent inflammatory bowel disease. Immunol Res 2016;64:191-203. [PMID: 26659090 DOI: 10.1007/s12026-015-8737-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
707 Jeong EM, Son YH, Choi Y, Kim JH, Lee JH, Cho SY, Kim IG. Transglutaminase 2 is dispensable but required for the survival of mice in dextran sulfate sodium-induced colitis. Exp Mol Med 2016;48:e267. [PMID: 27811936 DOI: 10.1038/emm.2016.95] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
708 Kruse ML, Friedrich M, Arlt A, Röcken C, Egberts JH, Sebens S, Schäfer H. Colonic Lamina Propria Inflammatory Cells from Patients with IBD Induce the Nuclear Factor-E2 Related Factor-2 Thereby Leading to Greater Proteasome Activity and Apoptosis Protection in Human Colonocytes. Inflamm Bowel Dis 2016;22:2593-606. [PMID: 27661668 DOI: 10.1097/MIB.0000000000000925] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
709 Collij V, Festen EA, Alberts R, Weersma RK. Drug Repositioning in Inflammatory Bowel Disease Based on Genetic Information. Inflamm Bowel Dis 2016;22:2562-70. [PMID: 27753694 DOI: 10.1097/MIB.0000000000000912] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
710 Currò D, Ianiro G, Pecere S, Bibbò S, Cammarota G. Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders. Br J Pharmacol 2017;174:1426-49. [PMID: 27696378 DOI: 10.1111/bph.13632] [Cited by in Crossref: 82] [Cited by in F6Publishing: 90] [Article Influence: 11.7] [Reference Citation Analysis]
711 Vasovic M, Gajovic N, Brajkovic D, Jovanovic M, Zdravkovaic N, Kanjevac T. The relationship between the immune system and oral manifestations of inflammatory bowel disease: a review. Cent Eur J Immunol. 2016;41:302-310. [PMID: 27833449 DOI: 10.5114/ceji.2016.63131] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
712 Schindlbeck KA, Becker J, Berger F, Mehl A, Rewitzer C, Geffe S, Koch PM, Preiß JC, Siegmund B, Maul J, Marzinzik F. Impact of restless legs syndrome in patients with inflammatory bowel disease on sleep, fatigue, and quality of life. Int J Colorectal Dis 2017;32:125-30. [PMID: 27757540 DOI: 10.1007/s00384-016-2681-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
713 Yu Q, Mao R, Lian L, Ng SC, Zhang S, Chen Z, Zhang Y, Qiu Y, Chen B, He Y, Zeng Z, Ben-Horin S, Song X, Chen M. Surgical management of inflammatory bowel disease in China: a systematic review of two decades. Intest Res 2016;14:322-32. [PMID: 27799883 DOI: 10.5217/ir.2016.14.4.322] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
714 Tedjo DI, Smolinska A, Savelkoul PH, Masclee AA, van Schooten FJ, Pierik MJ, Penders J, Jonkers DM. The fecal microbiota as a biomarker for disease activity in Crohn's disease. Sci Rep 2016;6:35216. [PMID: 27734914 DOI: 10.1038/srep35216] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 7.3] [Reference Citation Analysis]
715 Guo J, Jiang X, Gui S. RNA interference-based nanosystems for inflammatory bowel disease therapy. Int J Nanomedicine 2016;11:5287-310. [PMID: 27789943 DOI: 10.2147/IJN.S116902] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 4.7] [Reference Citation Analysis]
716 Small CL, Xing L, McPhee JB, Law HT, Coombes BK. Acute Infectious Gastroenteritis Potentiates a Crohn's Disease Pathobiont to Fuel Ongoing Inflammation in the Post-Infectious Period. PLoS Pathog. 2016;12:e1005907. [PMID: 27711220 DOI: 10.1371/journal.ppat.1005907] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
717 Lopes F, Matisz C, Reyes JL, Jijon H, Al-Darmaki A, Kaplan GG, McKay DM. Helminth Regulation of Immunity: A Three-pronged Approach to Treat Colitis. Inflamm Bowel Dis 2016;22:2499-512. [PMID: 27575495 DOI: 10.1097/MIB.0000000000000889] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
718 Denson LA, Klein C. Granulocyte-Macrophage Colony Stimulating Factor Bioactivity and Mucosal Homeostasis in Crohn's Disease: A Role for Genetic Variation. Gastroenterology 2016;151:593-6. [PMID: 27590689 DOI: 10.1053/j.gastro.2016.08.042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
719 Fischer A, Zundler S, Atreya R, Rath T, Voskens C, Hirschmann S, López-Posadas R, Watson A, Becker C, Schuler G, Neufert C, Atreya I, Neurath MF. Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo. Gut 2016;65:1642-64. [PMID: 26209553 DOI: 10.1136/gutjnl-2015-310022] [Cited by in Crossref: 98] [Cited by in F6Publishing: 82] [Article Influence: 14.0] [Reference Citation Analysis]
720 Tziatzios G, Polymeros D, Spathis A, Triantafyllou M, Gkolfakis P, Karakitsos P, Dimitriadis G, Triantafyllou K. Increased levels of circulating platelet derived microparticles in Crohn's disease patients. Scand J Gastroenterol 2016;51:1184-92. [PMID: 27191369 DOI: 10.1080/00365521.2016.1182582] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
721 Levine AP, Pontikos N, Schiff ER, Jostins L, Speed D, Lovat LB, Barrett JC, Grasberger H, Plagnol V, Segal AW; NIDDK Inflammatory Bowel Disease Genetics Consortium. Genetic Complexity of Crohn's Disease in Two Large Ashkenazi Jewish Families. Gastroenterology 2016;151:698-709. [PMID: 27373512 DOI: 10.1053/j.gastro.2016.06.040] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 6.3] [Reference Citation Analysis]
722 Ashton JJ, Andreoletti G, Coelho T, Haggarty R, Batra A, Afzal NA, Beattie RM, Ennis S. Identification of Variants in Genes Associated with Single-gene Inflammatory Bowel Disease by Whole-exome Sequencing. Inflamm Bowel Dis 2016;22:2317-27. [PMID: 27537055 DOI: 10.1097/MIB.0000000000000890] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
723 Molina-Infante J, Schoepfer AM, Lucendo AJ, Dellon ES. Eosinophilic esophagitis: What can we learn from Crohn's disease? United European Gastroenterol J 2017;5:762-72. [PMID: 29026590 DOI: 10.1177/2050640616672953] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
724 Rivas MA, Koskela J, Huang H, Stevens C, Avila BE, Haritunians T, Neale BM, Kurki M, Ganna A, Graham D, Glaser B, Peter I, Atzmon G, Barzilai N, Levine AP, Schiff E, Pontikos N, Weisburd B, Karczewski KJ, Minikel EV, Petersen B, Beaugerie L, Seksik P, Cosnes J, Schreiber S, Bokemeyer B, Bethge J, Heap G, Ahmad T, Plagnol V, Segal AW, Targan S, Turner D, Saavalainen P, Farkkila M, Kontula K, Pirinen M, Palotie A, Brant SR, Duerr RH, Silverberg MS, Rioux JD, Weersma RK, Franke A, Macarthur DG, Jalas C, Sokol H, Xavier RJ, Pulver A, Cho JH, Mcgovern DP, Daly MJ, NIDDK IBD Genetics consortium, T2D-GENES consortium. Insights into the genetic epidemiology of Crohn’s and rare diseases in the Ashkenazi Jewish population.. [DOI: 10.1101/077180] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
725 Lira-Junior R, Figueredo CM. Periodontal and inflammatory bowel diseases: Is there evidence of complex pathogenic interactions? World J Gastroenterol 2016; 22(35): 7963-7972 [PMID: 27672291 DOI: 10.3748/wjg.v22.i35.7963] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 52] [Article Influence: 7.3] [Reference Citation Analysis]
726 Zhou G, Yu L, Yang W, Wu W, Fang L, Liu Z. Blockade of PLD2 Ameliorates Intestinal Mucosal Inflammation of Inflammatory Bowel Disease. Mediators Inflamm 2016;2016:2543070. [PMID: 27721573 DOI: 10.1155/2016/2543070] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
727 Luján-Sanchis M, Sanchis-Artero L, Larrey-Ruiz L, Peño-Muñoz L, Núñez-Martínez P, Castillo-López G, González-González L, Clemente CB, Albert Antequera C, Durá-Ayet A, Sempere-Garcia-Argüelles J. Current role of capsule endoscopy in Crohn’s disease. World J Gastrointest Endosc 2016; 8(17): 572-583 [PMID: 27668067 DOI: 10.4253/wjge.v8.i17.572] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
728 Mücke V, Mücke MM, Raine T, Bettenworth D. Diagnosis and treatment of anemia in patients with inflammatory bowel disease. Ann Gastroenterol 2017;30:15-22. [PMID: 28042234 DOI: 10.20524/aog.2016.0083] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
729 Hwang SW, Kwak MS, Kim WS, Lee JM, Park SH, Lee HS, Yang DH, Kim KJ, Ye BD, Byeon JS, Myung SJ, Yoon YS, Yu CS, Kim JH, Yang SK. Influence of a Positive Family History on the Clinical Course of Inflammatory Bowel Disease. J Crohns Colitis 2016;10:1024-32. [PMID: 26933029 DOI: 10.1093/ecco-jcc/jjw063] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
730 Deepak P, Fletcher JG, Fidler JL, Bruining DH. Computed Tomography and Magnetic Resonance Enterography in Crohn's Disease: Assessment of Radiologic Criteria and Endpoints for Clinical Practice and Trials. Inflamm Bowel Dis 2016;22:2280-8. [PMID: 27508513 DOI: 10.1097/MIB.0000000000000845] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.6] [Reference Citation Analysis]
731 Schoehl J, Mechie NC, Schwoerer H, Moerer O, Quintel M, Buck C, Ellenrieder V, Neesse A, Amanzada A. Severe Acute Respiratory Distress Syndrome during Infliximab Therapy in a Patient with Crohn Disease. Case Rep Gastroenterol 2016;10:574-80. [PMID: 27920644 DOI: 10.1159/000450676] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
732 Oikonomopoulos A, Polytarchou C, Joshi S, Hommes DW, Iliopoulos D. Identification of Circulating MicroRNA Signatures in Crohn's Disease Using the Nanostring nCounter Technology. Inflamm Bowel Dis 2016;22:2063-9. [PMID: 27542126 DOI: 10.1097/MIB.0000000000000883] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
733 Li J, Doty A, Glover SC. Aryl hydrocarbon receptor signaling involves in the human intestinal ILC3/ILC1 conversion in the inflamed terminal ileum of Crohn's disease patients. Inflamm Cell Signal 2016;3:e1404. [PMID: 28286805 DOI: 10.14800/ics.1404] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
734 Moćko P, Kawalec P, Smela-Lipińska B, Pilc A. Effectiveness and safety of vedolizumab for treatment of Crohn's disease: a systematic review and meta-analysis. Arch Med Sci 2016;12:1088-96. [PMID: 27695501 DOI: 10.5114/aoms.2016.61915] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
735 Candia R, Ibañez P, Nguyen GC. Colonoscopy-guided therapy for the prevention of post-operative recurrence of Crohn’s disease. Cochrane Database of Systematic Reviews 2016. [DOI: 10.1002/14651858.cd012328] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
736 Antoniou E, Margonis GA, Angelou A, Pikouli A, Argiri P, Karavokyros I, Papalois A, Pikoulis E. The TNBS-induced colitis animal model: An overview. Ann Med Surg (Lond). 2016;11:9-15. [PMID: 27656280 DOI: 10.1016/j.amsu.2016.07.019] [Cited by in Crossref: 169] [Cited by in F6Publishing: 176] [Article Influence: 24.1] [Reference Citation Analysis]
737 Ratsimandresy RA, Indramohan M, Dorfleutner A, Stehlik C. The AIM2 inflammasome is a central regulator of intestinal homeostasis through the IL-18/IL-22/STAT3 pathway. Cell Mol Immunol 2017;14:127-42. [PMID: 27524110 DOI: 10.1038/cmi.2016.35] [Cited by in Crossref: 84] [Cited by in F6Publishing: 91] [Article Influence: 12.0] [Reference Citation Analysis]
738 Melmed GY, McGovern D, Schreiber S, Kosutic G, Spearman M, Coarse J, Sandborn WJ. Early remission status predicts long-term outcomes in patients with Crohn's disease treated with certolizumab pegol. Curr Med Res Opin 2016;32:1937-41. [PMID: 27494777 DOI: 10.1080/03007995.2016.1221802] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
739 Li J, Ueno A, Fort Gasia M, Luider J, Wang T, Hirota C, Jijon HB, Deane M, Tom M, Chan R, Barkema HW, Beck PL, Kaplan GG, Panaccione R, Qian J, Iacucci M, Gui X, Ghosh S. Profiles of Lamina Propria T Helper Cell Subsets Discriminate Between Ulcerative Colitis and Crohn's Disease. Inflamm Bowel Dis 2016;22:1779-92. [PMID: 27243594 DOI: 10.1097/MIB.0000000000000811] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 7.7] [Reference Citation Analysis]
740 Masselli G, Mastroiacovo I, De Marco E, Francione G, Casciani E, Polettini E, Gualdi G. Current tecniques and new perpectives research of magnetic resonance enterography in pediatric Crohn’s disease. World J Radiol 2016; 8(7): 668-682 [PMID: 27551337 DOI: 10.4329/wjr.v8.i7.668] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
741 Timmermans WM, van Laar JA, van der Houwen TB, Kamphuis LS, Bartol SJ, Lam KH, Ouwendijk RJ, Sparrow MP, Gibson PR, van Hagen PM, van Zelm MC. B-Cell Dysregulation in Crohn's Disease Is Partially Restored with Infliximab Therapy. PLoS One 2016;11:e0160103. [PMID: 27468085 DOI: 10.1371/journal.pone.0160103] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
742 De Francesco F, Romano M, Zarantonello L, Ruffolo C, Neri D, Bassi N, Giordano A, Zanus G, Ferraro GA, Cillo U. The role of adipose stem cells in inflammatory bowel disease: From biology to novel therapeutic strategies. Cancer Biol Ther. 2016;17:889-898. [PMID: 27414952 DOI: 10.1080/15384047.2016.1210741] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
743 Nielsen OH, LaCasse EC. How genetic testing can lead to targeted management of XIAP deficiency-related inflammatory bowel disease. Genet Med 2017;19:133-43. [PMID: 27416006 DOI: 10.1038/gim.2016.82] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
744 Pagnini C, Menasci F, Desideri F, Corleto VD, Delle Fave G, Di Giulio E. Endoscopic scores for inflammatory bowel disease in the era of 'mucosal healing': Old problem, new perspectives. Dig Liver Dis 2016;48:703-8. [PMID: 27050942 DOI: 10.1016/j.dld.2016.03.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
745 Duque Ede A, Munhoz CD. The Pro-inflammatory Effects of Glucocorticoids in the Brain. Front Endocrinol (Lausanne) 2016;7:78. [PMID: 27445981 DOI: 10.3389/fendo.2016.00078] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 5.3] [Reference Citation Analysis]
746 Blander JM. Death in the intestinal epithelium-basic biology and implications for inflammatory bowel disease. FEBS J. 2016;283:2720-2730. [PMID: 27250564 DOI: 10.1111/febs.13771] [Cited by in Crossref: 104] [Cited by in F6Publishing: 106] [Article Influence: 14.9] [Reference Citation Analysis]
747 Ahmed I, Roy BC, Khan SA, Septer S, Umar S. Microbiome, Metabolome and Inflammatory Bowel Disease. Microorganisms. 2016;4:20. [PMID: 27681914 DOI: 10.3390/microorganisms4020020] [Cited by in Crossref: 105] [Cited by in F6Publishing: 108] [Article Influence: 15.0] [Reference Citation Analysis]
748 Aryan A, Azizi Z, Teimouri A, Ebrahimi Daryani N, Aletaha N, Jahanbakhsh A, Nouritaromlou MK, Alborzi F, Mami M, Basirat V, Javid Anbardan S. The Diagnostic Role of Magnetic Resonance Enterography as a Complementary Test to Colonoscopy in Active Crohn's Disease. Middle East J Dig Dis 2016;8:93-101. [PMID: 27252815 DOI: 10.15171/mejdd.2016.13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
749 Biancheri P, Foster MR, Fyfe MC, MacDonald TT, Sirohi S, Solanke Y, Wood E, Rowley A, Webber S, Walshe CA. Effect of Narrow Spectrum Versus Selective Kinase Inhibitors on the Intestinal Proinflammatory Immune Response in Ulcerative Colitis. Inflamm Bowel Dis 2016;22:1306-15. [PMID: 27104822 DOI: 10.1097/MIB.0000000000000759] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
750 Ginard D, Khorrami S, Pérez-carazo L, Tavío-hernández E, López-sanromán A, García-alvarado M, Muñoz F, Ibáñez-samaniego L, Marín-jiménez I, Guevara J, Casellas F. Efficacy and effectiveness of biologic therapy in inflammatory bowel disease. EFIFECT study. Gastroenterología y Hepatología (English Edition) 2016;39:369-376. [DOI: 10.1016/j.gastre.2016.05.008] [Reference Citation Analysis]
751 Chapman CG, Yamaguchi R, Tamura K, Weidner J, Imoto S, Kwon J, Fang H, Yew PY, Marino SR, Miyano S, Nakamura Y, Kiyotani K. Characterization of T-cell Receptor Repertoire in Inflamed Tissues of Patients with Crohn's Disease Through Deep Sequencing. Inflamm Bowel Dis 2016;22:1275-85. [PMID: 27135481 DOI: 10.1097/MIB.0000000000000752] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
752 Robertson J, Haas CT, Pele LC, Monie TP, Charalambos C, Parkes M, Hewitt RE, Powell JJ. Intestinal APCs of the endogenous nanomineral pathway fail to express PD-L1 in Crohn's disease. Sci Rep 2016;6:26747. [PMID: 27226337 DOI: 10.1038/srep26747] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
753 Mosli MH, Al-Harbi O, Feagan BG, Almadi MA. A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease. Saudi J Gastroenterol. 2015;21:185-197. [PMID: 26228361 DOI: 10.4103/1319-3767.161635] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
754 Stevenson L. How to Improve Your Success in Treating Mild and Moderate Inflammatory Bowel Disease. EMJ Gastroenterol 2016. [DOI: 10.33590/emjgastroenterol/10312456] [Reference Citation Analysis]
755 Stoppino LP, Della Valle N, Rizzi S, Cleopazzo E, Centola A, Iamele D, Bristogiannis C, Stoppino G, Vinci R, Macarini L. Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers. BMC Med Imaging 2016;16:37. [PMID: 27149857 DOI: 10.1186/s12880-016-0139-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
756 Ortiz-Masiá D, Cosín-Roger J, Calatayud S, Hernández C, Alós R, Hinojosa J, Esplugues JV, Barrachina MD. M1 Macrophages Activate Notch Signalling in Epithelial Cells: Relevance in Crohn's Disease. J Crohns Colitis 2016;10:582-92. [PMID: 26802079 DOI: 10.1093/ecco-jcc/jjw009] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
757 Baumgart DC, Bokemeyer B, Drabik A, Stallmach A, Schreiber S; Vedolizumab Germany Consortium. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice--a nationwide consecutive German cohort study. Aliment Pharmacol Ther 2016;43:1090-102. [PMID: 27038247 DOI: 10.1111/apt.13594] [Cited by in Crossref: 125] [Cited by in F6Publishing: 87] [Article Influence: 17.9] [Reference Citation Analysis]
758 Chen ML, Sundrud MS. Cytokine Networks and T-Cell Subsets in Inflammatory Bowel Diseases. Inflamm Bowel Dis 2016;22:1157-67. [PMID: 26863267 DOI: 10.1097/MIB.0000000000000714] [Cited by in Crossref: 83] [Cited by in F6Publishing: 80] [Article Influence: 11.9] [Reference Citation Analysis]
759